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Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease associated 
with a wide range of clinical features involving different organs and the prognosis is also highly 
variable.  It is a complex genetic trait in which more than 80 susceptibility loci show robust genetic 
association with disease risk. 
Firstly, I preformed eQTL mapping, incorporating co-localization analysis of GWAS in the 
functional immune cells, in order to identify likely causal genes.  The results indicate that eQTLs 
present in a diverse set of immune cells, encompassing both the innate and adaptive immune 
responses for more than half of the loci.  I then integrated genetics, epigenetics and gene 
expression to delineate the regulatory map of SLE risk loci across human cells and tissues.  Using 
GARFIELD and GoShifter, I demonstrated that SLE genetic associations displayed a marked 
enrichment pattern for areas of open chromatin in blood, including B cells, T cells, monocytes, 
and NK cells.  Moreover, I found that a large proportion (66%) of the SLE eQTLs showed to 
overlap with areas of open chromatin, denoting extensive local coordination of genetic influences 
on gene expression and epigenetics. 
SLE patients with renal involvement have more severe clinical outcomes and an increased 
mortality risk. By calculating the genetic risk score (GRS) using a list of SNPs that are reported to 
be significantly associated with SLE, I found a significant correlation between GRS and patients 
with renal involvement – the higher the GRS, the higher probability of getting renal disease.  The 
GRS also correlated inversely with age of SLE onset. 
As part of the functional study of post-GWAS, I investigated the protein expression of selected 
SLE-susceptibility gene products, namely Ikaros family members and OX40L, in a range of 
immune cells, using multi-parameter flow cytometry.  The results reveal some cellular specificity 
in gene expression in disease.  In particular, IKZF3 expression on activated regulatory T cell 
subsets was decreased, while OX40L expression on B cell subsets was increased in SLE. 
In summary, I combined eQTLs and epigenomes to identify the functional tissues and causal 
genes.  In addition, I measured the expression of OX40L and Ikraos family to help understand the 
cell effects at protein level. Finally, I found that the genetic risk factors that influence the severity 
of SLE are through a quantitative way but not qualitative way, suggesting that the GRS approach 
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Chapter 1. Introduction 
 
1.1 Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease 
characterized by a wide spectrum of signs and symptoms varying among affected individuals and 
can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous 
system, and haematopoietic system (Figure 1-1), thus the diagnosis of SLE remains challenging 
[1].  Marked differences in SLE population incidence and prevalence rates according to ancestry 
have been observed, being more prevalent in non-Caucasians populations with a significant sex 
disparity towards women during the years between menarche and menopause [2].  Although the 
exact cause of SLE is not fully understood, both genetic and environmental factors have been 
identified to influence the development of SLE.  Genetic interactions with environmental factors, 
such as UV light exposure and Epstein–Barr virus (EBV) infection, might initiate the disease, 
resulting in dysregulation in both innate and adaptive immune system.  
 
1.1.1  Epidemiology 
The overall incidence rates of SLE range from 0.3 - 23.7 per 100,000 person-years whereas 
prevalence rates vary approximately from 6.5 – 178.0 per 100,000 [2-4].  The incidence and 
prevalence rates of SLE are varied worldwide due to the genetic, environmental, 
sociodemographic and methodological issues.  Higher rates are observed in women and in non-
Caucasians.  The female/male ratio ranges from 3/1 in children to about 9/1 in women of child-
bearing age [5, 6].  People of Afro-Caribbean, African and Asian origin have a higher incidence 
than those of white European origin.  A UK study of immigrant women revealed a five-times higher 
prevalence of SLE in Afro-Caribbean and a three-times higher prevalence in African origin than 
in Caucasian [7].  Moreover, sex, age and ancestry are associated with disease expression in 
SLE patients.  A recent review by Pons-Estel et al showed that males, childhood-onset, and non-
Caucasians SLE patients have a more severe disease [8].  
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1.1.2  Aetiology 
The aetiology of SLE is multifactorial and poorly defined, requiring interplay among genetic 
predisposition, environmental triggers and hormonal factors. Familial aggregation and twin 
studies showed that the concordance rate in monozygotic twins (24%) is approximately ten fold 
higher than in dizygotic twins (2%) [9, 10].  A recent study from Taiwan reported that the heritability 
was 43.9% and the proportion of phenotypic variance explained by shared and non-shared 
environmental factors was 25.8 and 30.3%, respectively, suggesting non-heritable factors may 
play a considerable role in disease pathogenesis [11].  
The advent and application of Genome-wide association studies (GWAS) has dramatically 
advanced knowledge of the genetic cause of SLE.  Although in rare cases SLE may be caused 
by the deficiency of a single gene (e.g., the complement component C4) [12], the disease 
generally results from the combined effect of variants in a large number of loci.  Recent advances 
of SLE genetic studies are summarized in Section 1.2 (Page 26).   
Environmental factors, such as EBV infection, UV light exposure and certain drugs, might trigger 
the disease.  EBV infection may contribute to the activation of the innate immune system and B 
cell differentiation, leading to the stimulation of autoantibodies production [13].  Exposure to UV 
light, which might induce DNA breaks and lead to apoptosis, is one of the major factors known to 
promote the pathogenesis of SLE [14].  Certain drugs, like hydralazine, might trigger SLE through 
their effects on T cell DNA methylation [15, 16].  In addition, tobacco smoking [17] and silica [18] 
are found to be potential risk factors for SLE on the basis of their capacity to promote immune 
response.  
The causes of the sexual dimorphism in SLE remain largely unknown. The effect of exogenous 
hormones on the onset and flares of SLE suggests that hormonal factors represent a component 
in the pathogenesis of the disease [19].  The risk of SLE development in males is less than 
females of prepubertal age, but the skewing is less marked than in adults. Of interest, SLE is 
more common in males with Klinefelter syndrome, characterizing by a 47,XXY genotype, further 
supporting the limitations of the hormonal hypothesis and raising the possibility of a sex 
chromosome dose effect [20].  
 
1.1.3  Pathophysiology 
SLE is an autoimmune disease characterised by the overproduction of nuclear autoantibodies 
and proteins.  Although the exact mechanism of autoimmune responses is not fully understood, 
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both innate and adaptive immune disturbances occur in SLE.  SLE is widely thought to be a self-
immunization disease driven by defective clearance of dead cells.  The accumulation of apoptotic 
cells in various tissues and the signals released by them act as potential direct triggers of innate 
immune system activation.   Nucleic acid-containing immune complex and cytoplasmic RNA and 
DNA are potential stimuli for the activation of nucleic acid-responsive endosomal TLRs and TLR-
independent nucleic acid sensors, leading to the production of type I interferons (IFNs) [21].  
Type I IFNs not only activate dendritic cells (DCs) and nature killer (NK) cells involved in innate 
immunity, but also activate B cells and T cells to trigger the adaptive immune system.   T cells are 
recognised as the most efficient drivers of B cell differentiation [22].  Although lymphocytopaenia 
is a typical feature of SLE, specific T cell populations are expanded in SLE patients.  The 
expansion of T follicular helper (Tfh) cells promotes the differentiation of autoantibody-producing 
B cells [23].  The expansion of CD8+ memory the T cell population is associated with poor 
prognosis in SLE [24]. Regulatory T (Treg) cells, that have the function of suppressing immune 
response, are also considered to be an aspect of SLE pathogenesis [25].  However, reports on 
the numbers and functions of Treg in SLE are controversial.  Some studies report that Treg cells 
are depleted in patients with lupus nephritis [26-30], while other studies observe no alteration or 
increased level of Treg cells in SLE compared with those in healthy controls [31-33].  B cell 
function is also altered in SLE, leading to the production of autoantibodies, cytokines and 
augmented presentation of antigen to T cells.  Long-lived plasma cells are proposed sources of 
anti-Sm and anti-Ro autoantibodies that are refractory to anti-B cell therapy while circulating 
plasmablasts are sources of anti-dsDNA autoantibodies which are more amenable to B cell 




Figure 1- 1. Clinical heterogeneity of SLE. 
The multifaceted nature of SLE is shown by the number of different organ systems that can be 
affected. The average frequency of the most common complications is indicated in parentheses.  





Figure 1- 2. Aetiology and pathogenesis of SLE.   
In the scenario of deficient clearance of apoptotic cells, dying cells are prone to progress to 
secondary necrosis (1), which then exposes autoantigens in an inflammatory context. 
Undigested apoptotic remnants (SNEC) accumulate in germinal centres (2) and are presented 
by follicular DCs to autoreactive B cells, breaking tolerance to self.  Autoreactive B cells might 
undergo proliferation and activation, eliciting immune responses against nuclear components 
(3).  Antinuclear autoantibodies encounter nucleic-acid-containing apoptotic remnants either in 
circulation or deposited in tissues to form immune complexes (4). SNEC-containing immune 
complexes are cleared by blood-borne phagocytes, macrophages and DCs, which, in turn, 
secrete high amounts of inflammatory cytokines (5). The final outcome is multiple organ 
damage and, subsequently, enhanced cell death, closing a vicious circle that leads to the 
establishment of chronic inflammation (6). Steps 1–3 represent the events involved in the 
aetiology of SLE; steps 4–6 correspond to the description of the ‘lupus pathogen’ causing 
disease manifestations (pathogenesis). Abbreviations: DC, dendritic cell; PMN, 
polymorphonuclear leukocyte; SLE, systemic lupus erythematosus; SNEC, secondary necrotic 
cell-derived material.   Adapted from reference [36]. 
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1.2 Genetics of SLE 
Although the exact aetiology of lupus is not fully understood, a strong genetic link has been 
identified through the application of family and large-scale genome-wide association studies 
(GWAS).  The concordance rate in monozygotic twins (24%) is approximately ten fold higher than 
in dizygotic twins (2%) [9, 10].  Lawrence JS et al’s study in a European population from a family 
survey estimated the overall heritability of SLE to be 66 +/- 11% [37].  However, a recent study 
from Taiwan reported that the heritability was 43.9% (with 25.8% for shared environmental 
factors), suggesting non-heritable factors may play a considerable role in disease pathogenesis 
[11].  
 
1.2.1  Human genome variations 
The human genome contains various forms of variation and the most common one is single 
nucleotide polymorphisms (SNP) -- variants in an organism’s DNA sequence where more than 
one allele is present at a detectable frequency in the population.  SNPs can be classified into 
different groups depending on their positions and effects.  For example, a synonymous SNP is 
one located in a protein-coding region but doesn’t affect the amino acid sequence after translation.  
Other types of genetic variants include small indels (insertion and/or deletion) and structural 
variants.  A brief summary of the different types of human variations are summarised in Figure 1-
3.  In this thesis, only the effects of SNPs are evaluated. 
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Figure 1- 3. Variations in human genome. 
*SNP: Single nucleotide polymorphism; **CNV: copy number variation 
 
1.2.2 Insights from SLE GWAS 
As mentioned above, SLE is a disease with a highly genetic background but does not follow the 
Mendelian patterns of inheritance, and so it is termed a complex or non-Mendelian trait.  Complex 
traits are multi-factorial with both genetic and environmental contributions.  In addition, there is 
no single locus containing alleles that are sufficient for occurrence of disease in most cases.  
Genome-wide association studies (GWAS) are used to investigate the genetic basis of a disease 
by comparing a group of patients with disease to a group of healthy controls.   The advent and 
application of GWAS has dramatically advanced knowledge of the genetic aetiology of SLE.    
There have been seven SLE GWAS in the European population [38-44], six Asian GWAS [45-
50], and one GWAS of Amerindian ancestry [51], as well as subsequent meta-analyses and large-
scale replication studies [52-55], published since 2008.   
Currently, 84 genetic loci are implicated as SLE risk (Figure 1-4: The CIRCOS plot and Table 1-
1), which, in order to avoid likely spurious associations, includes genetic associations with a p-
value less than 5 ´ 10-8 tested in a total sample size of at least 1000 individuals.  The interactive 






























the following link: http://insidegen.com/insidegen-LUPUS-Associations.html.  Major findings from 
GWASs published in the last two years are summarized below. 
 
European GWAS 
The largest European GWAS of SLE conducted by our group [43], comprising 7,219 SLE cases 
and 15,991 controls of European decent, provided considerable power to detect disease risk loci.  
Notably, the study identified 43 susceptibility loci, ten of which were novel loci: SPRED2, IKZF2, 
IL12A, TCF7-SKP1, DHCR7-NADSYN1, SH2B3, RAD51B, CIITA-SOCS1, PLD2, and CXorf21.  
One of the great challenges posed by interpreting GWAS data is determining the causal genes 
implicated by the genetic association data.   As will be discussed in Section 1.3, my work makes 
a considerable contribution and not trivial effort in naming the genes in the above list (Table 1-1).  
Irrespective of the underlying causal genes, the European GWAS paper concluded that the 
heritability explained by the risk alleles mapped at these loci was 15.3%, which is a large increase 
over the 8.7% reported by So et al in 2011 using the same measure [56]. 
 
Asian GWAS 
An extensive large-scale fine mapping study using the Immunochip conducted in 4,478 SLE 
cases and 12,656 controls from six East Asian cohorts identified 10 novel loci [50] in Asians, 
encompassing GTF2IRD1-GTF2I, DEF6, IL12B, TCF7, TERT, CD226, PCNXL3, RASGRP1, 
SYNGR1, and SIGLEC6. Some of these were previously reported to be associated in Europeans, 
for example, DEF6 and TCF7. The identification of these risk loci increased the explained 
heritability to 24% in Asian SLE.  Nevertheless, the Immunochip was designed from 
predominantly European genetic information and will therefore be less informative and not as 
representative of the genetic variation in Asian populations as it is in Europeans [57]. 
 
Trans ancestry meta analyses of GWAS 
A comparison of genetic association signals across the genome in European and Asian 
populations suggested that SLE susceptibility loci were shared extensively between both 
populations [54].  This motivated a trans ancestral approach at the genome-wide level to provide 
evidence of shared genetic components in the two populations and a search for additional SLE 
associated loci.  The study by Morris and Sheng et al [54], that combined three GWAS from two 
ethnicities: two Chinese (a total of 1659 cases and 3,398 controls) and one European (4,044 
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cases + 6,959 controls), found evidence of considerable commonality in terms of SLE association 
signals as well as mapping novel susceptibility loci, including CD45, IKBKE, LBH, LPP-TPRG1-
AS1, ATXN1, BACH2, GTF2I, JAK2, RNASEH2C, and ZFP90.   Notably, this study suggested 
that the increased prevalence of SLE in non-European (including Asians) has a genetic basis by 
a comparison of genetic risk scores (GRS) between populations.  Moreover, by using all 
genotyped SNPs (DNA chip) to calculate heritability explained, the explained variation (Vg) 
increased to 28% in Chinese subjects and 27% Europeans using the GCTA algorithm [58] .  While 
there are still some uncertainties in the methodology for calculating heritability explained, this 
shows very strong evidence that we are making progress on the understanding of SLE heritability. 
The latest large-scale trans ancestral study using Immunochip [59], comprising three ancestries: 
European (EA: 6,748,cases and 11,516 controls), African-American (AA: 2,970 case and 2,452 
controls), and Hispanic Amerindian (HA: 1,872 cases and 2,016 controls), identified eight novel 
loci for EA (TMEM39A-TIMMDC1, DGKQ, LRRC16A, SLC17A4, OLIG3-LOC100130476, 
FAM86B3P, PKIA-ZC2HC1A, and GRB2 ), two for AA ( PTTG1-MIR146A and PLAT) and two for 
HA (GALC and CLEC16A ).  By comparing results across different populations, both ancestry-
dependent and ancestry-independent contributions to SLE risk were identified with the caveat of 
unequal cohort sizes.  The study reveals further evidence of sharing of genetic risk loci between 
ancestries as well as evidence that each individual population carries unique genetic risk factors 
at the locus level and at the allelic level. 
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1	 1p36.11	 rs4649203	 24519920	 G	 intergenic		 IL28RA	 Chinese	 24070858	






3	 1q23.3	 rs1801274	 161479745	 C	 missense	 FCGR2A	 European	 26502338	
4	 1q25.1	


















rs704840	 173226195	 G	 intergenic		 European	 26502338	
rs1418190	 173361979	 G	 intergenic		 Chinese	 25890262	
rs4916219	 173373183	 A	 intergenic		 Chinese	 25890262	
5	 1q25.3	























rs10911628	 184649503	 NA	 intergenic		 EDEM3	 European	 24871463	

















8	 1q42.3	 rs9782955	 236039877	 C	 intron	 LYST	 European	 26502338	
























10	 2p22.3	 rs13385731	 33701890	 G	 intron	 RASGRP3	 Chinese	 19838193	
11	 2p14	 rs6740462	 65667272	 A	 intron	 SPRED2	 European	 26502338	
12	 2p13.1	
rs4852324	 74202578	 T	 intron	 DGUOK-
TET3	
Asian		 23273568	
rs6705628	 74208362	 C	 non	coding	 Asian		 23273568	
13	 2q24.2	
rs2111485	 163110536	 G	 intergenic		
IFIH1	
European	 26502338	





rs3821236	 191902758	 NA	 intron	
STAT4	
Korean	 23740238	
rs7601754	 191940451	 NA	 intron	 Asian		 19225526	
rs11889341	 191943742	 T	 intron	 European	 26502338	
rs10931481	 191954852	 T	 intron	 European	 23053960	
rs6736175	 191946322	 C	 intron	 European	 26502338	
15	 2q34	 rs3768792	 213871709	 C	 3'-UTR	 IKZF2	 European	 26502338	
16	 3p14.3	













rs6445975	 58370177	 C	 intron	 European	 18204446	
rs9311676	 58470351	 C	 intergenic		 European	 26502338	
17	 3q13.33	









rs1131265	 119222456	 G	 synonymous	 European	 28714469	
rs6804441	 119260944	 A	 intron	
CD80	
Asian		 23273568	
rs2222631	 119272391	 G	 intron	 Asian		 25862617	
18	 3q25.33	 rs564799	 159728987	 C	 intron	 IL12A	 European	 26502338	












21	 4p16	 rs4690229	 970724	 T	 3'-UTR	 DGKQ	 European	 28714469	
22	 4q21.3	 rs340630	 87958395	 A	 intron	 AFF1	 Japanese	 22291604	
23	 4q24	
rs10028805	 102737250	 G	 intron	
BANK1	
European	 26502338	
rs17266594	 102750922	 C	 intron	 Chinese	 19357697	



















25	 5p15.33	 rs7726159	 1282319	 A	 intron	 TERT	 Asian		 26808113	













rs2421184	 159459931	 A	 intron	 IL12B	 Asian		 26808113	
























rs36014129	 25884519	 A	 intron	 SLC17A4	 European	 28714469	










rs2246618	 31478986	 A	 upstream		 MICB	 European	 23084292	








rs8192591	 32185796	 G	 missense	 NOTCH4	 European	 23084292	





















rs3748079	 33588147	 C	 5'-UTR	 ITPR3	 Japanese	 18219441	
















rs10807150	 35304497	 C	 intron	 DEF6	 Asian		 26808113	





























rs6932056	 138242437	 C	 intergenic	 TNFAIP3	 European	 26502338	





































rs1167796	 75173180	 G	 intron	
HIP1	
Chinese	 19838193	
rs6964720	 75180344	 NA	 intron	 Asian		 26663301	
39	 7q32.1	


















rs12537284	 128717906	 A	 intergenic	 European	 18204446	









rs6985109	 10767748	 A	 intron	 XKR6	 European	 18204446	
rs7836059	 11272164	 T	 intron	 C8orf12	 European	 18204446	




rs7812879	 11340181	 A	 intergenic	
BLK	
Chinese	 19838193	





rs2248932	 11391650	 A	 intron	 Chinese	 19838193	
42	 8q12	 rs7829816	 56849386	 C	 intron	 LYN	 European	 18204446	
























rs7097397	 50025396	 G	 missense	
WDFY4	
Asian		 20169177	





rs1913517	 50119054	 A	 intron	 Chinese	 19838193	







































rs2009453	 65632057	 C	 intron	 PCNXL3	 Asian		 26808113	
51	 11q13.4	














rs11603023	 118486067	 T	 intron	
PHLDB1	
Asian		 24001599	
rs4639966	 118573519	 G	 downstream		 Chinese	 19838193	
rs10892301	 118735476	 G	 intergenic	 CXCR5	 Asian		 24001599	
53	 11q24.3	






rs7941765	 128499000	 C	 downstream		 European	 26502338	
54	 12p13	
rs12822507	 12773521	 A	 intron	 CREBL2	 Asian		 23273568	
rs10845606	 12834894	 C	 intron	 GPR19	 Asian		 23273568	
rs34330	 12870695	 C	 5'-UTR	 CDKN1B	 Asian		 23273568	
55	 12q12	 rs10506216	 43130885	 T	 intergenic	 PRICKLE1	 European	 26316170	
56	 12q23.2	 rs4622329	 102321935	 A	 intron	 DRAM1	 Asian		 23273568	



















rs1059312	 129278864	 C	 synonymous	
SLC15A4	
European	 26502338	
rs10847697	 129299385	 A	 synonymous	 Chinese	 19838193	
59	 13q14.11	 rs7329174	 41558110	 G	 intron	 ELF1	 Asian		 21044949	
60	 14q13.2	 rs8016947	 35832666	 A	 intron	 NFKBIA	 Chinese	 24070858	
61	 14q24.1	 rs4902562	 68731458	 A	 intron	 RAD51B	 European	 26502338	
62	 14q31	 rs11845506	 88383035	 C	 intron	 GALC	 Hispanic	 28714469	
63	 15q14	
rs12900339	 38635185	 A	 intergenic	 RASGRP1	 Asian		 26808113	
rs11073328	 38764843	 NA	 intron	 FAM98B	 European	 24871463	
64	 15q24	
rs34933034	 75079474	 NA	 intron	
CSK	
European	 23042117	
rs2289583	 75311036	 A	 intron	 European	 26502338	
65	 15q26.2	 rs8023715	 97607681	 NA	 intergenic	 SPATA8	 European	 24871463	
66	 16p13	




rs9652601	 11174365	 G	 intron	 European	 26502338	
rs12599402	 11189888	 A	 intron	 Chinese	 20805369	
67	 16p11.2	
rs16972959	 23901376	 A	 intron	 PRKCB	 Chinese	 21134959	




rs34572943	 31272353	 A	 intron	 European	
26502338,	
18204446	
rs11574637	 31368874	 C	 intron	 European	 18204098	










rs2934498	 85968282	 G	 intergenic	
IRF8	
Chinese	 25890262	













71	 17p13.2	 rs2286672	 4712617	 T	 missense	 PLD2	 European	 26502338	
72	 17q12	 rs2941509	 37921194	 A	 3'-UTR	 IKZF3	 European	 26502338	
73	 17q25	 rs930297	 73404537	 A	 intergenic	 GRB2	 European	 28714469	
74	 18q22.2	 rs1610555	 69875911	 T	 intron	 CD226	 Asian		 26808113	
75	 19p13	































76	 19q13.41	 rs2305772	 51530488	 G	 missense	 SIGLEC6	 Asian		 26808113	




78	 20q13.13	 rs11697848	 48575315	 NA	 intergenic	 RNF114	 European	 24871463	
79	 22q11.21	




rs131654	 21917190	 A	 intron	 Chinese	 19838193	
rs7444	 21976934	 C	 	3'-UTR	 European	 26502338	
80	 22q13.1	 rs61616683	 39359768	 T	 intron	 SYNGR1	 Asian		 26808113	
81	 Xp22.2	
rs7062536		 12839152	 	A	 intron	 PRPS2	 Asian		 25149475	
rs3853839	 12907658	 G	 3'-UTR	 TLR7	 Asian		 20733074	
82	 Xp21.2	 rs887369	 30577846	 C	 synonymous	 CXorf21	 European	 26502338	
































Figure 1- 4. SLE risk loci in genomic context 
The CIRCOS plot shows genes located within the SLE risk loci (84 in total) according to their 
genomic position. The full list of variants and locus genes for this plot is summarized in Table 1-
1.  The red block in each chromosome indicates the centromere of the chromosome.  Each 
chromosome arm is divided into cytogenetic bands of hg19.  
 
 
1.2.3 Missing heritability 
In summary, the chip heritability identified by the latest GWAS have explained around 28% of the 
disease heritability: a marked improvement on 8.3% calculated in 2011 [56].  Although the overall 
heritability of complex disease is complicated to estimate, a study in a European population from 
a family survey did estimate a heritability of 66 +/- 11% for SLE [37], indicating there is more than 































































































































































































































































43.9% (with 25.8% for shared environmental factors) estimated from a Taiwanese population [11], 
there is still one third of heritability left to explain.  Explanations for the missing heritability, 
including larger numbers of variants of smaller effect, rarer variants (possibly with larger effects) 
that are not present on genotyping arrays or structural variants poorly captured by existing arrays, 
as well as epigenetic modifications, have been suggested [60].  Innovations in genotyping and 
sequencing technologies, like the Immunochip platform [50, 59], and next generation sequencing 
(NGS, as described below) will advance the investigation into common and rare variants and 
potential effects on the immune system, enhancing our understanding of the genetic risk of SLE. 
The linkage disequilibrium (LD) that exists in the human genome facilitates the mapping of risk 
loci by reducing the number of genetic variants required for GWAS; however, the same correlation 
between genetic polymorphisms at these susceptibility loci then obscures attempts to identify the 
actual causal allele(s) at risk loci. Bayesian fine mapping approaches had been proposed to 
derive smaller sets of SNPs (termed ‘credibility sets’) as the most likely causal variants at risk loci 
[61].  Nevertheless, statistical methods are inadequate to fully resolve the problem caused by LD.  
In order to further pursue likely causal SNPs within any given credibility set, mapping across 
ancestries can be applied to narrow down the target set of SNPs and the functional effect of SNPs 
can be studied in silico.  As the majority of variants within causal credibility sets are non-coding 
[62, 63], function is inferred using gene transcript expression data and epigenetic modification 
data (as described in Section 1.3).  
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1.3  Functional annotation of genetic variants 
More than 80 susceptibility loci are now reported to show robust genetic association with SLE.  
Nevertheless, the overwhelming majority of these loci (90%) lie in noncoding regions of the 
genome [64].  In the post-GWAS era, a major challenge is linking GWAS findings to additional 
molecular function in order to better understand the identity of the genes that underlie the genetic 
associations.  It is essential to bridge the gap between genotype and function in order to fully 
exploit the potential of GWAS.  Otherwise, the results from GWAS are essentially a list of genomic 
positions.  Furthermore, identification of molecular intermediaries, such as RNAs or proteins, 
between genotype and disease provides practical implications for developing pharmacological 
interventions. 
 
1.3.1  Incorporating gene expression profiling to infer causal genes 
It is now possible to investigate the effect of risk variants on level of intermediate molecules, for 
example, gene expression, methylation, protein abundance or metabolite levels, due to the 
advances in a variety of ~omics techniques.  Genetical genomics, which combines genome-wide 
expression profiling and genome-wide marker-based genotyping to members from a segregating 
population, has been proposed for discovering regulatory pathways [65].  This strategy takes 
advantage of the heritability of gene expression profiles to identify genetic variants that correlate 
with changes in gene expression [66-68]. 
 
Expression quantitative trait loci (eQTLs) 
An eQTL (expression quantitative trait locus) is a genetic element associated with the expression 
level of a given gene.  For the purpose of this thesis, the genetic element is a SNP and the 
expression level (mRNA abundance) of a given gene is considered as an intermediate molecular 
trait, i.e. ‘expression quantitative trait’.  As exemplified by the eQTL mapping literature, regulatory 
polymorphisms can be classified as “in cis” or “in trans” on the basis of their physical distance 
from the regulated gene.  Regulatory variation that is in the vicinity of the target gene is classified 
as being cis, while trans-eQTLs are SNP-gene pairs that are further away from each other (Figure 
1-5).  A cis association is often defined as the variant being present in a ±1Mb window surrounding 
the transcription start site (TSS) of the gene, and trans effects are defined as associations 
involving SNPs elsewhere in the genome [69]. 
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Comprehensive eQTL mapping can provide evidence for interpreting GWAS associations and 
constructing potential genes interaction networks [65].  Recent research has found that over 40% 
of trait-associated SNPs are more likely to have a cis-acting effect on gene expression [70].  
Another important potential advantage of studying eQTLs is that they can provide insight into the 
disease mechanism and underlying pathways. The simple integration of trait association with 
gene expression data in disease relevant cell types has indicated the probable causal gene(s) in 
a number of instances.  For example, variants that associated with asthma, locating across a 
large block (200kb) encompassing 19 genes, were found to increase the expression of a single 
gene in LCL: ORMDL3 (Sphingolipid Biosynthesis Regulator 3) [71].  The expression of ORMDL3 
was found to associate with the abnormalities in endoplasmic reticulum-mediated calcium 
signalling and modulating the inflammatory responses [72].  
 
 
Figure 1- 5. eQTL Mapping.   
(a) A typical eQTL - many SNPs tested against levels of expression measured by a probe or 
by other means. The panel below illustrates the difference in distributions of expression values 
stratified by the SNP genotypes of the most significant SNP. (b) eQTLs can be classified 
according to their location (cis- or trans-) [69]. (c) eQTL mapping with linear regression. 
Genotype versus IKBKE (Inducible IkappaB Kinase) adjusted expression level in B cells, with 
the estimated regression line shown in green. The genotypes are codes as 0~2, termed 
‘dosage’, counting the number of reference alleles.  In this case, the dosage is counted on 
allele G, so genotypes of AA, AG and GG are coded as 0,1 and 2, respectively.  Data points 
that are not integer are obtained from imputation, arising from the probabilities of each 
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Application of eQTL mapping to GWAS results 
Assisted by dense genome coverage of the reference panel from the 1000 Genome project [74], 
imputation and Bayesian inference provided evidence for missense variants underpinning 
association for eight genes, including PTPN22, FCGR2A, NCF2, IFIH1, WDFY4, ITGAM, PLD2, 
and TYK2 [43].  However, as mentioned above, the majority (~ 90%) of disease associated loci 
in SLE are located outside of protein-coding regions, and so might exert their function through 
altering gene expression rather than by altering protein structure.  Of note, an over-representation 
(n=16) of transcription factors among the 43 SLE susceptibility genes have been annotated in our 
recent European GWAS [43], further indicating that perturbed gene regulation is a major 
functional risk factor for SLE.  eQTL mapping, which combines genome-wide expression profiling 
and genome-wide marker-based genotyping, takes advantage of the heritability of gene 
expression profiles to identify genetic variants that correlate with changes in gene expression.  
Some studies [50, 55] use public databases, such as the whole blood eQTL browser 
(http://genenetwork.nl/bloodeqtlbrowser/) [75], and tissue-specific GTEx portal 
(http://www.gtexportal.org/home/) [76],  to determine whether a disease-associated SNP is a 
significant eQTL.  Of note, limitations exist when applying eQTL analysis to the GTEx whole blood 
data sets; for example, we seek eQTL in specific immune cell subsets when studying autoimmune 
disease.  
In order to highlight potential causal genes at the susceptibility loci robustly, it is essential to 
integrate the disease association and eQTL data using a co-localisation approach. That is, to 
establish that the same genetic variants that underlie the disease association also underlie the 
eQTL.  The presence of LD in the genome can readily confuse this overlap.  Co-localisation 
methods, like the regulatory trait concordance (RTC) [77], conditional analysis [58], and Bayesian 
co-localisation [78] can be employed to infer that the disease association and eQTL have the 
same allelic basis.  As many variants have weak eQTL effects, erroneous conclusions will be 
made if analyses for co-localisation are not performed.  Many SNPs may be observed to be both 
eQTLs, even if weak, and also associated with the target phenotype (e.g. disease), so it is 
imperative to separate out a spurious eQTL overlap from ones that co-localise and hence makes 




Figure 1- 6. Illustration of co-localisation results.  
Left panel (A–B, FRK gene and LDL) is a negative co-localisation result and right panel (C-D, 
SDC1 gene and TC) is positive co-localisation result.  –log10(P) association P-values for 
phenotype (top: A and C) and –log10(P) association P-values for gene expression (bottom: B 
and D) at the FRK (left: A and B) and SDC1 locus (right: C and D), 1Mb range.  
Abbreviations: LDL: low density lipid; TC: total cholesterol.  Adapted from reference: 
doi:10.1371/journal.pgen.1004383.g001 [78] 
 
Cell and context specificity of regulatory variation 
Genetic variations regulate gene expression levels spatially and temporally, thus leading to the 
differentiation and maintenance of highly specialised cell and tissue types that underlie 
phenotypic differences across individuals [79].  In general, different cell types are thought to be 
governed by a set of master regulators – transcription factors and cis-regulatory factors that 
dictate gene expression for specific cell types [80].  As a result, recent studies in regulatory 
genomics have been performed across cell types [81].  Due to their accessibility, many eQTL 
studies have been performed in blood-derived cells, mostly in whole blood and in cell lines, i.e. 
LCL, a lymphoblastoid cell line that is derived from Epstein Barr Virus (EBV) transformation of 
 39 
peripheral blood B-lymphocytes.  LCL has been very important for the understanding of regulatory 
variations, particularly as a surrogate for immune cells [68, 82, 83]. However, there remain some 
questions on the physiological relevance of LCL, since its growth rate and EBV load are both 
correlated with gene expression levels [84].  Datasets derived from whole blood [75, 85, 86] have 
also been extensively used.  Though informative, there are some drawbacks - whole blood is a 
‘bulk’ tissue, which comprises a variety of cell types.  Subtle eQTLs in specific cell types may be 
diluted when assaying expression across the entire range of cell types [87].  These findings have 
propelled studies to measure gene expression directly in purified cell types [88] or decompose 
expression of bulk tissue into specific subsets statistically  [89, 90].  
Moreover, gene expression levels are also highly dependent on cellular contexts and 
environmental triggers [87].  A study of purified monocytes derived from 432 European individuals 
were assessed for gene expression ex vivo naïve and stimulated with either interferon-gamma 
(IFN-r) or lipopolysaccharide (LPS) at 2 and 24 hours (Figure 1-7).  The majority of cis-eQTLs 
were observed only under activation, and many can even possess opposing effect directions [73, 
91].  Another study in monocytes found that cis-eQTLs interacted with either age, sex, or smoking 
status [92] indicating the involvement of environment. 
 
 
Figure 1- 7. eQTLs display context and stimulus specificity.   
a) Context-specific directional eQTL effects. Expression of gene HIP1 in naive and stimulated 
monocytes stratified on variation of SNP rs1179625.  The minor allele [G] decreases 
expression of HIP1 in naïve monocytes, but increases expression after 24-hour LPS 
stimulation.  ns, not significant.  B) Induction by LPS reveals a stimulus-specific cis-eQTL for 




1.3.2  Integrating epigenetics to annotate functional/regulatory variants 
An approach that is complementary to eQTL analyses to examine the regulatory function of non-
coding genetic variants is to study gene regulation with epigenetics.  Epigenetic modifications, a 
term coined to describe genome-wide chromatin modification, including DNA methylation, histone 
modifications, chromatin accessibility, microRNA regulations, and 2D chromatin interactions [93], 
constitute an additional layer of genomic regulation, and may serve as a dynamic link between 
genotype and phenotype.  Such changes in DNA and chromatin structure correlate with changes 
in chromatin accessibility and transcription factor binding.  These epigenomes provide valuable 
information for prioritizing likely causal variants identified from GWASs.   For example, promoters 
active in a specific cell type can be used to prioritize eQTL variants of that cell type and then be 
used for identifying potential causal variants. 
The Encyclopedia of DNA elements (ENCODE) project (https://www.encodeproject.org/) [94] has 
systematically mapped regions of transcription, transcription factor association, chromatin 
structure and histone modification, and assigns biochemical functions for 80% of the genome, in 
particular outside of the protein-coding regions.  Overall, the project has provided an expansive 
resource to define functional DNA elements for biomedical research, although the available cell 
types or cell lines are limited.  The cells of closest immune relevance in ENCODE Tier 1 and Tier 
2 are LCLs (GM12878), B cells (CD20+) and monocytes (CD14+), as well as T cells (CD4+) and 
peripheral blood mononuclear cells (PBMC) in Tier 3.  A recent ImmunoChip study in Asians [50] 
took advantage of ENCODE data to map the underlying associated loci.  For example, one of the 
signals (rs73366469) identified in this study was located between two ‘general transcription factor’ 
genes, GTF2I and GTF2IRD1.  By integrating the ENCODE data, they found that an indel SNP 
rs587608058 (r2 = 0.81), ~1000bp from rs73366469, lay within a conserved enhancer, active 
chromatin and transcription factor binding sites in LCLs and CD4+ T cells.  In addition, this region 
was found to overlap the transcription start sites for GTF2I and VCF through chromatin interacting 
analysis and chromosome conformation capture [95], providing evidence for the potential causal 
variants and genes at this locus for further study.    
 
The Roadmap epigenomics project (http://www.roadmapepigenomics.org/) [96] integrated 
analysis of 111 reference human epigenomes to obtain a comprehensive map of the human 
epigenomic landscape across a large collection of primary cells (including immune cells) and 
tissues.  This map is extremely useful for studies of genome interpretation, gene regulation, 
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cellular differentiation, genome evolution, genetic variation and human disease.  In our meta 
GWAS analysis of Chinese and European data [54], histone modification markers, including 
acetylation markers (H3K27ac, H3K9ac) and methylation markers (H3K27me3 and H3K9me3), 
from blood cell types were used to investigate the potential regulatory function of the target risk 
loci.   For example, there are several genes, including SRGAP2, SRGAP2D, IKBKE, RASSF5, 
EIF2D and DYRK3, located within ±200kb of a lead GWAS SNP rs2297550.  This GWAS SNP 
was also found to be a putative eQTL for IKBKE, with the SLE risk allele correlated with reduced 
expression in CD4+ T cells, CD19+ B cells and NK cells, but with increased expression in CD14+ 
monocytes (Figure 1-5 c).  IKBKE encodes a noncanonical I-kappa-B kinase (IKK) that is 
essential in regulating inflammatory responses to viral infection by activating the type I interferon, 
NF-kB and STAT signalling pathways, suggesting IKBKE might be the potential causal gene.  
Moreover, there is an intense histone acetylation peak around the associated SNP rs2297550, 
indicating that rs2297550 may be a potential causal variant.   
 
Another recent completed large-scale epigenomic project, the Blueprint project 
(http://www.blueprint-epigenome.eu/) [97-99], has impressively shown how epigenetic 
information and analyses can help to study the cellular mechanisms associated with complex 
human diseases.  The Blueprint consortium generated three comprehensive reference panels, 
including genome (whole genome sequencing), transcriptome (RNA-seq), and epigenome (DNA 
methylation and histone modification), in three immune cells (Neutrophils, monocytes and T cells) 
from nearly 200 individuals to characterize the contributions of diverse genomic inputs to 
transcriptional variation.  Summary data from these panels can be accessed through 
http://blueprint-dev.bioinfo.cnio.es/WP10/ . High-resolution maps of promoter interactions [98] 
generated by ‘Promoter capture Hi-C’ (PChi-C) make it possible to study long range regulation in 
three-dimensional nuclear space.  By integrating PCHi-C data with disease-associated SNPs 
generated by GWAS, we can prioritize the putative target genes for the risk loci.  The promoter 
interactome’s map may serve as a more robust method to define cis-eQTL rather than by distance, 




1.4  From genetics to protein expression 
Genetic and epigenetic studies in SLE provide abundant data to address which molecules are 
likely to have functions in the pathogenesis of the disease.  In order to better understand the 
molecular mechanisms of these genes in the disease, it is enlightening to explore the protein 
expression of a susceptibility gene.  Protein expression is an informative intermediator to minimise 
the gap between genetics and phenotypes. As proteins are likely to be more directly mediating 
functional effects on cells than transcripts, one can predict that levels of protein will correlate 
better with phenotype than mRNA levels.  As part of the functional post-GWAS study, I will 
investigate the protein expression of selected genes that showed robust associations with SLE 
susceptibility [43], namely Ikaros family members and OX40L, in a range of immune cells, using 
multi-parameter flow cytometry.  In this section, I will summarise what is currently know of their 
underlying biology and provide justifications for why these genes were chosen for the follow up 
studies. 
 
1.4.1  Immunophenotyping of PBMC by flow cytometry 
SLE is an autoimmune disease involving both the adaptive and innate immune systems.  In 
addition, the target end organs can vary largely across SLE patients.  Therefore, the decision of 
what tissues and cell types are appropriate to perform follow up experiments is of great 
importance.  Fortunately, by integrative analysis of reference human epigenomes from the 
ENCODE [94] and Roadmap [96] projects with the SLE GWAS findings, I found that most of the 
regulatory genetic variants are enriched in blood (more details see Chapter 4. The Functional 
Analysis of SLE Genetics), providing robust evidence for further studies to focus on immune cells 
in blood.  Nevertheless, blood is a bulk tissue that comprises a variety of immune cells, e.g. B 
cells, NK cells, T cells, monocytes, and etc.  Therefore, a comprehensive immunophenotyping to 
scrutinize the subtle differences across discrete immune subsets is crucial to disentangle the 
functions of the target molecules in blood.   
Immunophenotyping is the analysis of heterogeneous populations of cells for the purpose of 
identifying the presence and proportions of the various populations of interest based on the types 
of antigens or markers on the surface of the cells [100].  Cell markers are a very useful way to 
identify a specific cell population, but they are often expressed on more than one cell type.   Flow 
cytometry has increasingly become a method of choice for the analysis of cellular phenotype and 
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function in the immune system.  It is arguably the most powerful technology available for probing 
human immune phenotypes, due to its ability to measure multiple parameters on many individual 
cells in a complex mixture like blood.  By evaluating the unique repertoire of cell markers using 
several antibodies together, each coupled with a different fluorochrome, a given cell population 
can be identified and quantified.  Many immunological cell markers are CD markers and these 
are commonly used for detection in flow cytometry of specific immune cell populations and 
subpopulations.  In addition, since a wide range of antibody reagents and protocols are available 
commercially, flow cytometry can be used to access not only the cell-surface protein but also that 
of intracellular transcription factors.  Therefore, immunophenotyping by flow cytometry will be 
used for the quantification of protein levels of the selected molecules, including the protein 
products of four individual SLE risk genes: IKZF1, IKZF2, IKZF3 and OX40L.  A typical flow 
cytometry experiment is showed in Figure 1-8. 
 
 
Figure 1- 8. A typical flow cytometry experiment 
Sample preparation from blood often involves Ficoll gradient separation of peripheral 
mononuclear cells (PBMC), and sometimes cryopreservation, before staining with the 
fluorescent antibody conjugates.  Instrument setup is to set the voltage gains for the 
photomultiplier tubes (PMTs) in order to get the optimal detector sensitivity.  Data acquisition 
involves passing the stained cells through a laser beam, and then recording the fluorescence 
emission from all of the bound antibody conjugates of each single cell by the fluorescence 
detector.  Finally the data analysis reports the cell populations of interest. Ref., reference; SD, 
standard deviation. Adjusted from reference [100]. 
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1.4.2  The Ikaros family of transcription factors 
Immunological homeostasis including proliferation, survival, and cellular differentiation, are 
mostly governed by transcriptional regulators that mediate appropriate changes in gene 
expression [101].  The Ikaros gene family encodes zinc finger transcription factors, comprising 
Ikaros (also called IKZF1), Helios (IKZF2), Aiolos (IKZF3), Eos (IKZF4) and Pegasus (IKZF5), 
which are involved in lymphoid development and differentiation [102] and are central to successful 
decision making during haematopoiesis and to the maintenance of a functional immune system.  
The so-called ‘zinc finger’ superfamily is characterized by the presence of conserved zinc finger 
motifs.  Differential splicing of exons of the Ikaros gene generates multiple isoforms of several 
Ikaros family members. These transcription regulators participate in a complex network of 
interactions with other gene regulatory factors, e.g. activation of STAT4 [103], other family 
members (e.g. IKZF1 can modulate the expression of IKZF2 [104] ) and a raft of other 
transcriptional regulators modulate their function and regulate important cell-fate decisions during 
haematopoiesis, particularly in the development of the adaptive immune system [105].   
IKZF1, the founder and most studied member of the family, acts as a strong tumour suppressor 
in B-cell acute lymphoblastic leukemia (ALL) [106].  Deletion of IKZF1 is of high frequency in 
BCR-ABL1–positive ALL (a known very-high-risk ALL subtype) and is identified as a strong 
predictor of poor outcome in ALL patients [107].  Insights from several GWASs, including SLE 
(Figure 1-9) [108], inflammatory bowel disease (IBD) [109], Stevens-Johnson syndrome (SJS) 
[110] and Type I diabetes [111], show that the IKZF1 has been implicated in the susceptibility to 
autoimmune diseases, indicating the crucial role of IKZF1 regulation in the maintenance of self-
tolerance. 
Another two members from the Ikaros family, namely IKZF2 and IKZF3, are shown to be 
associated at a genome-wide level of significance within the meta-analysis in the largest 
European GWAS study as well (Figure 1-9) [43].  Helios, encoded by IKZF2, is a highly conserved 
transcription factor expressed in early hematopoietic progenitors of the bone marrow and a high 
level in thymus-derived regulatory T cells (Treg) [112]. Chromatin-immunoprecipitation (ChIP) 
experiments indicated that Helios binds to the FoxP3 promoter and knocking-down Helios with 
siRNA oligonucleotides resulted in down-regulation of FoxP3 [113].  Studies by Alexander T et al 
found that Foxp3(+) Helios(+) Treg, unlike Foxp3(+) Helios(-) Treg, were significantly increased 
in SLE patients and expanded in active SLE, suggesting the functional suppressive capacity of 
Helios in Treg  [114].   
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Aiolos, encoded by IKZF3, expresses its highest level in mature peripheral B cells and plays a 
key role in B-cell differentiation and malignancies [102, 115].  It has also been reported to control 
T cell death by regulating the expression and localization of Bcl2 [116].  Sun J et al showed that 
Aiolos-deficient mice develop the symptoms of human SLE, indicating that normal Aiolos function 
is necessary in the maintenance of immune homeostasis [117].  Moreover, genetic 
polymorphisms in IKZF3 have been reported to be associated with the risk of multiple immune-
related diseases, not only SLE (Figure 1-8), but also asthma [118], rheumatoid arthritis [119], and 
ankylosing spondylitis [120] . 
 
1.4.3  The TNF superfamily gene TNFSF4/OX40L 
Research over the last decade has shown that one of the most prominent interactions in the 
TNFR/TNF superfamily members is that between TNFRSF4 (OX40L, CD134) and its partner 
TNFSF4 (OX40L, CD252) [121].  They are rapidly emerging as key players in their ability to 
regulate conventional CD4 and CD8 T cells and modulate NKT cell and NK cell function.  The 
primary source of OX40L is likely to be activated antigen presenting cells (APCs), including B 
cells [122], mature conventional dendritic cells (cDCs) [123], Langerhans cells [124], NK cells, 
and macrophages [125].  It is noteworthy that OX40L is not expressed on quiescent APCs, but is 
rapidly up-regulated upon activation.  Of interest, OX40L has also been detected on the surface 
of activated CD4 and CD8 T cells [126].  While the expression of OX40 - the receptor of OX40L, 
is dependent on the activation of the T cell [127]. 
GWAS and family-based studies [128] have underlined the importance of TNFSF4 as a SLE 
susceptibility gene (Figure 1-9), with an increased expression of TNFSF4 transcript in individuals 
carrying the disease risk allele [129].  The increased expression of TNFSF4 may act by 
destabilizing peripheral tolerance through inhibiting the generation of IL-10-producing CD4+ type 
I regulatory T cells [130].  Blocking OX40L has exerted strong reduction in disease activity or a 
complete lack of disease in multiple animal models of inflammatory and autoimmune disease 
[121].  The role of TNFSF4 in the pathogenesis of SLE highlights the importance of the role of the 
T cell-APC interaction in this disease, suggesting this molecule may be an attractive novel 
therapeutic target.  Future studies will be needed to explore the molecular mechanism of OX40L 




Figure 1- 9. LocusZoom plots of SLE GWAS signals of target genes.  
These plots were generated using LocusZoom (http://locuszoom.sph.umich.edu/).  Data are 
taken from the Meta-analysis of Chinese and European SLE GWAS [54]. The GWAS SNP 
(lowest association P-value) at each locus is highlighted.  P-values are from a meta-analysis of 
3 GWAS cohorts (one European GWAS and 2 Chinese GWASs).  Note that the Genome 
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1.5  Genetic risk loadings and kidney involvement in SLE 
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease 
characterized by a wide spectrum of signs and symptoms varying among affected individuals and 
can involve many organs and systems, including the skin, joints, kidneys, lungs, central nervous 
system, and haematopoietic system [1].  Lupus nephritis (LN) is the most common cause of 
morbidity and mortality.  In particular, kidney involvement is one of the most worrisome 
manifestations of SLE.  Patients with kidney disease are likely to have more severe clinical 
outcomes and a shorter lifespan.  30-60% of adults and up to 70% of children with SLE have 
renal disease, characterized by the glomerular deposition of immune complexes and an ensuring 
inflammatory response [131].  Genetic ancestry influences the incidence and prevalence of SLE 
and kidney involvement, being more frequent in Hispanics, Africans and Asians than in 
Caucasians [2, 132-134].   Currently, renal disorder in SLE is classified according to the American 
College of Rheumatology (ACR) renal criteria, i.e., persistent proteinuria and cellular casts (red 
blood cells, granular, tubular, and/or mixed).  However, not all patients will response to the therapy, 
indicating that additional information focused on mechanism of the tissue involvement is required.   
Moreover, the early detection of kidney involvement in SLE is useful because early treatment can 
be applied to reduce the accumulation of renal disability. 
Although the exact aetiology of lupus is not fully understood, a strong genetic link has been 
identified through the application of family [11, 37] and twin studies [10].  SLE does not follow the 
Mendelian patterns of inheritance, and so it is termed a non-Mendelian disease or complex trait.  
Complex traits are multi-factorial with both genetic and environmental contributions.  In addition, 
there is no single locus containing alleles that are sufficient for disease in most cases.  GWAS 
has been successfully used to investigate the genetic basis of a disease by comparing a group 
of patients with a specific disease to a group of healthy controls, which dramatically advanced 
knowledge of the genetic aetiology of SLE.   Our recent review has summarized a total of 84 
genetic loci that are implicated as SLE risk [64].  Despite the advances in the genetics of SLE, it 
is not clear how to utilise genetic information for the prediction of SLE risk or severity in clinical 
practice.  A critical first step is to understand the role of aggregate genetic risk factors, rather than 
associations of individual alleles with SLE.   
A Genetic risk score (GRS) summarizes risk-associated variations across the genome by 
aggregating information from multiple risk SNPs.  There are two basic ways to calculate the GRSs, 
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i.e.  the simplest GRS counts disease-associated alleles and the weighted GRS counts the alleles 
at each SNP weighted by the log Odds Ratio for each SNP.  Because GRSs pool information 
from multiple SNPs, each individual SNP is not so influential on the summary measurement. Thus, 
the GRS is more robust to imperfect linkage for any tag SNP and causal SNP, and less sensitive 
to minor allele frequencies [135-138].  As the number of SNPs included in a GRS grows, the 
distribution of values approaches normality, even when individual risk alleles are relatively 
uncommon. Therefore, a GRS can be an effective means of constructing a genome-wide risk 
measurement that summarises an individual’s genetic predisposition to SLE.  Hence, we 
investigated the usefulness of an aggregate measure of risk of SLE renal disease that is based 




Chapter 2.  Methods 
 
In this chapter, I will summarise all the methods and materials used in this thesis, including the 
samples source for the genome-wide association studies and for the functional experiments, the 
public datasets for the inference of functional context and genes, as well as the software and 
online tools for the data analyses. 
 
2.1 Samples source 
I used two cohorts of unrelated Systemic Lupus Erythematosus (SLE) cases of European descent, 
including the largest SLE GWAS study (SLE main cohort) [43], and the SLEGEN cohort [41] for 
the genome-wide association studies.  The enrolment of these cases has been described in 
previous publications [41, 43]. Clinical sub-phenotypes of all patients were documented according 
to the standard American College of Rheumatology (ACR) classification criteria.  Subgroups of 
patients with kidney involvement, lupus nephritis (LN), or without LN were identified according to 
the ACR criteria recorded by physicians.  To be more specific, patients who had persistent 
proteinuria defined as a spot urine protein/creatinine ratio of >0.5 or greater than 3+ on a urine 
test strip, and/or cellular casts including red blood cells (RBC), hemoglobin, granular, tubular or 
mixed were diagnosed as LN [139].  
For the samples in the functional experiments (Section 2.6 Immuno-phenotyping), ethical 
approval was obtained from the institutional review committee of King’s College London (Study 
Ref: 07/H0718/049).  All SLE patients and healthy controls were given information sheets and 
verbal explanations of what the research entailed.  Informed written consent was obtained from 
all subjects.  
 
2.2 Genome-wide association study (GWAS)  
2.2.1  SLE GWAS 
SLE GWAS was performed in the SLE main cohort in this thesis. The SLE main cohort comprised 
4,036 individuals with SLE (cases) and 6,959 controls, genotyped using either the HumanOmni1-
Quad chip or the Illumina HumanOmni2.5 BeadChip [43].  The final SNP set included 644,674 
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markers that were present on both chips.  Four principal components were used as covariates to 
correct for population structure. For imputation, data were pre-phased using the SHAPEIT 
algorithm [140] and then imputed to the density of the 1000 Genome reference data (phase 3 
integrated set, release 20130502) [74] by my colleagues David Morris and Philip Tombleson (data 
unpublished). All case-control analysis was carried out using the SNPTEST algorithm [141] by 
David Morris.  In this study, SNPs with imputation INFO scores of <0.7 and MAF < 0.001 were 
removed from further analysis.  After quality control (QC), there are 21,431,070 SNPs left for 
further analysis.  A standard threshold of P = 5 × 10−8 was used to report genome-wide 
significance.  More details about the original GWAS can be found in References [43, 54].   
 
2.2.2  SLE Renal GWAS within SLE cases  
Patients with renal disease were considered as more severe than patients without.  Hence, I 
tested genome-wide associations within SLE cases, i.e., associations of patients with renal 
disease (SLE Renal+) and patients without renal disease (SLE Renal-).  The SLE renal GWASs 
were performed in two cohorts mentioned above, i.e., the SLE main cohort and the SLEGEN 
cohort.  Only patients with clinical renal sub-phenotype were included in this section.  Following 
quality control, the sample size of patients with renal disease (SLE Renal+, more severe) were 
1152 and 146 and and patients without renal disease (SLE Renal-, less severe) were 1949 and 
378 in the SLE main cohort and SLEGEN cohort, respectively.    
Following the same procedures of data processing of the original GWASs, only markers with an 
IMPUTE info score ³ 0.7 and MAF ³ 0.001 were included in further analysis.  All case-control 
analysis was carried out using the SNPTEST algorithm [141]. Moreover, genome-wide 
association meta-analysis in the SLE main cohort and SLEGEN cohort was performed using R.  
A standard threshold of P ≤ 5 × 10−8 was used to report genome-wide significance and a P < 1 × 
10−5 was used to report suggestive associated signals.    
All the significant or suggestive SLE/Renal associated loci identified from GWASs were annotated 
by ANNOVAR [142], a software that utilizes up-to-date information to annotate SNPs, such as 
inferring their cytogenetic bands, examining their functional consequences on genes, finding 
variants in conserved regions, or identifying variants reported in dbSNP and the 1000 Genome 
Project.  The required input of ANNOVAR is a list of variants with chromosome, start position, 




2.3 Enrichment of GWAS SNPs in functional epigenomes 
2.3.1  GARFIELD enrichment analysis 
To systematically characterize the cellular and regulatory contribution of genetic variations 
implicated in SLE/Renal disease, I used a non-parametric enrichment analysis approach, 
GARFIELD (GWAS analysis of regulatory or functional information enrichment with LD correction) 
[143].  Briefly, this method takes summary statistics from genome-wide association studies to 
calculate the fold of enrichment, i.e., the enrichment of SLE associated variants in functionally 
annotated regions, at given significance thresholds. The algorithm then tests the statistical 
significance of the observed enrichment via permutation testing while accounting for LD (linkage 
disequilibrium), MAF (minor allele frequency) as well as local gene density.   
 
Epigenome regulatory maps 
The genome-wide functional regulatory data derived from DNase-seq, i.e., DNase I hyper 
sensitive sites (DHS), were obtained from ENCODE and the NIH Roadmap Epigenomes [94, 96], 
which are available in almost all cell types and tissues, providing an overview of the enrichment 
pattern of the SLE/Renal disease associated variants.  DHS data was processed and adapted 
into the GARFIELD package by the software developer [144].  
 
Processing GWAS summary statistics 
To remove possible biases due to linkage equilibrium (LD) between variants, the correlation 
between two SNPs within a 1MB window is calculated and is considered as independent if a r2 ≤0.1.  The genetic linkage map for the European population was computed from the UK10K 
sequence data on 3,621 samples from two population cohorts (TwinsUK and ALSPAC) [145] and 
embedded as part of the GARFIELD package.  Next, from the genome wide variants for each 
phenotype (SLE or Renal disease), the algorithm pruned the SNPs by sequentially removing 
variants with r2>0.1 and within 1MB window from the most significantly trait-associated variant, 
and created an independent set of SNPs while retaining the most significant SNPs for each region.  
Then each independent SNP is annotated and considered as overlapping with a functional 
element (i.e. DHS) if the SNP itself resides in the according genomic region or at least one of its 
proxies (within 500kb) in LD with it (r2>=0.8) does.  
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Calculating fold of enrichment  
To see the enrichment of GWAS signals within DHS, I used GARFIELD to calculate the fold of 
enrichment (FE) as the proportion of the SNPs that fall in DHS as well as have a P-value less 
than threshold T, divided by the fraction of total number of SNPs within DHS.  Specifically,   
Fold of Enrichment(t) =  
"#$ "$"# "  
where N is the total number of pruned SNPs, %& is the total number of SNPs that fall in DHS 
regions, %'  is the total number of variants with P value less than threshold t, %&'  denotes the 
number of SNPs with P value less than t and fall within DHS.  That is, the denominator (%& %) is 
the proportion you would randomly expect to fall in DHS regions, while the numerator (%&' %') is 
the proportion you observe at a given GWAS p-value threshold.  
   
Permutation testing and multiple testing adjustment.  
To estimate the proportion of times a random selection of SNPs (matching SNPs according to 
MAF, distance to nearest TSS and number of LD proxies) would have a higher fold of enrichment 
than observed, permutation testing was applied.  I used 10,000 permutations to obtain P-values 
for fold of enrichment in this thesis.  Bonferroni adjustment was applied to account for the multiple-
testing burden, which is the effective number (424) of annotations (Supplementary Table 2-1) 
used for enrichment analysis.  The overall procedures of GARFIELD are summarised in Figure 
2-1.   
In this thesis, fold of enrichment of the SLE GWAS was calculated at eight genome-wide 
significance thresholds (T) (1 × 10–8 to 1 × 10−1) in DHS hotspots of all the tissues and for each 
set tested their enrichment significance at the four most stringent levels (1 × 10–8 to 1 × 10−5).   
For the SLE renal GWAS, I calculated fold of enrichment of its statistics at six genome-wide 
significance thresholds (T) (1 × 10–6 to 1 × 10−1) in DHS hotspots of all the tissues and for each 
set tested their enrichment significance at the four levels (1 × 10–6 to 1 × 10−3).    
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Figure 2- 1. GARFIELD method flow. 
The ‘Input Data’ panel consists of genome-wide genomic coordinates for a functional annotation 
of interest, a list of LD tags for each variant from a reference population, and a set of genome-
wide summary statistics (every single SNP’s p-value for association with a target trait).  Given 
these inputs, the method performs greedy pruning to reduce the genome-wide variants to an 
independent set using LD and distance information by removing SNPs with r2 >0.1 and within a 
1Mb window of the most significant SNP.  The ‘Statistic’ panel presents the LD tagging annotation 
step, which annotates each SNP with a regulatory feature if either the SNP, or a correlated SNP 
(r2 >0.8), physically overlaps the feature; and the fold enrichment (FE) statistic at different GWAS 
P-value thresholds.  The ‘Null distribution’ panel describes the permutation procedure for 
producing a null distribution for test statistic. Namely, it involves a large number of permutations 
for each annotation while performing ‘feature matching’ on variants by MAF, TSS distance and 
number of LD proxies (r2 >0.8).  Finally, the ‘Test’ panel shows the calculation of empirical 
enrichment P-value. 
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2.3.2  GoShifter – Genomic Annotation Shifter 
Though GARFELD shows a comprehensive overview of which annotations the phenotype 
associated variants are enriched in, specific loci that contribute to the enrichment in particular 
annotations remain unknown.  Therefore, GoShifter [146] is used to explore what phenotype 
associated loci are enriched in the target annotations.   GoShifter is similar in methodology to 
GARFIELD, but takes different data format as input -  a list of target loci / SNPs, which is more 
flexible for specific analyses and returns more informative output.    
Briefly, this algorithm will subset SNPs that are in strong LD (r2 >= 0.8) with the target SNPs 
according to 1000 Genome Phase 3 reference genome of European ancestry [74], and randomly 
shift positions of annotation within each locus whilst fixing positions of SNPs to generate a null 
distribution.  For each annotation (X), it quantifies the observed overlap - the proportion of loci 
where at least one SNP overlaps. Then it calculates the “delta-overlap” parameter to quantify the 
effect size of the observed enrichment – the difference between the observed proportion of loci 
overlapping X and the mean proportion of loci overlapping X under the null.  The larger the delta-
overlap, the stronger of enrichment.  See Figure 2-2 for the schematic of the GoShifter Method. 
In this thesis, I downloaded all significant peaks (FDR ≤ 0.01) of DHS for the target cell types 
from Roadmap Epigenome Project 
(http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/narrowPeak/) and re-
formatted using the 200bp region around the peak summit.  For each cell type, the proportion of 
SLE risk SNPs that overlapped with DHS was calculated by GoShifter.  It randomly shifts the 
peaks whilst retaining the positions of the SNPs and re-calculate the frequency of overlap.  This 
was carried out for 1,000 times (permutations) to draw the null distribution. The P-value was 
calculated as the proportion of iterations for which the number of overlapping loci was equal to or 
greater than that for the tested SNPs (P < 0.05 used as significance cut-off).  Finally, I obtained 
a list of loci that overlap the annotation (informative loci) in the observed data from GoShifter.   
Moreover, an ‘‘overlap score’’ was calculated to prioritize the informative loci.  The overlap score 
is computed only for the loci that overlap the annotation in the observed data. It is the probability 
that each locus overlaps an annotation by chance and defined as ls/n, where ls is the number of 
shifting iterations for which at least one SNP within an individual locus overlaps the annotation, 
and n is the total number of iterations.  Loci with low scores are higher-priority candidates for 
further investigations, as they drive the signiﬁcant enrichment observations. 
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Figure 2- 2. GoShifter method flow. 
 (A) To define the target loci, GoShifter started by searching for SNPs in LD (r2 > 0.8) with the 
index SNP (i.e. GWAS lead SNP) using the 1000 Genome Project reference data set.  (B) To test 
the statistical signiﬁcance of an overlap between trait-associated SNPs (square is the index SNP 
and dot is the SNP in strong LD with the index SNP) and an annotation X (showed in black/yellow 
lines, of which yellow lines represent the overlapping of target SNP and annotation X).  GoShifter 
first randomly shifted X sites within each locus and quantiﬁed the proportion of SNPs overlapping 
X (shaded boxes). Then it generated a null distribution from these proportions by repeating the 
shifting process over a large number of iterations.  The significance of the observed overlap was 
estimated by comparing to a null distribution generated by random shifting of X sites (black 
arrows) within each locus.  The P value was computed as the proportion of iterations for which 
the number of overlapping loci was equal to or greater than that for the tested SNPs.  Modified 
from [146]. 
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2.4 eQTL mapping 
2.4.1  Allelic association from SLE GWASs 
SLE associated loci taken forward for eQTL analyses in this chapter are derived from a review 
[64] that summarised all recent SLE GWASs from several ancestries, including European, Asian 
and Amerindian, as well as subsequent meta-analysis and largescale replication studies.  In this 
chapter, I defined the SLE ‘lead GWAS SNP’ at each locus according to their publications, either 
the SNP with the lowest P-value or the SNP with the greatest evidence to be a missense variant.  
I omitted SNPs located within the expanded Major Histocompatibility Complex (MHC) region (chr6: 
29,000,000 – 35,000,000) and non-autosomal regions.  In total, 95 GWAS SNPs, summarised in 
Supplementary Table 2-2, were taken for further eQTL analyses. 
 
2.4.2  eQTL cohorts  
Genome-wide gene expression and genotyping data sets applied in this thesis to eQTL analysis 
are summarized in Table 2-1.  Data sets in ex vivo B cells [73], NK cells (unpublished, from 
Professor Julian Knight’s group) and monocytes (naïve, and stimulated by LPS and IFN) [91] are 
derived from European population.  Data sets in CD4+ T cells and CD14+ monocytes of European 
American (EUR), African American (AFR) and East Asian (EAS) populations are from Towfique 
Raj et al [147].  A Whole blood data set of 2,765 individuals is from the Consortium for the 
Architecture of Gene Expression (CAGE) project, which consisted of data from five cohorts [148].  
A data set with LCL is part of the HapMap 3 Project, which included genotypes and gene 
expression from five populations: African (AFR), American (AMR), East Asian(EAS), European 





Table 2- 1. Cohorts for eQTL analyses 







B cell 280 
Monocyte (Naïve) 432 
Monocyte (LPS2) 261 
Monocyte (LPS24) 322 
Monocyte (IFN) 367 
NK cell (not 
published) 245 








CD4+ T cell 213 
AFR 
Monocyte 112 
CD4+ T cell 112 
EAS 
Monocyte 78 


















v.3, HT12 v.4) 
EUR Whole blood 2765 
a. Abbreviations for all the populations/ancestries are: EUR = European; AFR = African; EAS = 
East Asian; AMR = American; SAS = South Asian. 
b. Monocyte (LPS2): gene expression levels were detected after exposing primary monocytes 
to lipopolysaccharide (LPS) for 2 hours of LPS stimulated.  Similarly, LPS24 referred to 24 
hours of LPS stimulation.  Monocyte (IFN): gene expression level was detected after primary 
monocytes were exposed to interferon-γ (IFN) for 24 hours. 
 
 
2.4.3  MatrixEQTL 
All eQTL analyses assumed an additive model and were performed using linear regression, as 
implemented in the R package, MatrixEQTL [150].  Cis associations were limited to the variants 
and probes that are less than 1Mb apart (i.e. a 2Mb window centred on a target position), while 
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trans associations were tested for all SNP-probes elsewhere.  For both cis and trans analyses, I 
defined a False Discovery Rate (FDR) of 0.01 by including tests across all loci for genes within a 
1Mb window, as calculated by MatrixEQTL, which supports separate p-value thresholds and 
FDR calculation for cis- and trans-eQTLs.  Figure 2-3 shows the general work flow of MatrixEQTL 




Figure 2- 3. General work flow of MatrixEQTL.   
Genotyping data of SLE associated SNPs and gene expression data from data sets shown in 
Table 3-1 are extracted and formatted as input file for R package MatrixEQTL.  SNP-gene pairs 
with a FDR ≤ 0.01 were exported for further analyses. 
 
 
2.4.4  Co-localization analysis – Regulatory Trait Concordance (RTC) score 
Interrogating the GWAS SNPs for significant association with gene expression has been widely 
employed to explain GWAS results [151, 152].  However, the ubiquity of regulatory variation 
throughout the human genome [153] makes it very likely that the overlaps between the eQTLs 
and the complex trait loci are coincidental.  This is due to the linkage disequilibrium (LD) of the 
genome, which makes functionally uncorrelated variants statistically correlated.  This will become 
particularly problematic as statistical power increase in eQTL with the growing sample size of the 
study cohort, as well as the availability of summary eQTL results from the public data browser 
[75, 76].  In these cases, many observed eQTL and GWAS associations are likely to be driven by 
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two independent causal variants.  Therefore, overlaps between eQTL and GWAS loci will need 
to be evaluated in the context of the genome’s correlation structure.  
In this thesis, an empirical methodology (regulatory trait concordance – RTC) developed by Nica 
et al [77] is implemented.  I calculated the RTC scores [77] for all eSNP-eGene pairs with FDR 
 0.01 to test whether observed associations between SNPs and expression levels of local 
genes were due to chance.  This score is generated by testing the null hypothesis that the GWAS-
associated SNP and the best eSNP (within an interval between two recombination hotspots) are 
tagging two separate effects and the observed eQTL is purely due to the LD between the GWAS-
associated SNP and the 'true' eSNP, that is, to distinguish the accidental co-localisations from 
the true sharing of causal variant.  The process of calculating the RTC score for each eSNP-
eGene pair is as demonstrated in Figure 2-4. 
Firstly, genotypes for SNPs locating in between a recombination hotspot [154] for a target region 
as well as expression data of the target eGenes are subset from available data sets. Then I 
perform a linear regression on gene expression against genotypes and obtain the residuals from 
regression, as well as the Top eSNP.  Following a second round of linear regression of residuals 
against the best eSNP, I rank all the SNPs in the interval and calculate the RTC using the following 
formula:  
)*+ = 	./01/ − 	)304563/	/01	./01/  
Where ./01/ is the total number of tested SNPs in between the recombination hotspot region; )304563/	/01 is the rank of the lead GWAS SNP according to the P-value from the second round 
of linear regression, i.e., )304563/	/01	= 0 if the GWAS SNP is the same as the eSNP, that is, the 
GWAS SNP has the largest impact on the eGene.  Given this, the RTC score will always be in 
the range of 0 < RTC ≤ 1, with values close to 1 indicating the co-localisation of the GWAS effect 
and the eQTL effect.  In this thesis, I used a cut-off of RTC ≥ 0.95 as significant co-localisation of 
these two traits for causality inference.  As RTC scores have a uniform distribution, setting an 
RTC threshold of 0.95 sets the type I error rate to be 0.05.  We suggest that the gene expression 
analyses provide some support for likely causal genes, but we note that proof of true causality 




Figure 2- 4. General procedures of calculating RTC scores.  
1Hot Spot Regions refer to regions in a genome that exhibit elevated rates of recombination relative to a 
neutral expectation [154].  2 eGene refers to a gene whose expression level is correlated with genomic 
variants.  3eSNP refers to a SNP that is correlated with the expression of one or more genes. 
 
 
2.5 Genetic risk loadings 
2.5.1 GRS calculation  
Genetic risk scores (GRS) were calculated using R according to the method described by Hughes 
et al [155], taking the number of risk alleles (i.e., 0, 1 or 2) for a given SNP and multiplying it by 
its corresponding β coefficient, i.e. the natural log of its odds ratio (OR).  The cumulative risk 
score in each subject was calculated by summing the risk scores from the loci summarized in the 
recent review [64] for calculating the cumulative genetic risk score: 
Genetic	risk	score = 	 ABCBDB  
where n represents the number of SLE risk loci, Gi is the number of risk alleles at a given SNP, 
and CB is indicates the effect size of the risk SNP i. 
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In this study, an overall GRS was created using 78 SLE susceptibility loci (without the X 
chromosome), consisting of 95 SNPs in the non-MHC region and 7 independent SNPs in the 
MHC region (defined as chr6: 29,000,000 – 35,000,000).  The allele information (i.e., risk allele, 
MAF and OR) for the 95 non-MHC SNPs are summarized from the published SLE GWAS [64], 
while for the MHC region, the allele information were derived from the SLE main cohort [43] by 
step-wise conditional analysis, see Table 2-2.  Each GRS for both SLE cohorts [41, 43, 46] was 
generated by weighting each risk allele using the effect size reported by their corresponding 
studies as shown in Supplementary Table 2-2 and Table 2-2.  Analysis was carried out using R 
3.3.2 (https://www.r-project.org/).   
 
Table 2- 2. Independent SNPs in the MHC region. 
SNP chr pos(hg19) Risk allele Alt allele* OR 
P value in 
SLE main 
cohort 
rs115032094 6 31340001 G A 1.70 6.50E-08 
rs146903072 6 31847180 G A 2.49 5.00E-14 
rs2596504 6 31319029 T C 1.97 3.68E-75 
rs3134978 6 32651477 T A 2.32 5.34E-99 
rs389884 6 31940897 G A 2.54 2.70E-102 
rs9270782 6 32569119 G A 1.22 6.48E-11 
rs9271636 6 32592119 G C 1.24 9.43E-11 
*Alt allele: the alterative allele of SNP. 
 
2.5.2 GRS categories 
Since a continuous score is difficult to interpret on an individual level when a physician needs to 
explain the results of the GRS to a patient, we partitioned SLE patients into different categories 
of renal risk.   These categories were created from the mean and SD from the control samples 
(SLE renal-) that were specific to each population.  The seven groups were defined as 0.25, 0.75 
and 1.25 SD from the mean; the extreme groups were less than 1.25 or greater than 1.25 SD 
from the mean.  To be more detailed, the ranges for the seven groups are defined as: (-, mean 
- 1.25SD), (mean - 1.25SD, mean  0.75SD), (mean  0.75SD, mean - 0.25SD), (mean - 
0.25SD, mean + 0.25SD), (mean + 0.25SD, mean + 0.75SD), (mean + 0.75SD, mean + 1.25SD), 
(mean + 1.25SD, +).  The division of our score into seven groups provided a robust distribution 
that enabled us to break down the groups with the highest and lowest risk but still ensure that 
there were statistically sufficient numbers of individuals with renal disease and without in the 
 62 
extreme categories.  To avoid exaggerating the odds ratio associated with a specified subject 
group, I used the largest subset of individuals that contained the mean of SLE patients without 
renal disease as the reference group [136].  These individuals can be regarded as those with the 
mean risk of the assessed population of SLE cases.  Within each dataset, I used a chi-square 
test to study the association of allGRS with renal disease and compared each group of allGRS 
with the reference group 4.  The chi-square test for trend was used to calculate p-values for trend.  
We also calculated the odds ratios of renal disease comparing the individuals in the highest 
allGRS group (G7) with those in the lowest allGRS group (G1). 
 
2.5.3 Receiver Operator Characteristic (ROC) curves for model evaluation 
To determine how well the allGRS discriminates cases (SLE renal+) and controls (SLE renal-), I 
generated receiver operator characteristic (ROC) curves by plotting the sensitivity for the 
continuous allGRS score against ‘1- specificity’ and calculating the area under the ROC curve 
(AUC) for each cohort.  To assess the degree to which the age of SLE onset contributes to the 
prediction, I plotted ROC curves for allGRS that excluded and included the age of disease onset.  
The AUC was compared by use of a non-parametric approach, as described by De Long and 
colleagues [156].  When available, additional covariates were considered: in the SLE main cohort, 
sex and four principle components from its SLE GWAS were added to the model; and in the 
SLEGEN cohort, all the participants are women, thus only the three principle components from 
the original GWAS were added to the model. 
 
 
2.6 Immuno-phenotyping by Flow Cytometry 
2.6.1  PBMC isolation 
This work is approved by the institutional review committee of King’s College London (Study Ref: 
07/H0718/049).  20 patients with SLE were recruited from Kidney Clinics of Guy’s Hospital, King’s 
College London.  The diagnosis of SLE was established according to the 1982 revised American 
College of Rheumatology criteria.  Disease activity was evaluated with the SLE disease activity 
index score (SLEDAI) [157] by experienced clinicians.  Clinical characteristics of patients with 
SLE are summarised in Table 2-3.  22 healthy individuals matched for gender and age were 
recruited as controls.  All the blood samples are collected after obtaining informed consent. 
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Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized peripheral venous 
blood by using Histopaque gradients (Sigma, #H8889) and Leucosep™ Centrifuge Tubes (VWR, 
#227290).  PBMCs were washed twice using phosphate-buffered saline (PBS) (Life Technologies, 
#14190169) with 2% Bovine Serum Albumin Powder (BSA) (SLS, #A3912) and re-suspended in 
PBS.   
 
Table 2- 3. Clinical characteristics of SLE patients. 
 
 Notes: Sex: 1=[male], 2=[female]; Others: 1=[YES], 2=[NO]; na: not available. SLEDAI was recorded at the 
time of sample collection while other clinical information was extracted from historical databases. 
 
 
2.6.2  Flow cytometry for Immuno-phenotyping 
The experiment was designed to measure the protein level of OX40L, IKZF1, IKZF2, and IKZF3 
across various cell types simultaneously.  As showed in Table 2-4, each sample of PBMCs was 
divided into 16 proportions and stained with the appropriate antibody-fluorescence conjugates 
both on the surface and inside the cells.  PBMCs were stained using the best concentration of 
each antibody obtained by gradient titration, summarized in Table 2-5.   
The detailed protocol of PBMC surface staining to determine the immune sub-populations is 
showed in Appendix C.  After staining, PBMCs were washed and re-suspended in staining buffer 
(BD Horizon™, #563794), and fixed in fixative buffer (BD Cytofix™, #554655).  Intracellular 
staining of IKZF1, IKZF2, and IKZF3 or isotype control were performed according to the 
manufacturer’s protocol.  The stained cells were analysed within 24 hours in a BD Fortessa 
System (BD Biosciences, San Jose, CA), followed by analysis using FlowJo software (Tree Star, 
San Carlos, CA). Figure 2-5 outlines the work flow of this experiment. The gating strategies for 
Patient AgeOnset SLEDAI SEX Malar Photosensitive Oral	ulcers Arthritis Serotosis Renal Anti-dsDNA C3_low C4_low
P1 27 4 2 2 2 2 1 2 na na na na
P4 32 na 1 1 1 1 1 2 1 1 2 2
P6 39 na 2 1 1 1 2 2 na na na na
P7 31 12 2 1 1 1 2 2 2 na na na
P8 38 6 2 1 2 2 1 2 2 na na na
P10 na 2 2 2 2 1 2 na na na na na
P11 23 10 2 1 1 1 1 1 1 na na na
P13 na 8 2 na na na na na na na na na
P14 40 4 2 1 1 2 1 na na na na na
P15 na 2 2 2 2 1 1 na na na na na
P16 23 8 2 1 1 2 1 2 1 1 1 1
P17 25 4 2 2 1 1 1 1 2 1 2 2
P18 25 6 2 2 2 1 1 1 2 2 2 2
P19 39 na 2 1 1 2 1 2 2 2 2 2
P20 26 4 2 2 2 2 1 2 2 2 2 2
P21 21 2 2 na na na na na na na na na
P22 na na 1 1 2 1 1 1 na na na na
P23 16 2 2 1 1 1 1 2 2 1 1 1
P24 13 8 2 1 2 2 2 2 1 na na na
P26 na na 2 na na na na na na na na na
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the immune subsets in this experiment mainly follow the standardized Human 
Immunophenotyping Consortium (HIPC) phenotyping panel [100] outlined in Figure 2-6, with 
minor adjustments.  
For the data presentation and statistical analysis, I used R (http://www.r-project.org/) and 
GraphPad Prism 7 (http://www.graphpad.com/).  Generally, quantitative data were expressed as 
the mean with the 95% confidence interval (95% CI).  Statistical significance was determined by 
analysis of variance or Student’s t-test. Correlation tests were determined by Spearman rank 
correlation or Pearson correlation when appropriate.  All tests were followed by adjusting for 
multiple comparisons using Benjamini & Hochberg (1995), also known as the FDR (false 
discovery rate) [158].  A FDR (q-value) ≤ 0.05 was considered as statistically significant.   
 
Note: For the FACS experiment, I worked closely with my colleague Mr. Christopher 
Pinder at the beginning (October 2014 ~ November 2014).  Mr. Pinder designed the 
experiment and showed me how to perform the experiments.  I then took over this project 
after he left for a new job in Imperial College London (November 2014 ~ now). 
 
Table 2- 4. Experimental design for measuring the protein expression of IKZF1-3 and OX40L. 
Panels IKZF IC IKZF1 IKZF2 IKZF3 
Panel 1 Isotype control FITC OX40L PE 
IKZF1 FITC    
Isotype control PE 
IKZF2 FITC   
OX40L PE 
IKZF3 FITC   
OX40L PE 
Panel 2 Isotype control FITC OX40L PE 
IKZF1 FITC    
Isotype control PE 
IKZF2 FITC   
OX40L PE 
IKZF3 FITC   
OX40L PE 
Panel 3 Isotype control FITC OX40L PE 
IKZF1 FITC    
Isotype control PE 
IKZF2 FITC   
OX40L PE 
IKZF3 FITC   
OX40L PE 
Panel 4 Isotype control FITC OX40L PE 
IKZF1 FITC    
Isotype control PE 
IKZF2 FITC   
OX40L PE 
IKZF3 FITC   
OX40L PE 
Note that due to the markers availability and the multi-colour limitation of the flow machine, IKZF1/2/3 were 
all stained with secondary fluorescence, i.e., Anti-IKZF1 IgG + IgG FITC.   It will then generate 4 samples 
for each panel including the isotype control.  The OX40L was stained on the surface with anti-OX40L PE, 
and the PE isotype control were adding to the samples other than the ones with FITC isotype control.   
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Table 2- 5. Summary of full panels’ fluorescent antibody conjugates. 
 
a. Brightness: The Fluorophore Brightness Index Score is a relative indication of fluorescence intensity above 
the background for each fluorophore antibody conjugation (1=dim, 5=brightest). NA, not available. 
  
Panel Marker Fluorophore Brightness a Provider Catalogue
Best Concentration 
(µL in 50 µL master 
mix)
IKZF1 NA NA R&D Systems CBGA0212111 1.0
IKZF2 NA NA Santa Cruz Biotechnology sc-9864 1.0
IKZF3 NA NA Santa Cruz Biotechnology sc-160013 1.0
Normal Goat IgG 
Isotype control NA NA Santa Cruz Biotechnology sc-2028 0.5
IKZF Secondary Alexa Fluor 488 3 BD Biosciences 557721 0.5
OX40L PE 5 Cambridge Biosciences 326308 5.0
Mouse IgG1 
Isotype control PE 5 Cambridge Biosciences 400114 5.0
Viability Dye Live/Dead Blue NA Life Technologies L-23105 1.0
CCR7 Brilliant Violet 421 5 BD Biosciences 562555 5.0
CD4 PE/Texas Red 4 Life Technologies MHCD0417 4.0
CD45RA Brilliant Violet 785 3 Cambridge Biosciences 304140 4.0
CD38 APC 5 Cambridge Biosciences 356606 2.0
CD8 Alexa Fluor 700 2 Cambridge Biosciences 300920 4.0
CD3 APC/Cy7 2 Cambridge Biosciences 300318 4.0
HLA-DR PerCP/Cy5.5 3 Cambridge Biosciences 307630 4.0
CXCR3 Brilliant Violet 605 5 Cambridge Biosciences 353728 5.0
CCR6 PE/Cy7 4 Cambridge Biosciences 353418 2.0
CD25 Brilliant Violet 605 5 Cambridge Biosciences 302632 20.0
CD4 PE/Texas Red 4 Life Technologies MHCD0417 4.0
CCR4 APC 5 Cambridge Biosciences 359408 1.0
CD127 PE/Cy7 4 Cambridge Biosciences 351320 8.0
CD45RO Brilliant Violet 785 3 Cambridge Biosciences 304234 8.0
CD3 APC/Cy7 2 Cambridge Biosciences 300318 4.0
HLA-DR PerCP/Cy5.5 3 Cambridge Biosciences 307630 4.0
CD24 PerCP/Cy5.5 3 Cambridge Biosciences 311116 12.0
CD19 Brilliant Violet 421 5 Cambridge Biosciences 302234 4.0
CD27 Brilliant Violet 785 3 Cambridge Biosciences 302832 8.0
CD38 APC 5 Cambridge Biosciences 356606 2.0
CD20 PE/Cy7 4 Cambridge Biosciences 302312 4.0
CD3 APC/Cy7 2 Cambridge Biosciences 300318 4.0
CD138 Alexa Fluor 700 2 Cambridge Biosciences 356512 20.0
IgD Brilliant Violet 605 5 BD Biosciences 563313 20.0
CD56 Brilliant Violet 605 5 Cambridge Biosciences 318334 8.0
CD123 APC 5 Cambridge Biosciences 306012 4.0
CD11c PE/CF594 4 BD Biosciences 562393 4.0
CD16 Brilliant Violet 785 3 Cambridge Biosciences 302045 4.0
CD3 APC/Cy7 2 Cambridge Biosciences 300318 4.0
CD19 Brilliant Violet 421 5 Cambridge Biosciences 302234 4.0
CD20 PE/Cy7 4 Cambridge Biosciences 302312 4.0
CD14 Alexa Fluor 700 2 Cambridge Biosciences 301822 4.0
HLA-DR PerCP/Cy5.5 3 Cambridge Biosciences 307630 4.0
All
Panel 1 (T-cells)
Panel 2 (Treg 
Cells)
Panel 3 (B-cells)





Figure 2- 5. Work flow of flow cytometry. 
Draw blood from volunteers (SLE patients and healthy controls) and separate PBMC using a 
Histopaque.  Stain cells with fluorescent antibody conjugates, including surface staining for cell 
markers and OX40L, as well as intracellular staining for IKZF family and their corresponding 
secondary antibodies.  After the staining, setup the instrument (BD LSRFORTESSA) to acquire 
and record events. Perform primary data analysis using FlowJo_V10 (http://www.flowjo.com/) 
to gate the target populations and export the numerical data, comprising cell counts of all the 
subpopulations being analysed and the protein expression level of IKZF1, IZKF2, IKZF3 and 
OX40L on these populations. Statistical analysis and data presentation are carried out by R 




Figure 2- 6. Identification of immune cell subsets by eight-colour antibody staining. 
The figure shows the cell populations that can be identified using the markers targeted by each 
of the five antibody cocktails of the Human Immunophenotyping Consortium (HIPC) 
phenotyping panel shown in TABLE 5-2. CCR, CC-chemokine receptor; CXCR3, CXC-
chemokine receptor 3; DC, dendritic cell; NK, natural killer; PBMC, peripheral blood 
mononuclear cell; Th, T helper; Treg, regulatory T.  The classification of NK cells were revised 





Chapter 3.  Expression Quantitative Trait Loci (eQTL) 
Mapping and Causality Inference  
 
Chapter summary 
Recent GWASs have identified more than 80 loci underlying susceptibility to SLE.  However, 
85~90% of these loci are located outside of protein-coding genes, suggesting that the mechanism 
underlying their role in disease risk involves changes in gene regulation; they likely exert their 
functional effect through altering gene expression rather than by altering protein structure [62, 
159].  Thus, it is of particular importance to elucidate the actual functions of variants identified as 
associated with disease.  In the post-GWAS era, the greatest challenge is in combining GWAS 
findings with additional molecular data to functionally characterize the relationship between 
genetic variants and complex traits.  It is now possible to investigate the effect of risk variants on 
intermediate molecular levels, for example, gene expression, methylation, protein abundance or 
metabolite levels, due to the advances in a variety of ~omics techniques.  In this Chapter, I will 
focus on studying gene expression (transcription) as an intermediator to illustrate the potential 
links between genotypes and phenotype.    
I performed eQTL (expression Quantitatively Trait Loci) mapping, incorporating co-localization 
analysis of genetic association, in immune cells (i.e., T cells, B cells, Monocytes, NK cells, as well 
as whole blood), in order to identify likely causal genes.  I found that eQTLs present in a diverse 
set of immune cells, encompassing both the innate and adaptive immune responses for almost 
half of the loci.  Through comprehensive eQTL mapping using a variety of available datasets, I 
have identified cell-specific and context-specific eQTLs.  By mapping eQTL across populations 
in LCL, I demonstrated the effectiveness of trans-ethnic eQTL mapping to identify potential causal 
genes.  Furthermore, I have identified trans-eQTLs, providing evidence for further functional 
studies to elucidate the underlying regulatory networks implicated in the pathogenesis of SLE.   
 
3.1  Discovery of SLE candidate-causal eQTLs (eSNPs) and eGenes 
In order to highlight potential causal genes at the susceptibility loci, the 95 SLE risk variants at 77 
loci summarized in my review [64] (Supplementary Table 2-2) were tested for correlation with 
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gene expression in ex vivo in various cell types, including T cells, B cells, natural killer (NK) cells, 
stimulated and resting monocytes, whole blood and LCL (EBV-transformed lymphoblastoid cell 
lines), and across populations in some of the cell types (i.e., CD4+ T cells, CD14+ Monocytes, 
and LCL), comprising cells from Europeans, East Asians, and African Americans.  Details of the 
eQTL cohorts can be found in Chapter 2, Section 2.4.2.  In addition, I calculated RTC scores to 
test if the overlap of eQTL and disease association is coincidental.  A RTC score threshold of 
0.95 was set, which is equivalent to a type 1 error of 0.05.  An example of co-localisation analysis 
of eQTL and GWAS is shown in Figure 3-1.  All significant eQTLs across all available datasets 
where eQTLs were found in at least one cell type or one population are displayed in Figure 3-2 
and Table 3-1.  In total, 49.5% (47/95) of the SLE-associated variants are found to be statistically 
significant eQTLs (eSNPs), which regulated the expression of 96 eGenes.  By significant, I mean 
a FDR ≤ 0.01 and a RTC ≥ 0.95 in at least one of the data sets being tested.   
When classifying the eQTLs by the distance between eSNPs and eGenes, 72% (34/47) of the 
significant eQTLs are cis-eQTLs and 17% (8/47) are trans-eQTLs.  Of note, 11% (5/47) of the 
eQTLs show both cis- and trans- effects, indicating the ‘mediation’ effect on the trans-eGenes by 
the cis-mediators [160].  Trans-eQTLs are of special interest due to their effects on downstream 
genes which are not implicated by GWAS, and thereby potentially have the ability to reveal 
molecular pathways leading to disease [161].  These results, consistent with other studies on the 
genetics of gene expression [162, 163], showed a substantially higher number of genes are 
regulated by cis-eQTL rather than trans-eQTLs.  A reason for this imbalance might be that a 
trans-eQTL is believed to be an indirect association and is beneath the level of detection in most 




Table 3- 1. All Significant eQTLs in SLE. 
eQTLs chr eGenes LCLa whole blood 
T 
cells mono.naive





rs4649203 1 IFNLR1 ns NA 4.80 ns ns ns ns cis 
rs2476601 1 PALM 11.52 ns ns ns ns ns ns trans 
rs1801274 1 FCGR2A ns ns ns ns 4.512 ns ns cis 
rs1801274 1 FCGR2B ns ns ns -4.96 ns ns ns cis 
rs17849502 1 WNT2 7.52 NA ns NA NA NA NA trans 
rs17849502 1 LMO3 6.98 NA ns NA NA NA NA trans 
rs17849502 1 IGFBP3 7.52 NA ns NA NA NA NA trans 
rs2297550 1 IKBKE ns ns -5.59 5.69 5.319 ns ns cis 
rs3024505 1 IL10 ns ns ns ns 4.279 ns ns cis 
rs13385731 2 VIL1 -6.72 NA ns ns ns ns ns trans 
rs13385731 2 LGALS2 -6.96 NA ns ns ns ns ns trans 
rs13385731 2 RASGRP3 ns NA ns ns ns ns ns cis 
rs13385731 2 FAM98A ns NA ns ns -7.789 ns ns cis 
rs2111485 2 IFIH1 ns ns ns ns -5.762 ns ns cis 
rs6445972 3 PXK ns ns 6.39 ns ns ns ns cis 
rs6445972 3 ABHD6 ns ns ns -8.06 -7.434 ns 7.99 cis 
rs1132200 3 DAZL -5.89 ns ns ns ns ns ns trans 
rs564799 3 IL12A ns ns ns ns ns 6.02 ns cis 
rs4690229 4 DGKQ 4.73 44.447 4.66 28.55 26.575 24.13 ns cis 
rs4690229 4 IDUA ns 13.050 ns ns ns ns ns cis 
rs4690229 4 UVSSA ns 5.278 ns ns ns ns ns cis 
rs4690229 4 CTBP1 ns -4.429 ns ns ns ns ns cis 
rs340630 4 TM4SF19 5.88 ns ns ns ns ns ns trans 
rs7708392 5 SLC36A1 ns 4.883 ns ns ns ns ns cis 
rs7708392 5 ANXA6 ns -6.778 ns ns ns ns ns cis 
rs36014129 6 HAND1 6.63 NA ns ns ns ns ns trans 
rs36014129 6 ITGAM 5.97 NA ns ns ns ns ns trans 
rs36014129 6 TLR4 5.76 NA ns ns ns ns ns trans 
rs36014129 6 GJB6 6.30 NA ns ns ns ns ns trans 
rs36014129 6 TRIM36 5.90 NA ns ns ns ns ns trans 
rs36014129 6 BTN3A2 -5.73 NA -11.76 ns ns ns ns cis 
rs36014129 6 BTN2A2 ns NA 4.88 ns ns 4.14 ns cis 
rs36014129 6 HIST1H4L ns NA -8.75 ns ns ns ns cis 
rs36014129 6 HMGN4 ns NA ns ns 4.788 ns ns cis 
rs36014129 6 BTN2A1 ns NA ns ns -4.336 ns ns cis 
rs2327832 6 LCN8 13.85 ns ns ns ns ns ns trans 
rs2327832 6 PERP ns -3.619 ns ns ns ns ns cis 
rs4917014 7 RSAD2 ns 5.728 ns ns ns ns ns trans 
rs4917014 7 IFI6 ns 6.295 ns ns ns ns ns trans 
rs4917014 7 IFI44 ns 5.887 ns ns ns ns ns trans 
rs73135369 7 CLEC4C 5.67 NA ns NA NA NA NA trans 
rs1167796 7 PMS2P3 ns -5.303 ns ns ns ns ns cis 
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eQTLs chr eGenes LCLa whole blood 
T 
cells mono.naive





rs4728142 7 TNPO3 ns ns -4.20 ns ns ns ns cis 
rs2070197 7 RNF126P1 8.28 ns ns ns ns ns ns trans 
rs2980512 8 NEIL2 ns 7.704 ns ns ns ns ns cis 
rs2980512 8 FDFT1 ns 11.412 ns ns ns ns ns cis 
rs2980512 8 MFHAS1 ns ns ns ns -5.890 -6.76 ns cis 
rs2980512 8 PRAG1 ns ns ns ns 7.418 ns ns cis 
rs2736340 8 FAM167A 9.76 24.193 ns ns ns 23.59 ns cis 
rs2736340 8 BLK -6.59 -14.310 ns ns ns -13.80 ns cis 
rs2736340 8 MTMR9 ns ns ns ns -3.811 ns ns cis 
rs7829816 8 BEX2 ns 5.316 ns ns ns ns ns trans 
rs1966115 8 ZC2HC1A -8.95 ns ns ns -24.242 -25.35 -4.70 cis 
rs877819 10 WDFY4 ns ns ns ns ns ns ns cis 
rs4917385 10 USMG5 -9.40 -62.957 ns ns ns ns ns cis 
rs4917385 10 C10ORF32 ns ns ns ns ns ns ns cis 
rs4917385 10 IFNLR1 ns -4.209 ns ns ns ns ns cis 
rs12802200 11 TMEM80 ns ns ns ns ns ns ns cis 
rs12802200 11 DRD4 ns 7.067 ns ns ns ns ns cis 
rs12802200 11 HRAS ns ns ns 9.56 6.686 ns ns cis 
rs494003 11 RNASEH2C ns ns ns ns ns ns ns cis 
rs494003 11 AP5B1 ns 5.048 ns ns ns ns ns cis 
rs494003 11 CTSW ns -9.640 ns ns ns ns ns cis 
rs494003 11 MUS81 ns ns ns ns ns -4.21 ns cis 
rs494003 11 FIBP ns ns ns ns 5.278 ns ns cis 
rs4639966 11 TMEM25 ns 11.549 ns ns ns ns ns cis 
rs4639966 11 CD3D ns -4.731 ns ns ns ns ns cis 
rs4639966 11 IFT46 ns ns ns ns -3.925 ns ns cis 
rs34330 12 APOLD1 ns NA 4.96 ns ns ns ns cis 
rs10774625 12 ACAD10 ns NA ns ns -3.786 ns ns cis 
rs11073328 15 FAM98B ns ns ns ns ns ns -4.90 cis 
rs2289583 15 ULK3 ns 7.112 ns ns ns ns ns cis 
rs2289583 15 C15ORF39 ns ns ns ns 9.012 ns ns cis 
rs2289583 15 FAM219B ns ns ns ns -4.326 ns ns cis 
rs2289583 15 CSK ns ns ns 5.77 ns ns ns cis 
rs9652601 16 SOCS1 ns ns ns ns -7.065 ns ns cis 
rs16972959 16 PRKCB -4.33 ns ns ns ns ns ns cis 
rs7197475 16 PRR14 ns -3.762 ns ns ns ns ns cis 
rs7197475 16 ZNF689 ns ns ns -8.30 -3.832 -4.97 -4.21 cis 
rs7197475 16 MAPK3 ns ns ns -4.67 ns ns ns cis 
rs34572943 16 DPEP3 6.82 ns ns ns ns ns ns trans 
rs34572943 16 ITGAM ns ns ns ns -9.507 ns ns cis 
rs34572943 16 PYCARD ns ns ns ns -5.703 ns ns cis 
rs1170426 16 ZFP90 -4.38 ns ns ns ns ns ns cis 
rs2280381 16 IRF8 ns ns ns -4.86 ns ns ns cis 
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T 
cells mono.naive





rs2286672 17 RNF167 ns NA ns ns 3.922 ns 5.27 cis 
rs2941509 17 ZPBP2 5.18 ns ns NA NA NA NA cis 
rs2941509 17 IKZF3 ns 8.120 ns NA NA NA NA cis 
rs3093030 19 INPP4A 5.84 NA ns ns ns ns ns trans 
rs3093030 19 ICAM1 ns NA ns ns -5.023 ns ns cis 
rs3093030 19 ICAM4 ns NA ns -10.34 -5.502 ns ns cis 
rs3093030 19 ILF3-AS1 ns NA ns ns 3.627 ns ns cis 
rs2304256 19 TYK2 ns -7.009 ns ns ns ns ns cis 
rs2304256 19 TMED1 ns 4.313 ns ns ns ns ns cis 
rs2305772 19 ZNF175 -4.18 ns ns ns -4.787 ns ns cis 
rs7444 22 UBE2L3 7.41 26.325 ns ns ns ns ns cis 
rs61616683 22 SYNGR1 9.16 18.660 ns ns ns 7.93 15.59 cis 
Number in the cell is the t-statistics from the eQTL analysis with the effect direction based on the 
SLE risk allele.  a. t-statistics in the LCL column shows the summary results from all populations 
as described in Table 2-1.  b. t-statistics in the ‘mono.naive’ column shows the summary results 
of naïve monocytes from Fairfax et al and Raj et al’s datasets.  c. t-statistics in the ‘mono.stimul’ 
column shows the summary results of all stimulated monocytes, including LPS2h, LPS24h and 






Figure 3- 1. Overview of co-localisation analysis of GWAS and eQTL. 
This figure shows an example of eQTL analysis and the application of RTC for the causality inference.  Firstly, 
I subset the genes within the cis-window (+/- 1Mb) of the disease-associated locus (rs2736340) and perform 
linear regression against the dosage of the SNP, coded as 0, 1, and 2, counting on the SLE risk allele ( in 
this case, the “T” allele).  Co-localisation analysis of the GWAS signal and the eQTL signal was performed 
by calculating the RTC score (more details in Chapter 2, Section 2.4.4).  SNP-expression pairs with RTC > 





Figure 3- 2. All cis-/trans-eQTLs in SLE.  
The outermost track of the concentric plot shows all the chromosomes clockwise.  Each chromosome arm 
is divided into cytogenetic bands of hg19.  The red block in each chromosome indicates the centromere of 
the chromosome.  The middle layer of the concentric plot shows genes located within the SLE risk loci 
according to their genomic positions.  The lines in the innermost of the plot indicate the significant eQTL-
eGenes across the whole genome.  Blue lines represent cis-eQTLs, while red lines represents trans-eQTLs   .  




3.2  Cell-specific eQTLs 
To investigate the general pattern of eQTLs across different immune cell types, I grouped the 
eQTLs that were identified in primary cells, including T cells, monocytes, B cells, and NK cells to 
gain an overview of the immune cell/cells preferences for the colocalising eQTLs.  Figure 3-3 
shows the SLE risk variants that have significant correlation with the expression levels of eGenes 
in at least one of the immune cell types.  Some of the eQTLs are significantly associated with the 
gene expression general to all cell types, like ZFP90 (Figure 3-4a).  A significant proportion of 
eQTLs have their own bias for particular immune subsets, in which they regulated the target gene 
expression.  For example, IFNLR1 (Interferon Lambda Receptor 1, or IL28RA) is found to be a 
candidate-causal gene specific to T cells (Figure 3-4b).  The IFNLR1/IL10RB dimer is a receptor 
for the cytokine ligands IFNL2 (Interferon Lambda 2) and IFNL3 (Interferon Lambda 3).  The 
ligand/receptor complex stimulates the activation of the JAK/STAT signaling pathway leading to 
the expression of IFN-stimulated genes, which contribute to the antiviral state.  Also, IFNLR1 is 
reported to be associated with Psoriasis [165]. 
The direction of effect of eQTLs, such as SYNGR1 (rs61616683) and DGKQ (rs4690229), are 
consistent across all cell types, with the SLE risk allele associated with increased gene expression.  
While eQTLs of ZFP90 (rs1170426), TNPO3 (rs4728142), and ZC2HC1A (rs1966115) are 
consistent with the SLE risk allele associated with reduced gene expression.  For a minority of 
eQTLs, associations were observed across cell types with opposing direction of effect.   For 
instance, an eSNP (rs6445972), locating in the intronic region of PXK in chromosome 3, is not 
only associated with the increased expression of PXK specific in T cells, but also affected the 
expression level of ABHD6 (a monoacylglycerol lipase involved in the endocannabinoid system), 
which is significantly upregulated in NK cells, while largely down-regulated in monocytes by the 
SLE risk allele (Figure 3-4c).  Another eSNP (rs2297550) is an eQTL for IKBKE (encoding IκB 
kinase epsilon (IKKε)), which potentially plays an important role in SLE through two underlying 
pathways: regulating NF-κB activation, which influences lymphocyte growth and differentiation, 
as well as regulating the type I interferon response, which is described in many SLE studies [166].  
Cis-eQTL analyses show that the SLE risk allele is in association with the up regulation of IKBKE 
expression in monocytes, whereas it leads to a down regulation in B cell and T cell (Figure 3-4d).  
This highlights the molecular basis of gene regulation at different layers of complexity, cell-type 




Figure 3- 3. Heat map of t-statistics for eQTLs in primary immune cells. 
The heat map includes all genes with evidence of cis-regulatory action by SLE-associated SNPs in at least 
one of immune subsets being tested.  The t-statistics was set to zero if the eQTL association is not significant 
(FDR >0.01 or RTC < 0.95) or the data is not available (either because the probe data failed quality control 
or the probe was not present on the experimental platform). For the significant eQTL associations, colours 
represent the t-statistics as follows: blue, t-stat < -20 (the GWAS risk allele reduces expression); green, t-
stat < -10 (the GWAS risk allele reduces expression); light yellow, -10 < t-stat < 10; orange, t-stat > 10 (the 
GWAS risk allele increases expression); red, t-stat > 20 (the GWAS risk allele increases expression).  
Clustering was performed on the cell types and genes. Each row represents one gene, which is shown as 




































































Figure 3- 4. Cell-specific eQTLs. 
Boxplots of eQTLs across various immune cell types.  eQTL of ZFP90 (a) is significant cross 
all four cell types being tested with consistent effect direction.  eQTL of IFNLR1 (b) is specific 
to CD4+ T cells.  eQTL of ABHD6 (c) has diverse effect direction across differen cell types, 
with an increase effect on T cells, B cells, and NK cells, while decrease in monocytes.  eQTL 
of IKBKE (d) also shows different effect directions on immune subsets.  The x-axis indicates 
the genotypes of the corresponding SNP and the y-axis represents the normalized gene 
expression.  Expression data for T cells are from Raj et al [147], and gene expression data of 
all the other immune cells are from Fairfax et al [73]. 
 
 
3.3  Context-specific eQTLs in monocytes 
The effect of a regulatory variant is not only dependent on the cell types as showed above in 
Section 4.2, but also related to the cellular and environmental context relevant to disease.  In 


















































































































































regulation only after pathophysiologically relevant immune stimuli [91].  In order to better 
understand the regulatory role of the SLE susceptibility loci upon triggering of immune response, 
I used gene expression data from naïve and stimulated (IFNγ-treated 24-hour, LPS-treated 2-
hour and LPS-treated 24-hour) monocytes derived from Fairfax et al [91] for eQTL analyses.  
Figure 3-5 shows the overall results of significant eQTLs in at least one condition of monocytes.   
There are some eQTLs showing strong effects on the expression of eGenes generally under all 
kinds of stimulations as well as the naïve state, such as DGKQ (rs4690229) (Figure 3-6a).  There 
are also constitutive eQTLs present in only naïve cells but no longer present after stimulation, 
such as CSK and IRF8.   
Nevertheless, a diverse set of immune-related genes were found to show eQTL only after 
induction with LPS or IFNγ, ranging from PYCARD (rs34572943), IFIH1 (rs2111485), IFT46 
(rs4639966), SIGLEC6 (rs2305772), SOCS1 (rs9652601), to key cytokines such as IL10 
(rs3024505).  For SOCS1, an eQTL was observed after 24-hour LPS stimulation, whereas no 
eQTL effect was apparent for IL10 on induction at either 2 hours or 24 hours of LPS stimulation, 
but was seen an up-regulation after 24-hour IFNγ (Figure 3-6b).  The expression of PYCARD (a 
key mediator in apoptosis and inflammation) was strongly correlated with rs34572943 after 
stimulation only after 24-hour treatment of LPS (Figure 3-6c).  Notably, this eSNP (rs34572943) 
is located in the intronic region of ITGAM (encoding CD11b, part of complement receptor 3; CR3), 
which has been found to be associated with SLE and systemic sclerosis in many studies as a 
result of missense variant [45, 167, 168], suggesting the multiple effects of this locus may be 
involved in SLE.  Of great interest, the risk allele of rs1801274 regulated the expression of multiple 
genes in a context specific manner, which decreased the expression of FCGR2B in naïve 
monocytes (Figure 3-6f), while increased the expression of FCGR2A after 2- or 24-hours LPS 
stimulation (Figure 3-6e).  FCGR2A and FCGR2B are both encoding Fc gamma Receptor II 
(FcγRII), members of immunoglobulin superfamily.  The process of binding FcγR with the Fc 
protein of Immunoglobulin G (IgG) is very important to trigger biological reactions, such as 
phagocytosis [169], indicating the regulatory roles of SLE risk alleles may be subjected to the 
disease status, such as quiescent or progressive [169, 170].  
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Figure 3- 5. Heat map of t-statistics for eQTLs in naïve and stimulated monocytes. 
The heat map includes all genes with evidence of cis-regulatory action by SLE-associated SNPs in at least 
one status of monocytes. Colour represents a t-statistics: a positive score (red and orange) indicates that 
SLE risk allele is positively correlated with gene expression, and a negative score (blue and green) indicated 
that the SLE risk allele is negatively correlated with gene expression.  The t-statistics was set to zero if the 
eQTL association is not significant (FDR >0.01 or RTC < 0.95) or the data is not available (either because 
the probe data failed quality control or the probe was not present on the experimental platform).  Clustering 
was performed on the stimulated conditions and genes. Each row represents one gene, which is shown as 
"eQTL_eGene".  Each column represents one cell type. Stimulated monocytes, either with 
lipopolysaccharide (LPS, 2 hours and 24 hours) or Interferon-γ (IFN, 24 hours).  All the expression data for 



















































































Figure 3- 6. Boxplots of context-specific eQTLs in monocytes. 
Boxplots of eQTLs in monocytes with various stimulations.  The x-axis indicates the genotypes of the 
corresponding SNP and the y-axis represents the normalized gene expression.  eQTL of DGKQ (a) is 
significant cross all four conditions in monocytes.  eQTL of IRF8 (b) is only significant in naïve monocytes.  
Both eQTLs of PYCARD (c) and SOCS1 (d) are only significant after treatment with LPS for 24 hours.  
rs1801274 (e and f) is an eQTL with multiple and context-specific effect. 
 
 
3.4  eQTLs across populations help to infer causal eGenes 
Trans-ethnic meta-analysis of GWASs across multiple populations can increase the power to 
detect disease associated loci if the underlying causal variants are shared between ancestry 
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rs1801274 − FCGR2B
mono_Naive mono_IFN mono_LPS2 mono_LPS24
P−value = 1.04e−06 P−value = 0.0584 P−value = 0.817 P−value = 0.000749
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populations had identified novel loci associated with SLE [54].  Given the promising application 
of trans-ancestry analysis, I used data downloaded from the HapMap 3 project [149] to map the 
underlying causal variants in the SLE risk loci.  By eQTL mapping of LCL across five populations, 
i.e., AFR, AMR, EUR, EAS, and SAS, I have identified significant eQTLs across different 
populations, see Figure 3-7.  Of note, more eQTL-eGene pairs have been found in the African 
population, which is characterized by greater levels of genetic diversity, extensive population 
substructure, and less linkage disequilibrium (LD) among loci compared to non-African 
populations [173].  For example, rs7444 is found to be a significant eQTL for UBE2L3 in AFR and 
EAS, but not in EUR.  For not significant in EUR, I mean the eQTL is significant (FDR ≤ 0.01) but 
with a low RTC (RTC ≤ 0.95).  Moreover, when analysing the rs7444-UBE2L3 gene pair in CD4+ 
T cells and CD14+ monocytes across AFR, ASN and EUR in the ImmVar datasets [147], I found 
a similar pattern (Figure 3-8) to that observed in LCL.  The RTC score is much lower in EUR, as 
there are many more SNPs in strong LD with the GWAS SNP within the region, than in AFR.  I 
conclude that eQTL analyses across various populations helps to identify candidate-causal 






Figure 3- 7. Heat map of t-statistics for eQTLs in LCL across populations. 
The heat map includes all genes with evidence of cis-/trans- regulatory action by SLE-associated SNPs in 
at least one of populations being tested. For the significant eQTL associations, colour represents a t-
statistics: a positive score (red and orange) indicates that SLE risk allele is positively correlated with gene 
expression, and a negative score (blue and green) indicated that the SLE risk allele is negatively correlated 
with gene expression.  The t-statistics was set to zero if the eQTL association is not significant (FDR >0.01 
or RTC < 0.95) or the data is not available (either because the probe data failed quality control or the probe 
was not present on the experimental platform). Clustering was performed on the populations and genes. 
Each row represents one gene, which is shown as "eQTL_eGene".  Each column represents one cell type. 
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Figure 3- 8. Co-localisation analysis populations of eQTL-eGenes. 
LocusZoom plots showed the co-localisation of regional P-values for SLE GWAS of the SLE main cohort 
[43] (top panel) and eQTLs in three populations. Data for eQTL Manhattan plot is derived from Raj et al. 
 
 84 
3.5  eQTLs with multiple effects 
Among the 47 significant eSNPs identified in this study, 21 (45%) have regulatory effects on the 
expression of more than one gene, resulting in a total of 71 eGenes, pointing out that the disease 
associated SNPs may be functionally potent in multiple genes.  For example, rs494003, located 
in the 3’-UTR of AP5B1 on chromosome 11, is significantly correlated with the expression of five 
genes, including AP5B1, RNASEH2C, CTSW, MUS81, and FIBP, with the effect directions varied 
across genes.  Of these genes, RNASEH2C is of particular interest, which encodes a nucleic acid 
repair enzyme - Ribonuclease H2 (RNase H2), in T cells and naïve monocytes.  RNase H2 
degrades RNA/DNA hybrids and removes unwanted ribonucleotides from DNA.  Recent research 
showed that RNase H2 deficiency associated with potentiation of innate immune signalling due 
to UV light irradiation and immune-stimulatory nucleic acid polyinosinic: polycytidylic acid [174].  
The risk variant that I have identified at this locus correlates with reduced expression of 
RNASEH2C transcript.  Taking together, these evidence supports a role of RNASEH2C in SLE 
pathogenesis. 
Independent signals - rs7197475 and rs34572943 that are reported to be associated with SLE 
are located near the ITGAM-ITGAX region in 16p11.2.  Of which, rs7197475 is found to regulate 
the expression of three cis-eGenes - PRR14, ZNF689 and MAPK3, while rs34572943 regulated 
the expression of two cis-eGenes - ITGAM and PYCARD.  Interestingly, MAPK3, encoding 
Mitogen-Activated Protein Kinase 3, is an essential component of the MAP kinase signal 
transduction pathway, whose deficiency are more potent to prime T cell response, thereby 
triggering the autoimmune response [175].  In my eQTL results, the SLE risk allele is correlated 
with declined expression of MAPK3 in monocytes, supporting its role in balancing the immune 
system. Moreover, ITGAM and PYCARD, encoding key components of inflammasomes, are 
specific to LPS late response (Figure 3-5).  These eQTL findings, taken together, provide insights 
for further study in the regulation network involved in this complex region (ITGAM-ITGAX) in terms 
of pathogenesis of multiple autoimmune diseases [38, 167, 176].  Other candidate-causal eQTLs 
with multiple functional effects include: rs1801274 is associated with the expression of both 
FCGR2A and FCGR2B; rs2736340 is associated with the expression of eGenes including 
MTMR9, BLK, FAM167A; and rs4690229 is associated with the expression of DGKQ, IDUA, 
UVSSA, and CTBP1.  Of which, some eGenes could be ‘passengers’ and may be real in terms 
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of genetic effects, yet have no direct bearing on disease risk.  For more multiple eQTLs, see Table 
3-1. 
 
3.6  Identifying SLE associated trans-eQTLs 
Trans-eQTL, whose associations involving distant genes, may reveal gene networks regulated 
by SNPs identified by GWAS and can provide unbiased insights into pathway identity and 
underlying biological processes.  Here I extended my eQTL analyses to include genes distant (> 
1MB) from each of the target 95 SLE GWAS SNPs.  With eQTL cohorts from a variety of 
resources, I was able to detect 13 trans-eQTLs, regulating the expression of 22 eGenes.  Among 
these trans-eSNPs, eight of them presented trans-effects only and five of them showed both cis- 
and trans-effect on multiple genes.  All the trans-eQTLs were identified in the whole blood cohort 
[148] or LCL cohort [149].  No significant trans-eQTLs were found in any of the immune subsets, 
which might be due to a lack of power.  Notably, more than half of the trans-eQTLs were found in 
the African populationassociating with the expression of 12 eGenes.  For instances, an eSNP 
rs13385731, locating at the intronic region of RASGRP3 (chr2), is significantly associated with 
the expression of LAMC2 (chr1) and VIL1 (chr2).  While eSNP (rs73135369, in the intronic of 
GTF2IRD1) is correlated with the expression of eGene - CLEC4C (chr12). 
An eSNP - rs36014129 (6p22.2, near the MHC), not only correlates with the expression of genes 
nearby - SLC17A1, BTN3A2, BTN2A2 and, HIST1H4L, but also genes further away - HAND1 
(chr5), ITGAM (chr16), TLR4 (chr9), GJB6 (chr13), and TRIM36 (chr5).  Of great interest, SLE 
risk SNPs within the ITGAM-ITGAX (16p11.2) region are eSNPs for multiple eGenes, including 
ITGAM, PYCARD, PRR14, ZNF689, and MAPK3, as well as DPEP3 in trans.   Through pathway 
analysis by IPA (Ingenuity Pathway Analysis) software (Version 01-07, QIAGEN Bioinformatics), 
I found that the eGenes regulated by these two SLE risk loci were enriched in the pathways highly 
correlated with the immune functions (Table 3-2), with the top canonical pathway being the 
Inflammasome pathway (P = 3.13E-04).  Moreover, the molecules contributing most to the 
enriched pathways were TLR4, MAPK3, ITGAM, and PYCARD, implying the crucial roles of these 
genes involved in the pathogenesis of SLE.  Moreover, I have identified two trans-eQTLs in whole 
blood.  Notably, one of them - rs4917014, locating near to IKZF1, is found to be a significant eQTL 
and affects the expression of RSAD2 (chr2), IFI6 (chr1), and IFI44 (chr1).  Of which, IFI6, 
encoding Interferon Alpha Inducible Protein 6, plays a critical role in the regulation of apoptosis 
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[177] and is involved in Interferon gamma signalling [178], suggesting its role in the pathogenesis 




Figure 3- 9. Heat map of t-statistics for SLE associated trans-eQTLs. 
The heat map includes all genes with evidence of trans-regulatory action by SLE-associated SNPs in at 
least one of datasets being tested.  The t-statistics is set to zero if the eQTL association is not significant 
(FDR >0.01 or RTC < 0.95) or the data is not available (either because the probe data failed quality control 
or the probe was not present on the experimental platform). For the significant eQTL associations, colours 
represent the t-statistics as follows: blue and green, t-stat < 0 (the GWAS risk allele reduces expression); 
lightyellow, t-stat = 0; orange and red, t-stat > 0 (the GWAS risk allele increases expression.  Clustering was 
performed on the cell types and genes. Each row represents one gene, which is shown as "eQTL_eGene".  
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Table 3- 2. IPA enriched pathways for eGenes regulated by risk regions in 6p22.2 and 
16p11.2	
 
Ingenuity Canonical Pathways Ratio * Molecules P-value ** 
Inflammasome pathway 1.00E-01 TLR4; PYCARD 0.0003162 
MIF-mediated Glucocorticoid Regulation 6.25E-02 TLR4; MAPK3 0.0008128 
MIF Regulation of Innate Immunity 5.00E-02 TLR4; MAPK3 0.0012589 
MSP-RON Signaling Pathway 3.08E-02 TLR4; ITGAM 0.0033113 
TREM1 Signaling 3.08E-02 TLR4; MAPK3 0.0033113 
Neuroinflammation Signaling Pathway 1.10E-02 TLR4; PYCARD; MAPK3 0.0053703 
LPS-stimulated MAPK Signaling 2.35E-02 TLR4; MAPK3 0.0056234 
Phagosome Formation 1.74E-02 TLR4; ITGAM 0.0100000 
PI3K Signaling in B Lymphocytes 1.64E-02 TLR4; MAPK3 0.0112202 
HMGB1 Signaling 1.59E-02 TLR4; MAPK3 0.0120226 
IL-12 Signaling and Production in 
Macrophages 1.59E-02 TLR4; MAPK3 0.0120226 
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 1.59E-02 TLR4; MAPK3 0.0120226 
Gap Junction Signaling 1.18E-02 GJB6; MAPK3 0.0208930 
Dendritic Cell Maturation 1.16E-02 TLR4; MAPK3 0.0213796 
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 1.12E-02 TLR4; MAPK3 0.0229087 
IL-8 Signaling 1.07E-02 ITGAM; MAPK3 0.0251189 
Role of NFAT in Cardiac Hypertrophy 1.03E-02 HAND1; MAPK3 0.0269153 
Integrin Signaling 1.02E-02 ITGAM; MAPK3 0.0275423 
Cardiac Hypertrophy Signaling 9.62E-03 HAND1; MAPK3 0.0309030 
IL-22 Signaling 4.17E-02 MAPK3 0.0316228 
IL-17A Signaling in Gastric Cells 4.00E-02 MAPK3 0.0323594 
Role of JAK family kinases in IL-6-type 
Cytokine Signaling 4.00E-02 MAPK3 0.0323594 
Colorectal Cancer Metastasis Signaling 8.89E-03 TLR4; MAPK3 0.0354813 
4-1BB Signaling in T Lymphocytes 3.12E-02 MAPK3 0.0416869 
Complement System 3.12E-02 ITGAM 0.0416869 
Oncostatin M Signaling 2.94E-02 MAPK3 0.0446684 
IL-17A Signaling in Fibroblasts 2.86E-02 MAPK3 0.0457088 
Thyroid Cancer Signaling 2.70E-02 MAPK3 0.0478630 
Notes: A list of eGenes that are regulated by the eSNPs (SLE GWAS SNPs) in 6p22.2 and 16p11.2 regions 
were used for the pathway enrichment analysis.  Pathways with a p-value ≤ 0.05 were listed.  * Ratio 
indicates the number of target genes overlapped with the pathway divided by the total number of genes in 





3.7  Discussion 
One of the central goals of human genetics is to understand how genetic variation alters the risk 
of human disease and how causal genetic variants inform mechanisms underlying these 
diseases. Most disease-associated variants are localized in non-protein-coding regions 
highlighting transcriptional regulation as a common theme in the mechanism of disease 
predisposition.  In this chapter, I integrated eQTLs and GWASs in order to offer new functional 
information about the aetiology of SLE.   eQTL analyses, along with RTC scores, have illuminated 
the location and impact of regulatory variants to the expression of any given gene, thereby 
extending our understanding of the gene-regulatory architecture.  By integrating the results of 
eQTL and RTC analysis, I found evidence to support the role of a single gene as candidate at a 
given locus.  My results suggested that SOCS1 (Suppressor of Cytokine Signalling 1) was a 
causal gene at the identified SLE associated SNP rs9652601 rather than CLEC16A, even though 
the risk variant resides within the latter one - a gene previously reported relating to other 
autoimmune diseases [179].    
Currently, eQTL analyses such as these have been mostly undertaken in cell lines, predominantly 
EBV-transformed lymphoblastoid cell lines (LCL) [180, 181].  However, my analyses have the 
advantage of including gene expression data from various resources.  I have shown that greater 
biological insight is gained from using gene expression data from immune subsets and monocytes 
with various treatments than using data from LCL only.  By using expression data from immune 
subsets, I have identified cell-specific eQTLs that implied a major function of the genes in 
particular cell types, e.g.  BLK in B cells and in IFNLR1 in T cells.  With eQTL mapping based on 
datasets of monocytes under different challenges (LPS and IFNγ), some regulatory variants 
display context-specific eQTL.  For instances, PYCARD and ITGAM were associated with the 
SLE risk variants only under the stimulation of LPS, while IFIH1 was specific to the challenge of 
IFNγ.  Moreover, as the physiological and environmental context in patients with specific disease 
are of high diversity, I emphasized the importance of studying disease-specific eQTLs to more 





Unlike cis-eQTL, trans-eQTL analysis performs association tests between GWAS SNPs and the 
expression targets in the genome-wide scale, as opposed to those located locally, which is 
recognized to be highly informative but challenging [161, 182].  In terms of information, trans-
eQTL has the potential to point toward novel mechanistic explanations for the GWAS risk loci.  
On the other hand, trans-eQTL analysis is usually subjected to heavy multiple testing burdens 
and requires a large sample size to obtain enough power for the detection of significance.  Thanks 
to the rich resources for the eQTL analyses for my study, I have identified several trans-eQTLs 
in the SLE risk regions.  For instance, rs4917014, an eSNP locating near to IKZF1, is found to 
affect the expression of RSAD2 (chr2), IFI6 (chr1), and IFI44 (chr1), consistent with Westra et al’ 
study [75].  Moreover, eGenes, that are regulated by risk regions at 16p11.2 and 6p22.2, including 
SLC17A3, TLR4, ITGAM, MAPK3 and PYCARD, may reflect novel potential regulatory networks 
predisposing to SLE. However, elucidating the mechanisms underpinning this observation 
requires further functional investigation.  
The trans-ancestral genome-wide association analysis has improved the resolution to identify 
disease risk genes.  Similarly, eQTL mapping across populations has an increasing power to 
detect the candidate-causal genes when incorporating with GWAS results.  An overwhelming 
example is the identification of UBE2L3 as a causal gene implied in SLE.  UBE2L3 has been 
widely studied and identified to implicate in SLE in functional studies [183].  However, analyses 
incorporating eQTL and RTC in a European population failed to recognize UBE2L3 as a causal 
eGene (RTC = 0.6) due to a large LD block surrounding the top GWAS SNP.  By eQTL mapping 
across populations, the ‘true’ causal gene was uncovered within the African population (RTC = 
1), in which, a narrow peak of eQTL signal was revealed (Figure 3-8). 
Although I have identified some intriguing eQTLs which are cell-specific or context-specific in this 
study, I may neglect other mild to modest eQTLs due to the relatively small sample size of the 
available datasets.  Take the Ikaros family of genes as examples, I failed to identify IKZF2 or 
IKZF3 as eGenes with the currently available datasets.  Nevertheless, the expression of 
IKZF1/IKZF2/IKZF3 were all found to be significantly correlated with their corresponding SLE 
GWAS signals in the Framingham Heart Study cohort, a whole blood dataset [85] with a sample 
size of over 5,000.  In addition, with the development of next generation sequencing (NGS) 
technologies, the resolution on measuring gene expression will be largely improved and the 
power to detect eQTLs will be undoubtedly extended.  Studies by my colleague - Odhams et al 
[184, 185] have shown that by profiling RNA-Seq data at multiple resolutions, more eQTLs had 
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been observed particularly at the exon-level.  Though expression data generated from MicroArray 
are a good surrogate for measuring transcript at probe level, using RNA-seq to quantify transcript 
level at multiple resolutions, including gene-, exon-, splice-junction, and isoform, will very likely 
advance our understanding of the implications of the genetic control of gene expression.  
Therefore, I emphasize that large RNA-seq datasets for eQTL studies should be generated 
across trait-associated cell types and under disease conditions. 
In summary, I have identified cell-specific and context-specific eQTLs by analysing data 
generating from a variety of immune subsets and monocytes triggered with different stimulations.  
By mapping eQTL across populations in LCL, I demonstrated the effectiveness of trans-ethnic 
eQTL mapping to identify potential causal genes.  Furthermore, I have identified trans-eQTLs, 
providing evidence for further functional studies to elucidate the underlying regulatory networks 





Chapter 4.  The functional analysis of SLE genetics 
 
Chapter Summary 
SLE is a complex autoimmune disease with a variety of organs and tissues involved, including 
the central nervous system, cutaneous complications, pleural effusion, pericarditis effusion, renal 
and gastrointestinal manifestations.  The range of symptoms of SLE can make the diagnosis 
complicated.  The likelihood of developing SLE has a genetic component and this genetic risk is 
inherited in a polygenic manner, in most cases.  The advent and application of genome-wide 
association studies (GWASs) over the last decade has dramatically advanced understanding of 
the genetics of SLE.  The explained heritability by genome-wide associated variants was reported 
to be 15% in the largest European population in 2015 by our group [43].  This study increased 
the number of SLE associated loci to 48.  In 2016, an Asian [ASN] GWAS [50] and a meta-
analysis between European [EUR] and ASN GWAS [54] were performed, and more novel loci 
were discovered.  Currently there are over 80 genomic loci robustly associated with SLE [64]. 
Genome-wide typed variants in both Chinese and European GWAS explain 28% of the heritability 
of SLE (chip heritability), with the target being between 42% – 66% [11].  Despite considerable 
success in identifying many SLE associated loci, the functional effects of the risk alleles for the 
majority of these loci remain to be defined.  Up to 90% of the risk variants are located outside the 
protein coding regions.  How these variants predispose to the disease and how these variants 
influence the phenotypes of patients remain unknown.   In this section, I explore the functional 
context of SLE associated variants by integrative analysis of epigenomic data from a variety of 
tissues and cell types in the human body.   
Firstly, I reanalysed the SLE associated signals in Europeans using re-imputed data.  Then I 
applied a non-parametric method, GARFIELD [144], along with regulatory epigenomes obtained 
from ENCODE and Roadmap to test whether the SLE associated loci are enriched in DNase 
hypersensitivity sites (DHS) and, if they are enriched, in what cell types/tissues.  I also use another 
algorithm, GoShifter [146], to find out what loci are contributing to the enriched cell type/tissue of 
DHS.  Moreover, by comparing if the SLE risk allele was associated with both gene expression 
and DHS hotspot, I found that 66% of the SLE eQTLs were shown to overlap with DHS hotspots, 
denoting extensive local coordination of genetic influences on gene expression and epigenetics.  
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To my knowledge, this is the first comprehensive study of the regulatory map of SLE risk loci 
across human cells and tissues.  I conclude that the SLE risk loci are primarily enriched in 
regulatory regions within a range of different immune cells and a large proportion of them were 
also shown to regulate to the expression of genes nearby. 
 
4.1 SLE GWAS findings 
My colleagues in my research group have re-imputed the genotyping data derived from the 
Illumina 1M Chip used to genotype 4,036 European SLE patients in the published GWAS [1].   
This re-imputed data, using the latest reference genome (Phase 3) released by the 1000 Genome 
Project [74], generating more than 80 million variants, has not yet been published.  SLE GWAS 
based on the high density imputed genotypes were performed using SNPTEST [141] by colleague 
David Morris.  SNPs with imputation INFO scores of <0.7 and MAF < 0.001 were removed from 
further analysis.  After quality control (QC), there are 21,431,070 SNPs left for further analysis. 
In total, there are 19,604 SNPs that reached genome-wide significance (p-value  5 × 10−8) in 
the association test, which mapped to 63 loci, with the MHC region defined as one extended 
region of 25Mb ~ 35Mb in chromosome 6.  For regions outside the MHC, the distance between 
SNPs inside the same locus is less than 1Mb.  Among the 62 non-MHC loci, 34 loci have more 
than one SNP that passed the genome-wide significance level due to LD, while the remaining 28 
loci have only one genome-wide significant SNP in their corresponding loci.  Table 4-1 shows all 
the loci and their lead GWAS SNPs.  I name these loci according to their positions (i.e. name of 
gene nearby).  Summary GWAS results genome-wide are shown in the Manhattan plot (Figure 
4-1).  Loci that have previously been shown to be significantly associated with SLE can be seen 




Table 4- 1. Summary of SLE risk SNPs for each chromosome. 
 
*: # QCed SNPs denoted the number of SNPs that passed QC criteria - imputation info score ≥ 0.70	and 
minor allele frequency (MAF) ≥ 0.001.  **: # Significant SNPs denoted the number of SLE risk SNPs that 
had a genome-wide significant P-value ≤ 5	×	10MN. 
 
  

























*: QC criteria for all the SNPs: Imputation info score  0.70 and minor allele frequency (MAF)  0.001.
**: Significant SNP denote a SNP that has a P-value  5E-08.
# QCed SNPs *
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Table 4- 2. SLE GWAS summary loci of the SLE main cohort. 
 
 
*balloon, there is only one genome-wide significant SNP in the region.   
LocusGenes topSNP chr pos alleleA alleleB Func.refGene MAF INFO	score OR P	value Notes
KAZN rs4661543 1 15229101 T G intronic 0.12392 1 1.3282549 9.399E-11 balloon*
NFIA-MGC34796 rs12081621 1 61943156 C T intergenic 0.0034561 1 6.5976927 8.716E-13 balloon
PTPN22-RSBN1 rs2476601 1 114377568 A G exonic 0.101273 1 0.7182382 8.382E-13
CFAP126-FCGR2A-HSPA6-
FCGR3A
rs6671847 1 161478810 G A intronic 0.487569 0.994824 1.2219134 3.594E-12
TNFSF4-LOC100506023 rs10912578 1 173251856 A G ncRNA_intronic 0.329585 0.984176 0.784179 2.239E-15
SHCBP1L-LAMC1-NMNAT2-
SMG7-AS1-NCF2-ARPC5
rs17849501 1 183542323 C T exonic 0.0773079 1 2.2427034 1.814E-59
ITGB1BP1 rs4074976 2 9546695 G T UTR3 0.0080946 1 2.8670109 2.714E-11 balloon
SPRED2-MIR4778 rs268124 2 65654364 C T intronic 0.253474 0.992707 1.2116596 7.64E-09
IL37-IL36G-IL1F10 rs13019891 2 113829869 G T intronic 0.399909 1 0.5688474 1.647E-83
LOC101927709-EN1 rs512681 2 119450163 C A intergenic 0.139245 1 0.7424001 8.749E-13 balloon
NEMP2-NAB1-GLS-STAT1-
STAT4
rs141442738 2 191955189 TATA T intronic 0.256394 0.99473 1.756115 1.157E-66
IKZF2 rs10048743 2 213890232 G T intronic 0.138199 1 0.7932888 2.038E-08
KCNE4-SCG2 rs10200680 2 223961877 C T intergenic 0.132924 1 0.7794981 4.963E-09 balloon
ALPPL2-ALPI rs2573219 2 233288667 A C intergenic 0.115098 1 1.8083141 1.133E-42 balloon
SATB1-AS1-KCNH8 rs11928304 3 18998569 A G intergenic 0.0056389 1 32.939416 1.95E-48 balloon
PXK-PDHB-KCTD6 rs11719330 3 58462163 G A intergenic 0.135823 0.87707 0.7615321 2.287E-09
H1FX-AS1-RPL32P3 rs9852014 3 129084581 A G intergenic 0.0940882 1 1.8576625 2.257E-36 balloon
PLSCR5-LINC02010 rs1464446 3 146601295 G T intergenic 0.160709 1 0.7216572 2.792E-16 balloon
IQCJ-SCHIP1-IL12A-AS1-IFT80-
TRIM59-KPNA4
rs80014155 3 159625393 C T intergenic 0.0105516 0.947037 2.7678753 7.383E-13
MIR1269A-LOC101927237 rs17087866 4 67876041 A G intergenic 0.0043656 1 9.4240035 2.591E-22 balloon
PPP3CA-BANK1 rs6532924 4 102239170 T C intronic 0.0048204 1 5.7565596 8.579E-17
FBXL7 rs13170409 5 15764650 A C intronic 0.0028649 1 5.4523134 7.854E-10 balloon
CDH18 rs141208658 5 20469875 T C intronic 0.0025154 0.778681 6.8943346 2.794E-08
ANKRD31 rs183086601 5 74366599 T C intronic 0.0028866 0.83443 9.276E-06 5.784E-11 balloon
VDAC1-TCF7 rs6899047 5 1.33E+08 G C intergenic 0.0535808 0.991903 1.4792364 3.177E-10
PPARGC1B rs1078324 5 1.49E+08 C A intronic 0.0407913 1 0.4859833 7.105E-20 balloon
TNIP1 rs6889239 5 1.5E+08 T C intronic 0.274556 0.999226 1.3250007 1.205E-18
PTTG1-MIR3142HG rs2431697 5 1.6E+08 T C intergenic 0.422738 1 0.8011076 2.601E-14





B3GAT2-OGFRL1 rs9969061 6 71862393 A G intergenic 0.0020919 1 13.297951 1.118E-13
PRDM1-ATG5 rs7768653 6 1.07E+08 C T intergenic 0.400953 0.994895 0.8127246 1.575E-12
LOC102724152-MEAT6 rs16895550 6 1.64E+08 T C intergenic 0.0039563 1 0.1116697 5.99E-11
TNFAIP3-PERP-LOC100507406-
LOC100130476
rs148314165 6 1.38E+08 GT G intergenic 0.0381637 0.985315 1.8423649 8.894E-17
DGKB-AGMO rs17168663 7 15139469 T G intergenic 0.0025011 1 7.1856789 7.767E-12 balloon
KCP-IRF5-TNPO3-TPI1P2 rs12531711 7 1.29E+08 A G intronic 0.13271 0.998103 1.8017673 7.065E-46
PLXNA4-FLJ40288 7:132339127 7 1.32E+08 T C ncRNA_intronic 0.0006517 0.977564 66078.585 2.764E-08
AKR1B15-BPGM rs10264693 7 1.34E+08 A G intergenic 0.0046385 1 43.298587 2.311E-42 balloon
PPP1R3B-LOC101929128 rs106380 8 9035078 G C intergenic 0.433186 0.988578 1.1748201 3.573E-08 balloon
XKR6-MTMR9-FAM167A-BLK rs2736332 8 11339965 G C intergenic 0.293333 0.979054 1.3212708 1.351E-18
LOC100507464-SNTG1 rs7386188 8 50609940 T G intergenic 0.0297863 1 1.650587 1.105E-08 balloon
SOX17-RP1 rs7823055 8 55511676 G T intergenic 0.449022 1 0.7080554 1.643E-34 balloon
LINC00708-LOC105376398 rs71287391 10 8446489 AT A intergenic 0.300557 0.774732 0.8185547 2.349E-08LocusGenes topSNP chr pos alleleA alleleB Func.refGene MAF INFO	score OR P	value Notes
MAP3K8-LYZL2 rs1034009 10 30757105 C A intergenic 0.0038199 1 5.8853723 7.129E-13 balloon
WDFY4 rs7097397 10 50025396 G A exonic 0.372105 0.978192 0.8236859 1.061E-10




rs4963140 11 588654 C T intronic 0.387644 0.995366 1.2210022 1.326E-11
PDHX-LOC100507144 rs353608 11 35101738 A G intergenic 0.455255 0.996157 1.2145104 2.042E-11
PIK3C2G rs12309414 12 18665717 A G intronic 0.0050478 1 29.327628 1.804E-42 balloon
HECTD4 rs7953257 12 1.13E+08 A T intronic 0.432067 0.933497 0.8486359 4.072E-08 balloon
PELI2-LOC101927690 rs17091347 14 56820049 T C intergenic 0.0043656 1 4.649176 8.662E-13 balloon
PRSS36-FUS-PYCARD-AS1-
TRIM72-ITGAM-ITGAX
rs8056944 16 31283744 C G intronic 0.159642 0.998965 1.7424776 2.871E-47
PRSS54-GINS3 rs140819743 16 58342077 AT A intergenic 0.303554 0.93452 0.8354849 1.883E-08 balloon
IRF8-LINC01082 rs8052690 16 85969738 A G intergenic 0.207513 0.988756 0.7373202 5.987E-17
MRM1-LOC102723471 rs8078864 17 35056109 T C intergenic 0.0069122 1 7.4873131 8.929E-29 balloon
GPATCH8 rs12948819 17 42521824 A G intronic 0.0033197 1 17.920226 2.982E-24 balloon
ICAM5-ZGLP1-FDX1L-ICAM3-
TYK2-CDC37-PDE4A
rs11085727 19 10466123 C T intronic 0.272683 0.980055 0.7895406 6.911E-13
LINC01751-LINC01706 rs56412650 20 7333291 C T ncRNA_intronic 0.0025214 0.976837 5.8133675 5.422E-09
CHMP4B-RALY-AS1-EIF2S2-
ASIP-AHCY-ITCH
20:32515626 20 32515626 G A intergenic 0.0011236 0.80031 45.627016 2.452E-10
UBE2L3-YDJC rs181361 22 21929566 A T intronic 0.212994 0.992962 1.2935754 9.716E-14
MIR3201-FAM19A5 rs7285053 22 48872193 T C intergenic 0.0043656 1 14.999397 4.038E-29 balloon








Figure 4- 1. Manhattan plot of SLE GWAS results in SLE main European cohort. 
The GWAS identifies 63 loci (P5 x 10-8) that are associated with SLE.  The log10 (P values) 
derived from the Wald statistic (logistic regression model) were plotted against chromosomal 
position.  Each point represents a SNP. The red line corresponds to the genome-wide significance 
threshold (P=5 x 10-8).  The blue line corresponds to P=1 x 10-5.   
 
 
4.2 Enrichment pattern of SLE risk loci 
The majority of the disease risk variants identified from the European SLE GWAS (and the other 
SLE GWAS) are located outside the protein coding regions of the genome.  Only four out of the 
62 loci have a top SNP that was located in an exonic region, while the remaining are intronic, 
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intergenic, or UTR, where the functional effects of the risk alleles are in general, poorly defined.  
To evaluate the functional properties of these variants, I estimated the extent to which these SLE 
associated variants were non-randomly distributed across various coding, non-coding regulatory 
and cell-type-specific elements across the genome.  424 genome-wide data sets derived from 
the most widely studied annotation type, DNaseI hypersensitivity sites (DHS) hotspots, from the 
ENCODE [94] and Roadmap projects [96] were retrieved for analyses (See Chapter 2. Methods).   
A nonparametric approach, GARFIELD [143], was applied to derive fold of enrichment statistics 
for SLE risk variants within each cell type/tissue, where SNPs were selected on the basis of their 
strength of association with SLE (GWAS P value).   Following the enrichment analysis, I found 
that genome-wide significant SLE associations (P = 110-8) are significantly (with an empirical P 
< 110-4 and Bonferroni adjusted P < 0.05) enriched in the DHS hotspots of immune cells 
involving in the adaptive immune response, including CD3 T cells (fold enrichment = 3.95), CD4 
T cells (fold enrichment = 2.81), CD8 T cells (fold enrichment = 3.34), CD19 B cells (fold 
enrichment = 3.81), and CD20 B cells (fold enrichment = 3.46), as well as cells that play a role in 
the innate immune response, comprising CD56 NK cells (fold enrichment = 3.54) and CD14 
monocytes (fold enrichment = 3.05).  Other cells and tissues that are significantly enriched for 
SLE risk loci include CD34 hematopoietic stem cells, lymphoblastoid cell lines (LCL) (fold 
enrichment = 3.57), fetal large intestine (fold enrichment = 2.59), fetal small intestine (fold 
enrichment = 2.40), fetal spleen (fold enrichment = 1.89), and breast (fold enrichment = 1.93).  
See Figure 4-2 and Table 4-3.   
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Table 4- 3. Summary statistics of SLE risk loci enrichment analysis by GARFIELD. 
Cell	type/tissue	 .	 .3		 	.O	 	.3O 	 FE	 Empirical		P	value	 Adjusted		P	value	
CD19+	B	cells	 295822	 24801	 288	 92	 3.81028	 <0.0001	 <0.05	
CD20+	B	cells	 295822	 29425	 288	 99	 3.45586	 <0.0001	 <0.05	
CD3+	T	cels	 295822	 21846	 288	 84	 3.94953	 <0.0001	 <0.05	
CD4+	T	cells	 295822	 22626	 288	 62	 2.81463	 <0.0001	 <0.05	
CD8+	T	cells	 295822	 18736	 288	 61	 3.34419	 <0.0001	 <0.05	
Th2	 295822	 23486	 288	 55	 2.40542	 <0.0001	 <0.05	
CD14+	Monocytes	 295822	 23602	 288	 70	 3.0464	 <0.0001	 <0.05	
CD56+	NK	cells	 295822	 19133	 288	 66	 3.54323	 <0.0001	 <0.05	
CD34+	stem	cells	 295822	 26574	 288	 64	 2.47378	 <0.0001	 <0.05	
LCL	 295822	 23283	 288	 81	 3.57342	 <0.0001	 <0.05	
Large	Fetal	Intestine	 295822	 22243	 288	 56	 2.58602	 <0.0001	 <0.05	
Small	Fetal	Intestine	 295822	 26923	 288	 63	 2.40356	 <0.0001	 <0.05	
Fetal	Spllen	 295822	 37979	 288	 70	 1.89318	 <0.0001	 <0.05	
Breast	(vHMEC)	 295822	 31864	 288	 60	 1.93414	 <0.0001	 <0.05	
Notes: N is the total number of pruned SNPs; %& is the total number of SNPs that fall in DHS 
regions (functional annotation); %' is the total number of variants with SLE GWAS P-value less 
than threshold t (in this table is 1	×	10MN); %&' denotes the number of SNPs with P value less than 
t and fall within DHS.  FE (fold of enrichment) is the proportion of the SNPs that fall in DHS as 
well as have a P-value less than threshold t, divided by the fraction of total number of SNPs within 
DHS, i.e., FE = (%&' %') (%& %). Empirical P value is the proportion of times a random selection 
of SNPs would have a higher FE than observed, which is calculated by 10,000 times of 
permutations.  Adjusted P value is the empirical P value accounting for multiple-testing burden 








Figure 4- 2. GARFIELD functional enrichment analyses.  
The wheel plot displays fold of enrichment in DHS hotspots for SLE GWAS statistics derived from 
the main SLE European cohort.  The radial axis shows fold of enrichment (FE) calculated at each 
of eight GWAS P-value thresholds (P < 1×10-1 to P < 1×10-8) for all 424 annotations.  Cell types 
are sorted by tissues, represented along the outside edge of the plot with font size proportional 
to the number of cell types from that tissue.  Fold of enrichment values at different thresholds are 
plotted with different colours inside the plot, with colour legends shown at the bottom.  Boxes and 
dots next to the tissue labels are coloured with respect to tissue, with colour legends shown on 
the right side.  Dots along the inside edge of the plot (legend at the right bottom to the big wheel 
plot) denote whether the enrichment is significant (if there is a dot present) or not (no dot) for a 
given cell type at four GWAS P value thresholds, from P < 1×10-5 (outermost dot) to P < 1×10-8 
(innermost dot).   
 
 
4.3 SLE risk loci that are enriched in target tissue/cell types  
According to the functional elements enrichment results from GARFIELD analysis, the functions 
of SLE risk loci are mainly enriched in immune cells, fetal intestine, spleen and breast.  In order 
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contributing to the overwhelming representation in these cell types and tissues.  I used GoShifter 
[146] to search for the loci that contributed most to the enrichment.  DHS epigenomes for the 
target cell types (Monocytes, NK cells, B cells, T cells, and LCL) and tissues (fetal large intestine, 
fetal small intestine, spleen, and breast) were extracted from 
(http://egg2.wustl.edu/roadmap/data/byFileType/peaks/consolidated/narrowPeak/?C=N;O=D)  
(Table 4-4) for GoShifter analysis. 
The locus score, indicating whether the tag SLE risk SNP (or SNPs in strong LD with the tagSNP, 
r2 ≥ 0.8) overlapped with the functional annotations being tested, for all SLE risk loci in each of 
the nine cell types/ tissues are shown in Table 4-5.  The lower the locus score, the better the co-
localization of target SNP and the functional annotation.  By clustering the locus score according 
to cell types/tissues, we can see that some of the cell types are closer than others (see Figure 4-
3).  For example, monocytes and NK cells are in the same cluster, which are both mainly involved 
in the innate immune system.  B cells are similar to LCL, as LCL is a B cell line transformed with 
EBV, leading to their commonalities.  In addition, fetal small intestine and fetal large intestine are 
in the same cluster and the loci that contribute to the significant enrichment are all overlapped 
with the ones enriched in blood (including NK cells, monocytes, B cells and T cells) and showed 
preference in T cells.  Almost one third of the loci overlapped with functional elements generally 
across a variety of cell types and tissues.  For example, UBE2L3 is significantly overlapped with 
DHS in all cell types and tissues.  But some of the loci are preferably in specific tissue, e.g. TERT, 
a gene involved in the Estrogen-Dependent Breast Cancer Signalling pathway, is overlapped with 
DHS in breast specifically.   
 




RoadmapIndex Celltype/Tissue GROUP STD_NAME TYPE ETHNICITY
E028 Breat	vHEMC Epithelial Breast	variant	Human	Mammary	Epithelial	Cells	(vHMEC) PrimaryCulture Caucasian
E029 CD14	Monocytes HSC	&	B-cell Primary	monocytes	from	peripheral	blood PrimaryCell Hispanic,	Unknown
E032 CD19	B	cells HSC	&	B-cell Primary	B	cells	from	peripheral	blood PrimaryCell Caucasian,	Hispanic
E034 CD3	T	cells Blood	&	T-cell Primary	T	cells	from	peripheral	blood PrimaryCell Caucasian,	Hispanic
E046 CD56	NK	cells HSC	&	B-cell Primary	Natural	Killer	cells	from	peripheral	blood PrimaryCell Caucasian,	Hispanic
E084 fetal	intestine	large Digestive Fetal	Intestine	Large PrimaryTissue Unknown
E085 fetal	intestine	small Digestive Fetal	Intestine	Small PrimaryTissue Unknown
E113 spleen Other Spleen PrimaryTissue Caucasian
E116 LCL ENCODE2012 GM12878	Lymphoblastoid	Cells PrimaryCulture Caucasian
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Table 4- 5. A summary ‘Locus Score’ of SLE loci that are enriched in target cell types/ tissues. 
Note: NA is not available, which means that specific locus does not overlapped with the DHS 
hotspots in the according cell type. The number in this table for each SNP and each cell type is 
the ‘locus score’ obtained from GoShifter. Locus score is the probability that each locus overlaps 
an annotation by chance and defined as ls/n, where ls is the number of shifting iterations for which 
at least one SNP within an individual locus overlaps the annotation, and n is the total number of 
iterations.  Loci with low scores are higher-priority candidates for further investigations, as they 
drive the signiﬁcant enrichment observations. For more details, refer to 2.3.2. GoShifter. 
 
  








rs2476601 1 PTPN22 NA NA NA NA NA 0.032 NA NA NA
rs1801274 1 FCGR2A_FCGR2B 0.441 NA NA NA NA NA NA NA NA
rs10911628 1 NCF2_EDEM3 0.339 0.322 NA NA NA NA 0.163 NA NA
rs34889541 1 PTPRC 0.409 NA 0.794 0.699 NA NA NA NA 0.587
rs3024505 1 IKBKE_IL10 0.349 0.482 0.234 0.299 0.472 0.088 0.095 0.686 0.31
rs9782955 1 LYST 0.44 0.227 0.429 NA 0.322 0.22 0.168 0.202 NA
rs7579944 2 LBH NA 0.547 0.721 NA 0.538 NA 0.404 0.433 0.572
rs6740462 2 SPRED2 NA NA NA NA NA 0.186 NA NA NA
rs6705628 2 DGUOK_CCT7 0.352 NA 0.341 NA 0.451 0.28 0.369 0.208 NA
rs3821236 2 STAT4 NA NA NA 0.467 NA 0.163 NA NA NA
rs3768792 2 IKZF2 NA 0.133 NA NA 0.889 NA NA NA NA
rs6445972 3 ABHD6_PXK NA 0.813 NA NA NA NA NA NA 0.815
rs2222631 3 GSK3B NA NA NA NA 0.249 NA NA NA NA
rs564799 3 IL12A 0.725 0.6 NA 0.447 0.778 0.684 NA NA 0.28
rs10936599 3 MYNN 0.687 0.596 0.549 NA 0.515 0.52 0.317 0.54 0.338
rs6762714 3 LPP_TPRG1_AS1 NA 0.123 NA NA 0.137 NA 0.076 0.066 NA
rs4690229 4 DGKQ_IDUA 0.387 NA NA 0.234 NA NA 0.357 NA NA
rs340630 4 PTPN13 NA NA NA NA 0.796 NA 0.679 0.429 0.738
rs10028805 4 BANK1 NA NA NA NA NA NA NA NA 0.329
rs907715 4 IL21 NA NA 0.143 NA NA 0.189 NA NA NA
rs7726159 5 TERT NA NA NA NA NA 0.204 NA NA NA
rs7726414 5 TCF7 NA NA 0.639 NA NA NA NA NA NA
rs7708392 5 ANXA6_SLC36A1 0.542 0.377 0.644 NA 0.63 NA NA 0.542 NA
rs2431697 5 PTTG1_UBLCP1 NA NA NA NA 0.186 NA NA NA NA
rs36014129 6 SLC17A1_BTN3A2 NA 0.484 NA 0.648 NA NA 0.832 NA NA
rs597325 6 BACH2 0.233 NA 0.714 0.357 NA NA NA NA NA
rs6568431 6 PRDM1_ATG5 NA 0.315 0.489 0.491 0.717 NA NA NA NA
rs6932056 6 IL22RA2_PERP 0.962 0.848 0.986 0.948 0.976 0.938 0.587 NA 0.642
rs849142 7 HOXA9 NA NA NA NA NA 0.53 NA NA NA
rs4917014 7 IKZF1 0.383 0.222 0.699 0.495 0.344 NA NA NA 0.266
rs73135369 7 CCL24_HIP1_NCF1 NA NA NA NA NA 0.234 NA NA NA
rs4728142 7 TNPO3 0.708 NA 0.888 NA NA NA NA NA NA
rs2736340 8 BLK_C8ORF13 0.723 0.873 NA 0.887 NA 0.734 NA NA 0.538
rs7829816 8 RPS20_PLAG1 NA NA NA NA 0.721 NA NA NA NA
rs1966115 8 PKIA_ZC2HC1A 0.47 0.536 0.4 NA 0.844 NA NA NA NA
rs877819 10 WDFY4 NA 0.247 NA NA 0.307 NA NA NA NA
rs4948496 10 ARID5B 0.825 0.918 0.92 0.685 0.876 0.709 0.945 0.86 0.848
rs4917385 10 USMG5 NA NA NA NA 0.25 NA NA NA NA
rs12802200 11 TMEM80_PHRF1 NA 0.938 0.932 0.709 NA NA NA NA NA
rs2732552 11 CD44 0.967 0.729 0.994 0.83 0.906 0.551 NA NA 0.531
rs494003 11 RNASEH2C_CTSW 0.405 0.483 0.429 0.354 NA 0.486 0.365 0.37 NA
rs3794060 11 PPFIA1 0.715 0.548 0.616 0.672 0.766 0.645 0.778 0.594 NA
rs6590330 11 FLI1 NA 0.184 0.763 0.521 0.403 0.55 NA NA NA
rs34330 12 APOLD1_HTR7P NA NA 0.61 NA NA 0.505 NA NA NA
rs4622329 12 NT5DC3 0.483 NA NA NA 0.265 NA NA NA NA
rs10774625 12 ATXN2 NA NA 0.422 NA NA NA NA NA NA
rs1059312 12 SLC15A4 0.954 0.991 0.997 0.98 0.998 0.441 NA NA 0.995
rs8016947 14 NFKBIA NA NA NA NA NA NA NA NA 0.237
rs2289583 15 CSK_ULK3 NA NA NA 0.464 0.576 0.414 NA 0.391 0.424
rs9652601 16 CLEC16A_SOCS1 0.456 0.869 0.883 NA 0.9 0.81 NA NA 0.769
rs7197475 16 ITGAM_MAPK3 0.706 0.832 0.765 0.557 0.521 0.647 0.585 0.496 0.348
rs223881 16 CCL22 0.203 NA NA 0.217 0.34 NA NA NA NA
rs1170426 16 ZFP90 0.789 0.921 0.931 0.939 0.761 0.979 0.717 NA 0.424
rs2280381 16 IRF8 0.734 0.574 NA 0.909 NA NA NA NA 0.249
rs2286672 17 RNF167 NA NA 0.554 NA NA NA NA NA NA
rs2941509 17 IKZF3 NA 1 1 1 1 0.907 0.982 0.729 1
rs930297 17 USP36_KIAA0195 0.495 0.56 0.462 0.296 0.314 0.162 0.286 0.3 NA
rs3093030 19 TYK2_ICAM1_ICAM4 0.991 0.995 0.995 0.995 0.986 0.821 0.765 0.793 NA
rs2305772 19 SIGLEC12_ZNF175 0.229 0.733 NA 0.384 0.404 NA NA NA NA
rs4810485 20 SLC35C2_PLTP 0.519 0.665 0.215 0.344 NA NA NA 0.11 NA
rs11697848 20 RNF114 0.985 0.963 0.987 0.776 0.955 0.939 0.999 0.944 0.939




Figure 4- 3. SLE associated loci that contributing to the enriched cell types/tissues.  
The ‘pseudo’ locus score derived from GoShifter is used to generate the heat map.  By ‘pseudo’, 
I mean that not the ‘real’ locus score that shown in Table 4-5, but rather the ‘1-locus score’ is 
applied.  For loci that show no-overlapping with DHS (locus score is ‘NA’ in Table 4-5), ‘-1’ is 
assigned as their ‘pseudo’ locus score to make sure all loci in all cell types have a ‘pseudo’ score 
for clustering.  Each column represents a cell type/tissue and each row represents a locus (named 
according to the genes nearby).  The redder, the better the overlap, while blue indicates no 
overlapping between the locus and the functional annotation. 
 102 
4.4 Integrating eQTL and epigenetics to annotate SLE risk loci  
Previous studies [96, 99] have shown that genetic, epigenetic and gene expression variance are 
strongly locally coordinated.  Thus, I sought to identify shared genetic effects to link SLE risk 
genes to their putative regulatory elements.  I considered all SLE risk alleles and asked whether 
the same variant / locus was associated with both gene expression and DHS hotspot.   For this 
purpose, I simply compared if the SLE eSNP (SLE risk SNP found to be an eQTL) was overlapped 
with the DHS hotspot in which cell(s).  By comparison, 66% (31/47) of the SLE eQTLs were shown 
to overlap with DHS hotspots (Table 4-6), denoting extensive local coordination of genetic 
influences on gene expression and DHS hotspots.  For example, SLE risk allele – rs564799 is an 
eQTL that regulating the gene expression of IL12A in B cells, which is overlapped with the DHS 
peak locating around IL12A in not only B cells, but also monocytes, NK cells, and LCL (Figure 4-
4), suggesting that the risk allele of SLE may regulate the expression of IL12A through the 




Table 4- 6.  Comparison of eQTL and DHS epigenetics in SLE risk loci. 
 
 
targetSNP chr Locus.gene eSNP? eQTL	in	which	cell(s) DHS	Hotspot	? DHS	overlapped	in	which	Immune	cells
rs4649203 1 IL28RA  T	cell 
rs2476601 1 PTPN22  LCL 
rs1801274 1 FCGR2A_FCGR2B  Monocytes  Monocytes
rs17849502 1 NCF2_EDEM3  LCL 
rs10911628 1 NCF2_EDEM3   Monocytes	+	B	cell
rs34889541 1 PTPRC   Monocytes	+	T	cell	+	NK	cell
rs2297550 1 IKBKE_IL10  T	cell	+	Monocytes 
rs3024505 1 IKBKE_IL10  Monocytes  Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs9782955 1 LYST   Monocytes	+	B	cell	+	T	cell	+	LCL
rs7579944 2 LBH   B	cell	+	T	cell	+	LCL
rs13385731 2 RASGRP3  LCL 
rs6740462 2 SPRED2  
rs6705628 2 DGUOK_CCT7   Monocytes	+	T	cell	+	LCL
rs2111485 2 IFIH1  Monocytes 
rs3821236 2 STAT4   NK	cell
rs3768792 2 IKZF2   B	cell	+	LCL
rs6445972 3 ABHD6_PXK  T	cell  B	cell
rs1132200 3 GSK3B  LCL 
rs2222631 3 GSK3B   LCL
rs564799 3 IL12A  B	cell  Monocytes	+	B	cell	+	NK	cell	+	LCL
rs10936599 3 MYNN   Monocytes	+	B	cell	+	T	cell	+LCL
rs6762714 3 LPP_TPRG1_AS1   B	cell	+	LCL
rs4690229 4 DGKQ_IDUA  LCL	+	WB	+	T	cell	+	Monocytes	+	B	cell  Monocytes	+	NK	cell
rs340630 4 PTPN13  LCL  LCL
rs10028805 4 BANK1  
rs907715 4 IL21   T	cell
rs7726159 5 TERT  
rs7726414 5 TCF7   T	cell
rs7708392 5 ANXA6_SLC36A1  WB  Monocytes	+	B	cell	+	T	cell	+	LCL
rs2431697 5 PTTG1_UBLCP1   LCL
rs36014129 6 SLC17A1_BTN3A2  LCL  B	cell	+	NK	cell
rs597325 6 BACH2   Monocytes	+	T	cell	+	NK	cell
rs6568431 6 PRDM1_ATG5   B	cell	+	T	cell	+	NK	cell	+	LCL
rs2327832 6 IL22RA2_PERP  LCL 
rs6932056 6 IL22RA2_PERP   Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs849142 7 HOXA9  
rs4917014 7 IKZF1  WB  Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs73135369 7 CCL24_HIP1_NCF1  LCL 
rs1167796 7 CCL24_HIP1_NCF1  WB 
rs4728142 7 TNPO3  T	cell	+	Monocytes  Monocytes	+	T	cell
rs2070197 7 TNPO3  LCL 
rs2980512 8 BLK_C8ORF13  WB 
rs2736340 8 BLK_C8ORF13  LCL	+	WB	+	B	cell  Monocytes	+	B	cell	+	NK	cell
rs7829816 8 RPS20_PLAG1  WB 
rs1966115 8 PKIA_ZC2HC1A  LCL	+	B	cell	+	NK	cell  Monocytes	+	B	cell	+	T	cell	+	LCL
rs877819 10 WDFY4  Monocytes  B	cell	+	LCL
rs4948496 10 ARID5B   Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs4917385 10 USMG5  LCL	+	WB  LCL
rs12802200 11 TMEM80_PHRF1  Monocytes  B	cell	+	T	cell	+	NK	cell
rs2732552 11 CD44   Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs494003 11 RNASEH2C_CTSW  Monocytes  Monocytes	+	B	cell	+	T	cell	+	NK	cell
rs3794060 11 PPFIA1   Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs4639966 11 TMEM25_CD3D_C11ORF60  WB 
rs6590330 11 FLI1   B	cell	+	T	cell	+	NK	cell	+	LCL
rs34330 12 APOLD1_HTR7P  T	cell  T	cell
rs4622329 12 NT5DC3   Monocytes	+	LCL
rs10774625 12 ATXN2  Monocytes  T	cell
rs1059312 12 SLC15A4   Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs8016947 14 NFKBIA  
rs11073328 15 SPRED1  NK	cell 
rs2289583 15 CSK_ULK3  WB	+	Monocytes  NK	cell	+	LCL
rs9652601 16 CLEC16A_SOCS1  Monocytes  Monocytes	+	B	cell	+	T	cell	+	LCL
rs16972959 16 PRKCB1  LCL 
rs7197475 16 ITGAM_MAPK3  WB  Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs34572943 16 ITGAM_MAPK3  LCL 
rs223881 16 CCL22   Monocytes	+	NK	cell	+	LCL
rs1170426 16 ZFP90  LCL	+	Monocytes  Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs2280381 16 IRF8  Monocytes  Monocytes	+	B	cell	+	NK	cell
rs2286672 17 RNF167  Monocytes	+	NK	cell  T	cell
rs2941509 17 IKZF3  LCL  B	cell	+	T	cell	+	NK	cell	+	LCL
rs930297 17 USP36_KIAA0195   Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs3093030 19 TYK2_ICAM1_ICAM4  LCL  Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs2304256 19 TYK2_ICAM1_ICAM4  WB	+	Monocytes 
rs2305772 19 SIGLEC12_ZNF175  LCL	+	Monocytes  Monocytes	+	B	cell	+	NK	cell	+	LCL
rs4810485 20 SLC35C2_PLTP   Monocytes	+	B	cell	+	T	cell	+	NK	cell
rs11697848 20 RNF114   Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs7444 22 UBE2L3  LCL	+	WB	+	Monocytes  Monocytes	+	B	cell	+	T	cell	+	NK	cell	+	LCL
rs61616683 22 SYNGR1  LCL	+	WB	+	Monocytes	+	B	cell	+	NK	cell 
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Figure 4- 4. An example of integrating eQTL and epigenetics to annotate SLE risk loci.  
a. The regional Manhattan plot by LocusZoom online tool (http://locuszoom.org) showed the –
log10 P value of eQTL from the SNPs in the region of chr3: 159,720,000 – 159,745,000 versus 
gene expression of IL12A in ex vivo B cell.  b. SNPs in strong LD (r2 ≥	0.8) with the GWAS SNP 
rs564799.  c. Signals of DHS peaks across different immune cell types (T cell, NK cell, Neutrophil, 
Monocyte, LCL and B cell).  Data for the tracks were downloaded from Roadmap Epigenomes 
(http://egg2.wustl.edu/r oadmap/data/) and plotted using UCSC genome browser (http://genome-
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Large-scale GWASs analysed using the results from large-scale Epigenomic projects, such as 
ENCODE and Roadmap, make it possible to systematically investigate the functional effects of 
risk alleles mapped in regions associated with complex traits. They have greatly enhanced the 
annotation of putative functional consequences of non-coding variants in cell/tissue specific 
contexts which link to the underlying pathogenesis of diseases.  However, current methods that 
aim to study SLE, a complex autoimmune disease involving many organs, are not robust due to 
the limited accessibility of the target organs from human beings.  Most of the studies that aim to 
investigate the mechanism of lupus use model animals (often mice) as surrogates, though 
realising the major differences between human and mice [186, 187]. Here, I used a total of 424 
genome-wide DHS hotspot annotations, derived from all the major organs and tissues of adults 
and fetus (Supplementary Table 2-1), incorporating genome-wide association summary results 
from the largest SLE cohort in European [43] to infer the regulatory role of SLE risk loci physically, 
i.e., in which tissue/s do the risk loci have their functions. 
 
According to the SLE GWAS in the largest European cohort with a considerable sample size 
(N=10995) [187], most of the disease associated loci are located outside coding regions, leading 
to a question of how these loci contribute to the susceptibility of the disease.  The genome is the 
assembly of DNA that makes each individual unique and the epigenome consists of proteins and 
chemical compounds that can attach to DNA and control the production of the genes in particular 
cells.  DNA elements that used to be defined as ‘junk’ have revealed their functions through 
marking the genome and changing the way cells use the DNA’s instructions [188, 189].  With the 
development of Epigenome Projects, rich resources of epigenome data are publicly available, 
facilitating improved understanding of non-coding DNA elements.  I used epigenomic data derived 
from the ENCODE and Roadmap Epigenome Projects [96, 99, 189, 190] to prioritize SLE-relevant 
tissues and cell types by looking for the enrichment of GWAS signals within these functional 
genomic regions.  Since DNaseI-seq identifies all genetic regulatory elements, including 
promoters, enhancers, silencers, insulators [191], and epigenomes generated by DNaseI-seq are 
available in almost all cell types and tissues, DHS hotspots serve as the best resource to search 
for the functional context for a target phenotype, in this case SLE. 
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GARFIELD is a non-parametric approach that leverages GWAS findings with regulatory or 
functional annotations to classify features relevant to a phenotype of interest.  Both epigenomic 
data derived from ENCODE and Roadmap, and a comprehensive LD map generated by UK10K 
sequence data [145] were pre-processed and embedded as part of the GARFIELD package, 
making it very straightforward to obtain a global view of the functional context of SLE genetic 
associations.  By applying GARFIELD, I found that SLE risk loci are enriched in regulatory 
elements in blood (B/T/NK/T cells, LCL), fetal intestine, and spleen, which are all critical in the 
innate and adaptive immune responses.  However, no significant enrichment in kidney was 
observed, indicating indirect regulatory effects on target organs.  A hypothesis is that risk alleles 
may assemble the circulating immune cells to target and accumulate in kidney, leading to lupus 
nephritis.  Nevertheless, GARFIELD focuses on genome-wide enrichment analysis, not the 
details of specific loci, which does not allow us to infer what SLE risk loci are contributing to the 
enrichment within the functional genome in particular cell types.  However, GoShifter is more 
adaptable and flexible enabling the user to infer functional disease associated loci and pinpoint 
putative causal variants.  Therefore, I applied both methods to obtain a global view of SLE 
functional context and infer the risk loci contributing to the target tissue and cell types.  Some SLE 
associated loci (Figure 4-3) were found to be enriched in DHS in immune cells, as well as in 
breast and intestine. 
I realized that applying DHS only to infer the functional context of SLE may miss some regulatory 
elements.  With the growing number of epigenomes becoming available, it would be better to 
integrate data from other resources, such like histone modifications and DNA methylation, to 
better understand the non-coding genome.  However, epigenomes derived from ChIP-seq (such 
as H3K4me1, H3K4me3, H3K9ac, and H3K27ac) were not available for all the cell types and 
tissues – certainly not as comprehensively as DHS.  Therefore, it would be biased (for false 
negatives) to use these regulatory epigenomes for the inference of functional context.  In this 
chapter, I used the DHS as the functional annotation, which included 424 epigenomes 
representing all the common cell types and tissue of human body, providing a comprehensive 
overview of what the potential functional context may be.  However, the functional regulatory 
annotations (DHS hotspots) are mainly derived from common cell types, while some of the 
potential rare cell types that are thought to be involved in SLE have not been characterized, such 
as plasma cells [192].  With the development of single cell RNA-sequencing (scRNA-seq)  [193, 
194], the resolution of identifying cellular differences has been largely extended, providing a better 
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understanding of the functions of rare cell populations.  Hence, it will be a necessity to perform 
scRNA-seq in target tissue and cell types to fully fine map the functional context. 
To the best of my knowledge, this is the first study of the functional context of SLE by integrating 
the epigenome and genome comprehensively and inferred the enrichment of SLE risk loci 
statistically.  Though SLE is a complex disease with multiple organs involved, the overall 
regulatory pattern of SLE risk loci showed a significant enrichment in innate and adaptive immune 
cells, as well as in spleen, breast and fetal intestine, suggesting that organs manifested in SLE 
may not be targeted directly to trigger their impairment.  Moreover, by using GoShifter, I have 
found specific loci contributing to the enrichment of specific cell types and tissues, providing 
evidence for further functional study.  Taken together, I have increased our understanding of 
GWAS findings and provided insights into the role of immune cells in dissecting the underlying 
mechanism or pathogenesis of the disease. 
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Chapter 5. Use polygenic risk score and age onset of 
SLE for the inference of lupus nephritis 
 
Chapter Summary 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a wide range of signs 
and symptoms among individuals and can involve many organs and systems.  In particular, 
kidney involvement is the most common sub-phenotype, affecting 30-40% of SLE patient of 
European descent and accounting for significant morbidity and mortality.  Genome-wide 
association studies (GWAS) have identified more than 80 loci that are associated with SLE.  
However, whether any of these genetic factors affect the sub-phenotype of SLE, i.e. lupus 
nephritis, is unknown. 
I performed independent GWAS and a meta-analysis of two European cohorts to test for genetic 
association with the development of lupus nephritis (LN). To accomplish this, I conducted an in-
case GWAS comparing the genetic data of those with renal disease, LN+ (Ncohort1 = 1152, Ncohort2 
= 146) and those without renal disease, LN- (N cohort1 = 1949; N cohort2 = 378).  The LN GWAS 
results were then combined with epigenetics data from ENCODE and Roadmap to study the 
enrichment patterns of LN risk variants.  I found no significant renal associated loci or enrichment 
of renal associations in DNase I hypersensitive (DHS) hotspots. 
I then calculated the genetic risk score (GRS) using SNPs reported to be significantly associated 
with SLE and found a significant correlation between the GRS and renal involvement and age of 
SLE onset in both European cohorts – the higher the GRS, the higher probability of renal disease 
(Pcohort1 = 7.2 x 10-7; P cohort2 = 0.00056) and younger age of SLE onset (Pcohort1 = 2.4 x 10-7; Pcohort2 
= 0.021).   
In conclusion, I found that genetic risk factors may influence LN in a quantitative way (multiple 
genes’ contribution).  Therefore, I suggest that a GRS together with information on non-genetic 
risk factors will be useful for early diagnosis of LN patients in a clinical or research setting. 
 
5.1  LN GWAS findings 
LN occurs in approximately half of all SLE patients, and its frequency ranges from 25 to 75% 
depending on the population studied [195].  About one third of European SLE patients experience 
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renal disease [196]. Until recently, one of the most common cause of death in SLE patients was 
kidney failure.  According to the lupus severity index (LSI) using the ACR criteria developed by 
Bello et al [197], renal involvement had the highest impact and particular strongly associated with 
disease severity, hence I chose LN as a representative sub-phenotype in this study. 
The LN GWAS in the SLE main cohort, which comprised 1152 SLE patients with renal disease 
(LN+) and 1949 patients without renal disease (LN-), did not identify any genome-wide significant 
associated loci (P  5 × 10−8) (Figure 5-1a). Consistently, no inflation (Genomic inflation factor: 
 = 1.014) was observed in the QQ plot (Figure 5-1d).  97 SNPs (35 regions) were observed to 
have less stringent associations with a P  1 × 10−5 (Supplementary Table 5-1).  Similarly, none 
of the SNPs reached genome-wide significance (P  5 × 10−8) in the SLEGEN cohort [41] ( = 
1.023) (Figure 5-1b and 5-1e) and 101 SNPs (23 regions) were observed to have a P  1 × 10−5 
(Supplementary Table 5-2).  However, none of the SNPs with P  1 × 10−5 in the main GWAS 
(Supplementary Table 5-1) replicated in the SLEGEN GWAS (Supplementary Table 5-2).   In 
addition, there is no variant that passed genome-wide significance in the meta-analysis of the 
SLE main cohort and SLEGEN cohort for LN GWAS ( = 0.9565)  (Figure 5-1c and 5-1f) and 92 
SNPs (21 regions) were identified to have less stringent associations with a P   1 × 10−5 
(Supplementary Table 5-3).   
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Figure 5- 1. Genome-wide scans of LN associated variants.  
 (Upper) Manhattan plots showing the -log10-transformed p values (y axis) against physical 
genomic position (x axis) for each SNP in (a) the SLE main cohort, (b) the SLEGEN cohort, and 
(c) the meta-analysis of these two cohorts.  The red horizontal line represents the threshold for 
genome-wide significance (P  5 × 10−8) and the blue horizontal line represents the threshold 
for suggestive significance (P  1 × 10−5). 
(Lower) Quantile-quantile plots showing the observed distribution of -log10-transformed p 
values (y axis) by the expected distribution (x axis) under the null hypothesis of no association 
(diagonal line) for (a) the SLE main cohort (genomic inﬂation factor, λ = 1.014), (b) the SLEGEN 




a SLE main cohort b SLEGEN cohort c Meta-analysis of two cohorts
λ = 1.014 λ = 1.023 λ = 0.9565
d SLE main cohort e SLEGEN cohort f Meta-analysis of two cohorts
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5.2  Less stringent LN-associated variants are not enriched in DHS 
Hotspots 
Most of the less stringent (P  1 × 10−5) LN risk variants identified in this study are located outside 
exonic regions, where the underlying molecular mechanisms are poorly defined.  To evaluate the 
functional properties of these variants, I estimated the extent to which these variants were non-
randomly distributed across various coding, non-coding regulatory and cell-type-specific 
elements across the genome.  424 genome-wide data sets derived from the most widely studied 
annotation type, DNase I hypersensitivity site (DHS) hotspots, from the ENCODE and Roadmap 
projects were retrieved for analyses.  A nonparametric approach, GARFIELD [143], was applied 
to derive fold of enrichment statistics for the suggestive SLE renal disease risk variants within 
each cell type/tissue where SNPs were selected on the basis of their strength of association (LN 
GWAS P value).  Following the enrichment analysis, I found that none of the suggestive LN 
genetic associations, either from the SLE main cohort, the SLEGEN cohort, or the meta-analysis 
of these two cohorts, were enriched in DHS hotspots in any of the cell types or tissues being 












Figure 5- 2. GARFIELD functional enrichment analyses of LN GWAS statistics. 
The wheel plot displays fold of enrichment in DHS hotspots for LN GWAS statistics of (a) the SLE main 
cohort, (b) the SLEGEN cohort, and (c) meta-analysis of these two cohorts. The radial axis shows fold 
enrichment (FE) calculated at each of six GWAS P-value thresholds: P < 1×10-1 to P < 1×10-6 for (a, b and 
c) for all 424 cell types.  Cell types are sorted by tissues, represented along the outside edge of the plot with 
font size proportional to the number of cell types from that tissue.  Fold enrichment values at different 
thresholds are plotted with different colours inside the plot, with colour legends shown at the bottom of each 
wheel plot.  Boxes and dots next to the tissue labels are coloured with respect to tissue, with colour legends 
shown on the right side.  Dots along the inside edge of the plot (legend at the right bottom to the wheel plot) 
denote whether the enrichment is significant (if there is a dot present) or not (no dot) for a given cell type at 
the GWAS P value thresholds, from the most significant P value (innermost dot) to the less significant P 
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5.3  Genetic risk loading of SLE is significantly correlated with LN 
Due to the lack of significant associations for LN within SLE patients, I calculated a genetic risk 
score (GRS) to see if the accumulative burden of SLE risk alleles was correlated with LN.  The 
GRS (see 2.5.1 GRS Calculation) were based on odds ratios reported for SLE susceptibility loci, 
which were summarized from the SLE GWAS studies [64].   The GRS in SLE patients and healthy 
controls for both independent cohorts from European population showed a clear higher GRS in 
SLE patients than healthy controls (Figure 5-3).    
In terms of the GRS in patients with and without renal disease, a significantly higher GRS was 
observed in the group of patients with LN+ compared to patients with LN- (Figure 5-3).  In the 
SLE main cohort, the mean (SD) of the GRS was 21.41 (2.06) for LN+ patients and 21.03 (2.12) 
for LN- patients (P = 7.2 x 10-7); the mean for the SLEGEN cohort was 21.66 (2.25) for LN+ 
patients and 20.89 (2.2) for LN- patients (P = 5.6 x 10-4).  Moreover, I saw a significant increasing 
trend of GRS over levels of diseases:  Healthy control, LN- patients, and LN+ patients, with a 
trend P-value = 1.10 x 10-270 in the SLE main cohort and a P-value = 6.55 x 10-48 in the SLEGEN 
cohort (Table 5-1). 
Another way to show the differences in the distribution of GRS between SLE patients with and 
without LN is to partition the participants. I did this by defining risk stratum, starting at the mean 
of GRS in the SLE main cohort and grouping individuals who were within 0.25 SD of the mean as 
category 4.  Individuals in category 4 can be regarded as those with the mean risk of renal disorder 
in SLE patients (Figure 5-4).  Six subsequent categories (1-3 and 5-7) are defined by the 
increasing intervals of GRS.  In the SLE main GWAS, individuals in category 7 (i.e., those with 
the largest GRS) had 1.20 times (95%CI: 0.92 -1.55) increased odds of developing renal disease 
compared with those in category 4 (Table 5-2).  While patients in category 1 (i.e., those with the 
lowest GRS) were less likely to have LN compared with people in category 4 (OR = 0.58, p-value 
= 0.0012).  When category 7 was compared with category 1, which contains the individuals with 
the lowest risk of renal involvement, there was a 2.05 (95% CI: 1.45 - 2.88) times increase in the 
odds of developing LN. The application of the GRS partitioning method in the SLEGEN cohort 
gave similar results: individuals in category 7 (i.e., those with the largest GRS) had a mean 
increase in odds of developing LN of 1.86 (0.92 - 3.77) compared with individuals in category 4.  
The risk increased to 2.99 (1.13 - 7.95) when category 7 was compared with category 1.   
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Table 5- 1. Summary of Genetic risk score GRS of the studied cohorts. 
 
Notes: GRS for SLE main cohort and SLEGEN cohort are generated by 95 non-MHC SNPs and 
7 MHC SNPs, a total of 102 SNPs.  All p-values were derived from two-tail t-test. 
 
 
a.                       SLE main cohort 
 
b.                         SLEGEN cohort 
 
Figure 5- 3. GRS over levels of disease: Controls / Lupus Nephritis (-) / Lupus Nephritis 
(+). 
The box-and-whisker plots show the summary GRS for each level of the disease in the SLE 
main cohort (a) and the SLEGEN cohort (b).  The bottom line of the box is the 1st quantile, the 
top line is the 3rd quantile, and the box is divided at the median.  The two whiskers outside the 
box extend to the smallest and largest observations within 1.5 times of interquartile range. On 
top of the boxplot is the strip chart, with each dot represent one individual. 
  
GRS	*	of	SLE GRS	of	Healthy	controls t	test	P-value GRS	of	LN+ GRS	of	LN- t	test	P-value
21.14	(2.1) 19.22	(1.87) 21.41	(2.06) 21.03	(2.12)
n	=	4036 n	=	6959 n	=	1152 n	=	1949
21.11	(2.25) 19.28	(1.92) 21.66	(2.25) 20.89	(2.24)






Table 5- 2. GRS and odds ratios of SLE renal disease in SLE main cohort and SLEGEN 
cohort 
 
Notes: Data are in n(%) and OR(95% CI).  
* OR is derived from the comparison of G1 VS G7.  All others use G4 as a reference group.  




Figure 5- 4. Distribution of GRS by SLE Renal risk categories.   
SLE renal risk categories for (a) the SLE main cohort and (b) the SLEGEN cohort. Seven 
categories of genetic risk are defined by the SLE main cohort, with G1 being the lowest risk 
category.  The distribution of LN- patients are plotted as green while LN+ patients are plotted as 
red. 
  
LN-	(frequency,	%) LN+	(frequency,	%) OR	(95%	CI) p-value
G1 198	(10.2) 	69	(5.99) 0.58286	(0.42335	-	0.80248) 0.0012
G2 264	(13.5) 	128	(11.1) 0.81094	(0.62041	-	1.06) 0.1424
G3 361	(18.5) 	208	(18.1) 0.96369	(0.76018	-	1.2217) 0.8064
G4 378	(19.4) 	226	(19.6) 1.0	(reference) 1.0000
G5 316	(16.2) 	220	(19.1) 1.1644	(0.91753	-	1.4777) 0.2333
G6 209	(10.7) 	142	(12.3) 1.1364	(0.86799	-	1.4878) 0.3891
G7 223	(11.4) 	159	(13.8) 1.1925	(0.91781	-	1.5494) 0.2107
G1	VS	G7	* … … 2.046	(1.4544	-	2.8782) 0.000049
LN-	(frequency,	%) LN+	(frequency,	%) OR	(95%	CI) p-value
G1 31	(8.2) 	7	(4.79) 0.62097	(0.24162	-	1.5959) 0.4418
G2 33	(8.73) 	9	(6.16) 0.75	(0.31338	-	1.7949) 0.6661
G3 65	(17.2) 	22	(15.1) 0.93077	(0.47519	-	1.8231) 0.9699
G4 66	(17.5) 	24	(16.4) 1.0	(reference) 1.0000
G5 43	(11.4) 	26	(17.8) 1.6628	(0.84679	-	3.2652) 0.1901
G6 33	(8.73) 	15	(10.3) 1.25	(0.57956	-	2.696) 0.7106
G7 34	(8.99) 	23	(15.8) 1.8603	(0.91837	-	3.7683) 0.1207
G1	VS	G7	* … … 2.9958	(1.1288	-	7.9509) 0.0426
SLEGE	Cohort
SLE	main	cohort













Risk Categories of SLE main cohort
LN-
LN+
Chi-square test for trend, p-value < 0.0001
















Chi-square test for trend, p-value = 0.0035
a. b.
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5.4  Age of SLE onset is significantly correlated with LN 
In terms of the age of SLE onset in patients of LN- and LN+, a significant earlier age onset was 
observed in the LN+ patients compared to LN- patients (Figure 5-5).  In the SLE main cohort, 
when testing the relationship between the age of SLE onset and LN in the SLE main cohort, the 
mean (SD) for age of SLE onset was 29 (12) for LN+ patients and 35 (13) for LN- patients (P = 
2.8 x 10-27); the mean for the SLEGEN cohort were 28 (11) and 35 (13) for patients of LN+ and 
LN-, respectively (P = 1.1 x 10-8). 
 
 
a.                       SLE main cohort 
 
b.                         SLEGEN cohort 
 
Figure 5- 5. Age of SLE onset in patients of Lupus Nephritis (-) / Lupus Nephritis (+). 
The box-and-whisker plots show the age of SLE onset for each level of the disease in the SLE 
main cohort (a) and the SLEGEN cohort (b).  The bottom line of the box is the 1st quantile, the 
top line is the 3rd quantile, and the box is divided at the median.  The two whiskers outside the 
box extend to the smallest and largest observations within 1.5 times of interquartile range. On 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































t−test: LN− vs LN+, p−value = 1.115e−08
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5.5  Use GRS and age onset of SLE to predict LN 
When testing the association of GRS with age-of-onset in the SLE main cohort, a significant 
correlation can be seen – the higher the GRS, the younger age of SLE onset (P = 2.4 x 10-7) 
(Figure 5-6).  This correlation can also be observed in the SLGEN cohort (P= 0.021).  In the SLE 
main cohort, when testing the relationship of GRS with age-of-onset separately in the LN+ and 
LN- patients, the GRS was negatively correlated with the age-of-onset in both LN+ group (P = 7.1 
x 10-5) and LN- group (P = 0.05).   In the SLEGEN cohort, the correlation of GRS was also 
inversely correlated with age-of-onset in the LN- group (p = 0.011), while in the LN+ group, no 
significant correlation was observed (P = 0.28). 
By adding the age-of-onset into the model for discriminating LN+ and LN- patients, the 
discrimination was significantly enhanced – the differences in AUC (the area under the receiver 
operating characteristic curve, a measure of the ability of a model to discriminate between LN+ 
and LN- patients) are statistically significant in both cohorts, see Table 5-6.  In the SLE main 
cohort, AUC for the genetic-only model was 0.596 and for the genetic plus age-of-onset model 
was 0.665.   In the SLEGEN cohort, AUC for the genetic-only model was 0.594; adding age-of-
onset to the model increased the AUC to 0.682.  The level of predictability remains modest, but 
our model clearly and consistently performs better than by chance (Figure 5-7).  
 
Table 5- 3. AUC for ROC curves and comparisons between models to predict susceptibility to 
SLE patients with renal involvement. 
Models	
SLE	main	cohort	 SLEGEN	cohort	
AUC	 p	value	 AUC	 p	value	
Model	1:	covariates	only	 0.573	 ..	 0.553	 ..	
Model	2:	GRS	with	covariates	 0.596	 0.000601*	 0.594	 0.0374*	
Model	3:	GRS	with	covariates	and	age-of-onset	 0.665	 1.46x10-9**	 0.682	 0.00148**	
*p value was generated from bootstrap test for two ROC curves (Model 1 VS Model 2); ** p value 
was generated from bootstrap test for two ROC curves (Model 2 VS Model 3).  PCAs are 
covariates derived from the GWAS of each cohort.  For the SLE main cohorts, the covariates 
included sex and four principle components derived from its original GWAS analysis.  For the 
SLEGEN cohort, all the SLE patients are female, only three principle components derived from 
its corresponding GWAS study were included. ROC=receiver operating characteristic.  AUC=area 
under the ROC curve. 
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a.                       SLE main cohort 
 
b.                         SLEGEN cohort 
 
Figure 5- 6. Association of GRS and Age of SLE onset. 
Plots of association of GRS and age of onset for (a) the SLE main cohort, and (b) the SLEGEN 
cohort.  GRS was rounded with two significant digits, which divided all samples into a serial of 
groups.  The box-and-whisker plots and linear regression lines (black for all SLE patients, green 
for LN- patients, Red for LN+ patients) show the Age of SLE onset (y axis) against allGRS (x-
axis).   
 
a.                       SLE main cohort 
 
b.                        SLEGEN cohort 
 
Figure 5- 7. Receiver Operating Characteristic (ROC) Curves for models predicting a 
diagnosis of LN in European cohorts.   
In the SLE main Cohort (a), the results for these separate models to predict patients of LN are 
plotted: Model 0: without GRS – only covariates are included (black); Model 1: GRS and 
covariates (orange); Model 2: GRS, Age of Onset and covariates (red).  In the SLEGEN Cohort 
(b), we repeated the analysis shown in (a).  The same presentation scheme is used. The 
participants are all female.  PCAs are covariates derived from the GWAS of each cohort. 
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All SLE Patients: beta = −0.65; P = 2.35e−07
LN− patients: beta = −0.634; P = 7.08e−05
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All SLE Patients: beta = −0.616; P = 0.0213
LN− patients: beta = −0.822; P = 0.0112
LN+ patients: beta = 0.459; P = 0.282



















Model 0: Renal ~ Covariates (SEX + PCs), AUC = 0.5729
Model 1: Renal ~ GRS + Covariates, AUC = 0.5963
Model 2: Renal ~ GRS + AgeOnset + Covariates, AUC = 0.6652



















Model 0: Renal ~ Covariates ( PCs), AUC = 0.5531
Model 1: Renal ~ GRS + Covariates, AUC = 0.6119
Model 2: Renal ~ GRS + Ageonset + Covariates, AUC = 0.69
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5.6  Discussion 
Until recently, the most common cause of death in SLE patients was kidney failure. Though with 
better therapies (e.g. dialysis and kidney transplantation), the frequency of death from kidney 
disease has decreased sharply, kidney failure is still potentially fatal in some people with SLE and 
causes significant morbidity.  According to the lupus severity index (LSI) using the ACR criteria 
developed by Bello et al [197], renal involvement had the highest impact and particularly more 
strongly associated with disease severity, hence I used renal involvement as a proxy of SLE 
severity in my study.  
In the SLE within-case renal GWAS studies, I observed no genome-wide significant signals in 
either the SLE main cohort or the SLEGEN cohort, or meta-analysis of these two.  Both datasets 
had genetic variants with less stringent P values (P  1 x 10-5) for renal association, but none of 
them were replicated in the other cohort.  Considering the sample size of both cohorts are 
relatively small, I applied an online genetic power calculator (http://zzz.bwh.harvard.edu/gpc/) to 
calculate the power of our current sample size for the GWAS study (Table 5-4).  If we assume 
the effect size of SLE renal risk allele is similar to the ones that seen in SLE GWAS, we expected 
that the odds ratio (OR) of the risk allele would be majorly between 1.0 and 2.0.  Therefore, I 
calculated the genetic power under a variety of parameters, including OR, risk allele frequency 
(RAF) and alpha.   As showed in Table 5-4, we have a power of  0.8 to detect a genetic risk 
variant who has an OR = 1.2 and RAF = 0.5 or an OR = 1.3 and RAF = 0.1 when alpha = 5 × 
10−8.  When the OR of the risk allele is  1.4, we have sufficient power to detect the genetic 
association of the common variants (RAF  0.05) at the GWAS significant threshold of P = 5 x 
10-8. 
Due to the lack of significant genetic associations in SLE Renal GWAS, I then tested the 
hypothesis that the genetic risk loading of SLE may correlate with kidney involvement in a 
quantitative way – multiple genes with modest effect size.   Therefore, a genetic risk score (GRS) 
summing up all the SLE risk is calculated.  In both European cohorts, the SLE main cohort and 
the SLEGEN cohort, the GRS is significantly higher in patients with renal disease than patients 
without.  In addition, patients with a higher GRS are more likely to have the renal involvement at 
younger age, indicating the strong genetic background of SLE development.  Patients with late 
onset are more likely to have lower GRS, as the onset of SLE at older age is more likely to be 
triggered by the cumulative deleterious environmental factors, such as UV, cigarettes, and virus.  
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These findings provide more evidence to support the opinion that younger-age onset lupus is 
generally more severe than older-onset lupus as reported previously [198-200]. 
One may argue that if the severity of SLE is driven by multiple genes’ contribution in a quantitative 
way, the more risk alleles that are added to the model, then the better the model would fit.  In this 
study, I show that a GRS is a useful tool for the classification of SLE renal+ and SLE renal- groups.  
The renal association P values of the 102 SNPs (of 78 SLE risk loci) in the SLE main cohort and 
the SLEGEN cohort are strongly inflated as show in the QQ plots (Figure 5-8), suggesting the 
cumulative genetic burden from multiple SLE risk genes with modest effect.  
In conclusion, I found that the genetic risk factors that influence the severity of SLE are through 
a quantitative way (multiple genes’ contribution), but not a qualitative way (no significant 
associations specific to SLE renal were identified in either SLE renal GWASs).  The inclusion of 
SLE risk alleles into a GRS can modestly predict the severity of SLE patients, shows consistent 
discriminatory ability in independent cohorts, and is enhanced by the inclusion of age-of-onset 
into the model.  Therefore, I suggest that the GRS will make a contribution to predicting renal 
disease in SLE patients in a clinical or research setting. 
 
Table 5- 4. Genetic power of current sample size under different parameters.  
 
*This table showed the genetic power for the sample size of 1100 (SLE Renal+) and 1980 (SLE 
Renal-) under a variety of ORs and RAFs.  Text in red indicates that we have a power of ≥ 0.8 
to detect the genetic associations under corresponding alpha, RAFs and OR. RAF = risk allele 




RAF 0.05 0.1 0.2 0.5 0.8 0.05 0.1 0.2 0.5 0.8 0.05 0.1 0.2 0.5 0.8
OR	=	1.1 0.00 0.02 0.07 0.20 0.05 0.00 0.00 0.03 0.10 0.02 0.00 0.00 0.01 0.03 0.00
OR	=	1.2 0.14 0.54 0.93 0.99 0.76 0.06 0.36 0.84 0.97 0.59 0.02 0.18 0.67 0.92 0.37
OR	=	1.3 0.73 0.99 1.00 1.00 1.00 0.56 0.97 1.00 1.00 0.99 0.34 0.91 1.00 1.00 0.95
OR	=	1.4 0.99 1.00 1.00 1.00 1.00 0.97 1.00 1.00 1.00 1.00 0.91 1.00 1.00 1.00 1.00
OR	=	1.5 0.89 1.00 1.00 1.00 1.00 0.78 1.00 1.00 1.00 1.00 0.58 1.00 1.00 1.00 1.00
OR	=	2.0 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Alpha = 1e-5 Alpha = 1e-6 Alpha = 5e-8
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Figure 5- 8. Quantile-quantile plots of LN GWAS results. 
QQ plots showed the observed distribution of -log10-transformed p values (y axis) by the 
expected distribution (x axis) under the null hypothesis of no association (diagonal line) for the 
SLE main cohort (a), the SLEGEN cohort (b) and the meta-analysis of these two cohorts 
(c).  The p-values for the QQ plots were derived from SLE renal association test of the 77 SLE 































SLE main cohort: QQ plot of Renal association P values of SLE.risk.SNPs

















































SLEGEN cohort: QQ plot of Renal association P values of SLE.risk.SNPs









































Meta cohort: QQ plot of Renal association P values of SLE.risk.SNPs










Inflation factor: lambda = 2.13
a b c
 122 
Chapter 6.  Functional studies of the Ikaros family and 
OX40L using Flow-cytometry 
 
Chapter Summary 
Previous studies on the Ikaros transcription factor family and TNF superfamily gene TNFSF4 
have shown that the genes encoding these proteins are candidate susceptibility genes in SLE 
and other autoimmune diseases.  Nevertheless, how these factors affect the pathogenesis of SLE 
remains largely unknown.  By measuring the protein level of OX40L, IKZF1, IKZF2, and IKZF3 
on the immune subpopulations in PBMC derived from 22 SLE patients and 20 healthy controls, I 
aim to tease out the contributions of specific cells for these molecular factors under disease status, 
providing clues for further experimental study.   
This study revealed, for the first time, the protein expression pattern of OX40L and Ikaros 
transcription factor family (IKZF1/2/3) across a range of immune cells, including T cells, B cells, 
monocytes, NK cells, dendritic cells, as well as their sub-populations.  Through the cell 
proportions analysis, I showed that cell proportions of immune cells derived from the adaptive 
immune system, such as B cells and activated CD4+ T cells, were increased, while innate immune 
cells like DCs and NK cell were decreased in SLE patients comparing to healthy controls.  In 
general, I observed a trend of increase for the protein level of OX40L and a trend of decrease for 
IKZF1, IKZF2 and IKZF3 in SLE patients, with some differences between cases and controls 
being statistically significant.  Specifically, OX40L on B cell subsets was significantly increased 
(p-value ≤ 0.05) in SLE patients, suggesting OX40L may be involved in the pathogenesis of SLE 
though its role in B cells.  Moreover, I showed that both IKZF1 and IKZF3 were significantly 
decreased in some of the activated CD4 T cells (p-value ≤  0.05) in SLE patients, such as 
activated Th2 cells, while no significant differences between cases and controls were observed 
for IKZF2.  Finally, by analysing the correlation between protein levels of target molecules with 
SLEDAI, I found that OX40L on Th17 cells was positively correlated with SLEDAI (p-value ≤ 0.05).  
A similar positive correlation pattern was observed for IKZF2 on non-classical monocytes and 
myeloid DCs, as well as IKZF3 on B cells (0.05 < p-value ≤ 0.10).   
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In summary, a comprehensive immunophenotyping of target molecules’ protein expression to 
scrutinize the subtle differences across discrete immune subsets provides insights into the 
functions of target molecules in the pathogenesis of SLE.  
 
6.1  Gating strategy for immune sub-populations 
Based on the promising SLE GWAS signals, I aimed to set up an antibody panel for the analysis 
of differential expression of IKZF1, IKZF2, IKZF3 and OX40L in innate immune cells (monocytes, 
dendritic cells (DCs), and NK cells) and adaptive immune cells (T cells and B cells) from patients 
and healthy controls.  The experimental design is showed in Chapter 2 Methods, Table 2-5. 
Gating of sample starts with the FSC-A and SSC-A to exclude the cell debris.  To exclude dead 
cells, a ‘viable gate’ was set, followed by gating on SSC-A and SSC-W for single cells, which 
were PBMC (peripheral blood mononuclear cells). For panel 1 (Figure 6-1), I drew gates for the 
CD3+ population from PBMC and then discriminated the T cells into CD4 and CD8 subsets.  They 
were then gated into Effector, Effector Memory, Central Memory and Naïve subpopulations by 
staining with CCR7 and CD45RA.  Specifically, in CD4 subset, CCR6 and CXCR3 were used for 
gating the Th17, Th1, Th1Th17, and Th2 subpopulations.  All the T cell subsets were then gated 
as the activated subpopulations with CD38+ and HLA-DR+ markers. 
For regulatory T cells of panel 2 (Figure 6-2), I drew gates based on the CD3+ and CD4+ markers 
to get the CD4+ T cells subset. They were then gated on CCR4+ CD25+ and CCR6- to 
discriminate the regulatory T cell (Tregs) subsets.  All the Tregs were then gated to separate 
Activated Treg, Memory Treg, and Naïve Treg subpopulations with CD45RO and HLA-DR 
markers. 
For the B cells panel (Figure 6-3), gating on the CD3- and CD19+ was the B cell population.  This 
was then discriminated into Non-switched Memory B cell, Double Negative B cell (DN B cell) by 
IgD and CD27 markers.  The IgD-CD27+ population was then gated on the CD20 and CD38 to 
discriminate the plasmablasts and Switched Memory B cell.  Another subset from PBMC was the 
CD3- CD20-, which was then separated as plasma cells by sequentially gating on the following 
markers: CD19-/CD138+/CD27high/CD38 high/IgD-. 
For panel 4 (Figure 6-4), gating on the CD3+ and CD56+ from PBMC was the NKT cells.   The 
gate on CD3- and CD19-  was discriminated into CD14+ monocytes, which were further 
discriminated into classical and non-classical subpopulations by the CD16 marker.  The CD14- 
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subset was gated to discriminate the NK cells by CD56+ and DCs by HLA-DR+.  The DCs were 
then divided into Plasmacytoid DCs (CD123+) and Myeloid DCs (CD11c+). 
In total, I have identified 51 cell subpopulations, four of which, i.e. Activated Effector CD4+ cell, 
Activated Effector CD8+ cell, Activated Central Memory CD8+ cell, and plasma cell, were 
removed due to their limited cells sample size (average cell counts of all samples < 100).  Hence, 
47 cell populations were used for the analysis of protein expression of target molecules.  The 
markers for each immune cell type are summarized in Table 6-1.   The expression levels of the 
target molecules are quantified by the median fluorescence intensity (MFI) of the corresponding 
antibody fluorophore conjugates, i.e., PE MFI for OX40L and FITC MFI for IKZF1, IKZF2, and 
IKZF3, as shown in Figure 6-5.  
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Table 6- 1. Surface markers for gating various cell populations. 
 
Panel Population Name Corresponding Markers
Total CD3+ T cells CD3+
Total CD4+ T cells CD3+/CD4+/CD8-
Activated CD4+ T cells CD3+/CD4+/CD8-/CD38+/HLA-DR+
Central Memory CD4+ T cells CD3+/CD4+/CD8-/CCR7-CD45RA-
Activated Central Memory CD4+ CellsCD3+/CD4+/CD8-/CCR7-CD45RA-/CD38+/HLA-DR+
Effector CD4+ T cells CD3+/CD4+/CD8-/CCR7-/CD45RA+
Effector Memory CD4+ T cells CD3+/CD4+/CD8-/CCR7-/CD45RA-
Activated Effector Memory Cd4+ T cellsCD3+/CD4+/CD8-/CCR7-/CD45RA-/CD38+/HLA-DR+









Total CD8+ T cells CD3+/CD4-/CD8+
Activated CD8+ T cells CD3+/CD4-/CD8+/CD38+/HLA-DR+
Central Memory CD8+ T cells CD3+/CD4-/CD8+/CCR7-CD45RA-
Effector CD8+ T cells CD3+/CD4-/CD8+/CCR7-/CD45RA+
Effector Memory CD8+ T cells CD3+/CD4-/CD8+/CCR7-/CD45RA-
Activated Effector Memory CD8+ T cellsCD3+/CD4-/CD8+/CCR7-/CD45RA-/CD38+/HLA-DR+
Naive CD8+ T cells CD3+/CD4-/CD8+/CCR7+/CD45RA+






DN B cells CD3-/CD19-/IgD-/CD27-
Naive B cells CD3-/CD19+/IgD+/CD27-/CD24low/CD38low
Transitional B cells CD3-/CD19+/IgD+/CD27-/CD24high/CD38high
Plasmablasts CD3-/CD19+/IgD-/CD27+/CD20-/CD38+
Switched Memory B cells CD3-/CD19+/IgD-/CD27+/CD20+/CD38-






CD16+ NK cells CD3-/CD19-/CD14-/CD56+/CD16+











Figure 6- 1. Gating strategy of Panel 1 (T cell subsets). 
Gating of the PBMC began with the FSC-A and SSC-A to exclude the cell debris.  To exclude 
dead cells, a ‘viable gate’ was set, followed by gating on SSC-A and SSC-W for single cells.  
Gating the CD3+ (APC/Cy7) population from PBMC and the discrimination of the T cells into 
CD4 (PE-Texas Red) and CD8 (Alexa Fluor 700) subsets.  They were then gated to Effector, 
Effector Memory, Central Memory and Naïve subpopulations by CCR7 (Pacific blue) and 
CD45RA (BV785).  Specifically, in CD4 subset, CCR6 (PE/Cy7) and CXCR3 (BV605) were 
used for gating the Th17, Th1, Th1Th17, and Th2 subpopulations.  All the T cell subsets were 
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Figure 6- 2. Gating strategy of Panel 2 (Regulatory T cell subsets).  
Gating of sample starts with the FSC-A and SSC-A to exclude the cell debris.  Gating on the 
CD3+ (APC/Cy7) and CD4+ (PE-Texas Red) was the CD4+ T cells subset. They were then 
gating on CCR4+ (APC), CD25+ (Qdot 605) and CD127 low (PE-Cy7) to discriminate the Treg 
subsets.  All the Tregs were then gated to Activate Treg, Memory Treg, and Naïve Treg 






























































































































FSC-A Indo-1(Violet): Live/Dead SSC-W
Qdot605: CD24APC-Cy7: CD3F







































Figure 6- 3. Gating strategy of Panel 3 (B cell subsets). 
Gating of sample starts with the FSC-A and SSC-A to exclude the cell debris.  Gating on the 
CD3- (APC/Cy7) and CD19+ (Pacific blue) were B cell population.  This was discriminated into 
Non-switched Memory B cell, DN B cell by IgD (Qdot 605) and CD27 (Qdot 800) markers.  The 
‘IgD-CD27+’ population was then gating on the CD20 (PE-Cy7) and CD38 (APC) to discriminate 
the plasmablasts and Switched Memory B cell.  The ‘IgD+CD27-’ population was gating on 
CD38 (APC) and CD24 (PerCP-Cy5.5) to discriminate the Naïve B cells and the Transitional B 
cells.  Another subset from PBMC was the CD3- (APC-Cy7) CD20- (PE-Cy7), which was then 
discriminated into plasma cells by CD19- (Pacific blue) CD138+ (Alexa Fluor 700), CD27high 
(Qdot 800), CD38 high (APC) and IgD- (Qdot 605) markers. 
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Figure 6- 4. Gating strategy of Panel 4 (NK, DC, and Monocytes). 
Gating of sample starts with the FSC-A and SSC-A to exclude the cell debris.  Gating on the 
CD3+ (APC/Cy7) and CD56+ (Qdot 605) from PBMC was the NKT cell.   The gate on CD3- 
(APC/Cy7) and CD19- (Pacific blue) was discriminated into CD14+ (Alexa Fluor 700) 
monocytes, which were further discriminated into classical and non-classical subpopulations by 
CD16 (Qdot 800) marker.  The CD14- (Alexa 700) subset was gated to discriminate the NK 
cells (CD56+ Qdot 605) and DCs (HLA-DR+ PerCp-Cy5.5).  The DCs were then divided into 
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Figure 6- 5. Quantification of protein expression of target molecules. 
Left panel - IKZF (FITC) expression signals on Treg subset. From top to down, the histograms 
were isotype control (red), IKZF1 (blue), IKZF2 (yellow), and IKZF3 (green). The protein level of 
IKZF1/2/3 was calculated by the following formula: MFI_IKZF – MFI_IsotypeControl.   
Right panel - OX40L (PE) expression on B cells subset.  The top right histogram was isotype 
control PE (blue) and the remaining three histograms were for OX40L PE.  The protein level of 
OX40L was calculated by the following formula: (MFI_OX40L(1) + MFI_OX40L(2))/2 – 
MFI_IsotypeControl.  Histograms with the same colour on the left and right panel indicate the 
corresponding FITC (IKZF1/2/3 or isotype control) and PE (OX40L or isotype control) were 






6.2  The cell counts of immune subsets in PBMC 
PBMC is a bulk tissue comprising many cell types, including B and T lymphocytes, monocytes, 
dendritic cells, and natural killer cells.  I analysed these composition data from flow cytometry 
using R and GraphPad Prism 7 to test if there is any difference between the immune cells 
composition in PBMC between patients and controls.  In total, 51 immune subsets were identified, 
while four of them, including Activated Effector CD4+ T cells, Activated Central Memory CD8+ T 
cells, Activated Effector CD8+ T cells, and plasma cells, were removed due to their relative small 
sample size, leaving 47 immune subsets for further analyses.  Figure 6-6 and Table 6-2 shows 
the summary statistics for the cell counts of all the 47 immune subsets and the absolute number 
of PBMC.  When examining the cell counts of these cell subsets between 22 SLE patients and 
20 healthy controls, I observed that the absolute number of PBMCs was decreased (P= 0.0196) 
in SLE patients (Mean = 248206) when comparing to healthy controls (Mean = 270539).   
Moreover, I found that immune subsets who had a significant decreased in the absolute cell 
counts in SLE patients were majorly innate immune cells, including NK cells (mean difference 
(95% CI): -14951 (-23473, -6430); P = 0.00108), NKT cells (-9494 (-14223, -4765); P = 0.000348), 
and Plasmacytoid DCs (-724 (-1141, -308); P = 0.00134), all with a FDR < 0.05.  While the cell 
counts of adaptive immune subsets were more likely to be elevated in SLE patients when 
comparing to controls, such as Th2 (16337 (188, 32486); P = 0.0476), Activated Th2 (186 (86, 
285); P= 0.000779), Activated Th1 (202 (27, 377); P = 0.0256), Activated CD4+ T cells (508 (165, 
850); P = 0.00499), Activated Central Memory CD4+ T cells (226 (42, 411); P = 0.0185), as well 
as DN B cells (963 (150, 1776); P = 0.0224).  Interestingly, the absolute number of Th1Th17 (-
6865 (-10859, -2870); P = 0.00125) and Effector Memory CD8+ T cells (-5958 (-11887, -29); P = 
0.0489) were decreased in SLE patients.  When examining the correlation between the cell counts 
of immune subsets and disease activity as measured by SLEDAI, I found that the absolute 
numbers of both monocytes (P = 0.055) and classical monocytes (P = 0.046) were positively 
correlated with SLEDAI [157] (Figure 6-7. a & b), while both naïve B cells (P = 0.038) and non-
switched memory B cells (P = 0.0036) were negatively correlated with SLEDAI (Figure 6-7. c & 
d), indicating the innate and adaptive immune system may have distinct functions in the 





Table 6- 2. The absolute number of immune subsets.  
 
Notes: colours in the table: 1) red indicates a significant difference of cell proportions between 
SLE and controls with a p-value ≤ 0.05 & q-value ≤ 0.05; 2) purple indicates a p-value ≤ 0.05 & 
q-value >	0.05. 
  
PANEL Cell	Type SLE	Mean Control	Mean Mean	difference	(95%	CI) p-value q-value
PANEL1 PBMC 248206 270539 -22333	(-40774,	-3893) 0.0196 0.105
PANEL1 CD3+	T	cells 145362 161786 -16424	(-39644,	6795) 0.158 0.323
PANEL1 CD4+	T	cells 102197 102497 -300	(-22694,	22094) 0.978 0.978
PANEL1 Central	Memory	CD4+	T	cells 41282 47837 -6555	(-19192,	6082) 0.3 0.427
PANEL1 Effector	CD4+	T	cells 1454 1823 -369	(-1745,	1007) 0.586 0.689
PANEL1 Effector	Memory	CD4+	T	cells 13361 16373 -3013	(-8650,	2625) 0.286 0.42
PANEL1 Naive	CD4+	T	cells 45749 36463 9286	(-6752,	25324) 0.246 0.385
PANEL1 CD8+	T	cells 34710 41578 -6868	(-21376,	7640) 0.344 0.476
PANEL1 Central	Memory	CD8+	T	cells 2983 3512 -529	(-2332,	1273) 0.556 0.67
PANEL1 Effector	CD8+	T	cells 7913 14481 -6568	(-14265,	1129) 0.092 0.24
PANEL1 Effector	Memory	CD8+	T	cells 6597 12555 -5958	(-11887,	-29) 0.0489 0.192
PANEL1 Naive	CD8+	T	cells 17210 11031 6179	(-309,	12668) 0.0611 0.205
PANEL1 DP	T	cells 1540 1219 321	(-419,	1061) 0.383 0.514
PANEL1 Th1 20297 27020 -6723	(-15722,	2276) 0.139 0.323
PANEL1 Th17 11045 14095 -3050	(-7250,	1150) 0.15 0.323
PANEL1 Th1Th17 5667 12531 -6865	(-10859,	-2870) 0.00125 0.0105
PANEL1 Th2 65189 48851 16337	(188,	32486) 0.0476 0.192
PANEL1 Activated	CD4+	T	cells 1159 651 508	(165,	850) 0.00499 0.0335
PANEL1 Activated	Central	Memory	CD4+	T	cells 456 230 226	(42,	411) 0.0185 0.109
PANEL1 Activated	Effector	Memory	CD4+	T	cells 250 112 138	(-2,	279) 0.0537 0.194
PANEL1 Activated	Th1 407 205 202	(27,	377) 0.0256 0.12
PANEL1 Activated	Th17 152 106 46	(-29,	122) 0.218 0.381
PANEL1 Activated	Th1Th17 120 104 16	(-31,	64) 0.493 0.626
PANEL1 Activated	Th2 282 96 186	(86,	285) 0.000779 0.0105
PANEL1 Activated	CD8+	T	cells 677 322 355	(-145,	855) 0.155 0.323
PANEL1 Activated	Central	Memory	CD8+	T	cells 90 47 43	(-4,	90) 0.0705 0.207
PANEL1 Activated	Effector	Memory	CD8+	T	cells 257 117 140	(-115,	395) 0.266 0.403
PANEL2 Treg 2427 2051 376	(-249,	1000) 0.228 0.381
PANEL2 Memory	Treg 2283 1929 355	(-243,	952) 0.235 0.381
PANEL2 Naive	Treg 139 119 20	(-37,	77) 0.481 0.626
PANEL2 Activated	Treg 362 251 111	(-72,	294) 0.221 0.381
PANEL3 B	cells 15736 10183 5553	(-609,	11715) 0.075 0.207
PANEL3 DN	B	cells 1745 782 963	(150,	1776) 0.0224 0.117
PANEL3 Naive	B	cells 7853 4764 3089	(-1389,	7566) 0.166 0.325
PANEL3 Transitional	B	cells 828 371 457	(-43,	957) 0.0711 0.207
PANEL3 Plasmablasts 1038 442 596	(-191,	1383) 0.13 0.322
PANEL3 Switched	Memory	B	cells 1693 1702 -9	(-594,	576) 0.975 0.978
PANEL3 Non-Switched	Memory	B	cells 2508 2039 469	(-1360,	2299) 0.604 0.692
PANEL4 DCs 6656 6930 -274	(-2865,	2317) 0.832 0.899
PANEL4 Myeloid	DCs 5697 5412 285	(-2122,	2693) 0.811 0.899
PANEL4 Plasmacytoid	DCs 533 1258 -724	(-1141,	-308) 0.00134 0.0105
PANEL4 NK	cells 19615 34566 -14951	(-23473,	-6430) 0.00108 0.0105
PANEL4 CD16+	NK	cells 17702 32469 -14766	(-23230,	-6303) 0.00116 0.0105
PANEL4 CD16-	NK	cells 1898 2081 -183	(-744,	378) 0.513 0.635
PANEL4 Monocytes 42018 40662 1355	(-12410,	15120) 0.842 0.899
PANEL4 Classical	Monocytes 37760 37999 -239	(-12392,	11913) 0.968 0.978
PANEL4 Non-classical	Monocytes 4219 2634 1585	(-874,	4045) 0.197 0.37












Figure 6- 6. The absolute number of immune subsets in patients and controls.  
Top panel: T cell subsets; Middle panel: Active T cell subsets; Bottom panel: monocytes, NK cells 
and DCs.  Cell types highlighted with light yellow boxes have passed the multiple testing 
adjustment with a q value  0.05.  Cell types highlighted with blue boxes have a p value  0.05 
but failed to passed the multiple testing adjustment. Y-axis is presented in a log10 scale. The cell 











































































































































































































































































































































































Figure 6- 7. Correlation between the absolute number of immune subsets and SLEDAI. 
Top panel: Positive correlation of SLEDAI with absolute number of Monocytes (a) and Classical 
monocytes (b).  Bottom panel: Negative correlation of SLEDAI with absolute number of Naïve 









































































































l Sample size: N=15
Spearman Correlation: P=0.0036






6.3  The cell proportions of immune subsets in PBMC 
Figure 6-8 and Table 6-4 shows the summary statistics for the proportions (percentage in PBMC) 
of all the 47 immune subsets.  When examining the relative frequencies of cell subsets between 
22 SLE patients and 20 healthy controls, I observed that Th2 cells were elevated (7.98 (2.2, 13.76), 
P = 0.00853), while Th1Th17 cells were decreased (-2.39 (-3.81, -0.97), P = 0.00155) in SLE 
patients compared to healthy controls.  When looking at the activated T cell panel, the frequencies 
of activated T cell subpopulations were higher in SLE than healthy controls, including activated 
central memory CD4+ T cell (0.1 (0.03, 0.18), P = 0.0104), activated effector memory CD4+ T 
cells (0.06 (0.01, 0.12), P = 0.0296), activated Th1 cells (0.09 (0.02, 0.16), P = 0.0138) and 
activated Th2 cells 0.08 (0.04, 0.13), P = 0.000812).  Notably, the proportion of B cells (2.65 (0.25, 
5.05), P = 0.032) and transitional B cells (0.21 (0, 0.41), P = 0.0461) were higher in SLE than in 
healthy control, while the proportion of NK cells (-4.03 (-7.52, -0.54), P = 0.0247) and 
Plasmacytoid DCs (-0.25 (-0.39, -0.1), P = 0.00188) was higher in controls than in patients When 
examining the correlation between the frequencies of immune subsets and disease activity as 
measured by SLEDAI [157], I found that NK cell frequencies and B cell frequencies were both 
negatively correlated with SLEDAI, suggesting that patients with more active SLE tended to have 






Table 6- 3. Proportion of immune cells in PBMC.  
 
Notes: colours in the table: 1) red indicates a significant difference of cell proportions between 
SLE and controls with a p-value ≤ 0.05 & q-value ≤ 0.05; 2) purple indicates a p-value ≤ 0.05 & 
q-value >	0.05; 3) grey and italic indicates the cell subpopulation is excluded due to the limited 
number of cell counts. 
 
 
PANEL Cell	Type SLE	Mean Control	Mean Mean	difference	(95%	CI) p-value q-value
PANEL1 CD3	T	cells 57.94 59.85 -1.91	(-9.64,	5.83) 0.618 0.687
PANEL1 CD4+	T	cells 40.66 37.86 2.81	(-5.07,	10.68) 0.475 0.609
PANEL1 Activated	CD4+	T	cells 0.48 0.24 0.24	(0.09,	0.39) 0.00236 0.0236
PANEL1 Central	Memory	CD4+	T	cells 16.61 17.68 -1.07	(-5.78,	3.64) 0.648 0.704
PANEL1 Activated	Central	Memory	CD4+	T	cells 0.19 0.09 0.1	(0.03,	0.18) 0.0104 0.0743
PANEL1 Effector	CD4+	T	cells 0.6 0.69 -0.09	(-0.63,	0.45) 0.741 0.756
PANEL1 Activated	Effector	CD4+	T	cells 0.03 0.01 0.03	(-0.02,	0.07) 0.231 0.374
PANEL1 Effector	Memory	CD4+	T	cells 5.41 6.09 -0.68	(-2.82,	1.45) 0.521 0.61
PANEL1 Activated	Effector	Memory	CD4+	T	cells 0.1 0.04 0.06	(0.01,	0.12) 0.0296 0.114
PANEL1 Naive	CD4+	T	cells 17.91 13.4 4.51	(-1.27,	10.29) 0.121 0.238
PANEL1 Th1 8.04 10.07 -2.03	(-5.43,	1.36) 0.232 0.374
PANEL1 Activated	Th1 0.17 0.08 0.09	(0.02,	0.16) 0.0138 0.0767
PANEL1 Th17 4.43 5.18 -0.75	(-2.29,	0.8) 0.334 0.464
PANEL1 Activated	Th17 0.07 0.04 0.03	(-0.02,	0.08) 0.196 0.35
PANEL1 Th1Th17 2.21 4.6 -2.39	(-3.81,	-0.97) 0.00155 0.0235
PANEL1 Activated	Th1Th17 0.05 0.04 0.01	(-0.01,	0.03) 0.244 0.381
PANEL1 Th2 25.98 18 7.98	(2.2,	13.76) 0.00853 0.0711
PANEL1 Activated	Th2 0.12 0.04 0.08	(0.04,	0.13) 0.000812 0.0203
PANEL1 CD8+	T	cells 13.82 15.45 -1.64	(-6.92,	3.65) 0.535 0.61
PANEL1 Activated	CD8+	T	cells 0.28 0.12 0.16	(-0.03,	0.35) 0.103 0.238
PANEL1 Central	Memory	CD8+	T	cells 1.19 1.32 -0.13	(-0.82,	0.56) 0.706 0.735
PANEL1 Activated	Central	Memory	CD8+	T	cells 0.04 0.02 0.02	(0,	0.04) 0.0447 0.136
PANEL1 Effector	CD8+	T	cells 3.13 5.37 -2.24	(-5.06,	0.58) 0.116 0.238
PANEL1 Activated	Effector	CD8+	T	cells 0.05 0.03 0.02	(-0.02,	0.07) 0.315 0.45
PANEL1 Effector	Memory	CD8+	T	cells 2.58 4.67 -2.09	(-4.29,	0.12) 0.063 0.175
PANEL1 Activated	Effector	Memory	CD8+	T	cells 0.1 0.04 0.06	(-0.04,	0.16) 0.212 0.366
PANEL1 Naive	CD8+	T	cells 6.9 4.09 2.81	(0.39,	5.24) 0.0246 0.103
PANEL1 DP	T	cells 0.66 0.45 0.21	(-0.16,	0.58) 0.259 0.392
PANEL2 Treg 0.97 0.74 0.23	(-0.03,	0.49) 0.0818 0.215
PANEL2 Activated	Treg 0.14 0.09 0.05	(-0.02,	0.12) 0.124 0.238
PANEL2 Memory	Treg 0.92 0.7 0.22	(-0.03,	0.47) 0.0867 0.217
PANEL2 Naive	Treg 0.05 0.04 0.01	(-0.01,	0.03) 0.267 0.393
PANEL3 B	cells 6.36 3.72 2.65	(0.25,	5.05) 0.032 0.114
PANEL3 DN	B	cells 0.71 0.29 0.42	(0.1,	0.74) 0.0123 0.0767
PANEL3 Naive	B	cells 3.11 1.74 1.37	(-0.38,	3.11) 0.118 0.238
PANEL3 Transitional	B	cells 0.34 0.13 0.21	(0,	0.41) 0.0461 0.136
PANEL3 Plasmablasts 0.47 0.16 0.31	(-0.08,	0.69) 0.11 0.238
PANEL3 Switched	Memory	B	cells 0.68 0.62 0.06	(-0.14,	0.27) 0.537 0.61
PANEL3 Non	Switched	Memory	B	cells 1.02 0.74 0.28	(-0.41,	0.97) 0.415 0.546
PANEL3 Plasma	cells 0.02 0 0.02	(0,	0.04) 0.0361 0.12
PANEL4 DCs 2.62 2.5 0.12	(-0.83,	1.07) 0.795 0.795
PANEL4 Myeloid	DCs 2.24 1.95 0.29	(-0.6,	1.18) 0.514 0.61
PANEL4 Plasmacytoid	DCs 0.21 0.45 -0.25	(-0.39,	-0.1) 0.00188 0.0235
PANEL4 NK	cells 8.36 12.39 -4.03	(-7.52,	-0.54) 0.0247 0.103
PANEL4 CD16+	NK	cells 7.54 11.63 -4.09	(-7.53,	-0.66) 0.0209 0.103
PANEL4 CD16-	NK	cells 0.81 0.75 0.06	(-0.23,	0.35) 0.664 0.706
PANEL4 Monocytes 17.18 14.7 2.49	(-3.35,	8.32) 0.389 0.526
PANEL4 Classical	Monocytes 15.35 13.72 1.63	(-3.28,	6.55) 0.501 0.61
PANEL4 Non-classical	Monocytes 1.81 0.97 0.85	(-0.35,	2.05) 0.158 0.293











Figure 6- 8. Immune cells composition of PBMC in patients and controls.  
Top panel: T cell subsets; Middle panel: Active T cell subsets; Bottom panel: monocytes, NK cells 
and DCs.  Cell types highlighted with light yellow boxes have passed the multiple testing 
adjustment with a q value  0.05.  Cell types highlighted with blue boxes have a p value  0.05 





























































































































































































































































































































































































Figure 6- 9. Correlation between the cell proportions of immune subsets and SLEDAI. 
Left panel. B cell proportions in SLE patients and healthy controls (a) and the correlation of 
SLEDAI and B cell proportions (c).  Right panel: NK cell proportions in SLE patients and healthy 





























Sample sizeSLE 20 + Control 22

























Sample sizeSLE 20 + Control 21
T test: P = 0.024




















































6.4  OX40L protein expression 
Figure 6-10 and Table 6-4 showed the average expression level of the OX40L in patients and 
controls among all cell types being analysed.  The expression level of OX40L was relatively low 
in all T cell subsets, with a MFI (median fluorescence intensity) ranged from 5 to 20, while the 
MFI on the activated Th1Th17 was obviously higher than others, ranging from 30 to 40.  When 
looking at the non-T cell panel showed in Figure 6-8, the expression of OX40L was much higher 
in patients than that in controls on B cells (48.5 (0.9, 96.2), P = 0.046) and Non-classical 
monocytes (32.9 (0.7, 65.1), P = 0.0455), indicating the protein level of OX40L was correlated 
with the disease status.  Previous studies have showed that the level of OX40L is significantly 
increased under the activation of immune system [201].  Moreover, OX40L is found to exclusively 
express on APCs (Antigen presenting cells, APC) and especially on activated cells, consistent 






Table 6- 4. Average level of OX40L on immune subpopulations in SLE and controls.  
 
Notes: colours in the table: 1) purple indicates a significant difference of OX40L between SLE and 
controls with a p-value ≤ 0.05 & q-value >	0.05; 2) grey and italic indicates the cell subpopulation 
is excluded due to the limited number of cell counts. 
 
 
PANEL Cell	Type SLE	Mean Control	Mean Mean	difference	(95%	CI) p-value q-value
PANEL1 PBMC 15.9 9.8 6.1	(0.8,	11.4) 0.0264 0.283
PANEL1 CD3	T	cells 7.2 5.9 1.4	(-1.9,	4.6) 0.396 0.554
PANEL1 CD4+	T	cells 8.7 7.4 1.3	(-3,	5.7) 0.542 0.658
PANEL1 Activated	CD4+	T	cells 16.5 12.6 3.9	(-4.7,	12.4) 0.365 0.532
PANEL1 Central	Memory	CD4+	T	cells 9.3 7.9 1.4	(-3.4,	6.1) 0.567 0.672
PANEL1 Activated	Central	Memory	CD4+	T	cells 18.7 7.9 10.9	(2.4,	19.3) 0.013 0.283
PANEL1 Effector	CD4+	T	cells 11.4 5.9 5.5	(-0.8,	11.8) 0.0863 0.297
PANEL1 Activated	Effector	CD4+	T	cells 15.1 38.1 -23	(-52.8,	6.8) 0.126 0.326
PANEL1 Effector	Memory	CD4+	T	cells 9.1 8.2 1	(-3.7,	5.6) 0.676 0.734
PANEL1 Activated	Effector	Memory	CD4+	T	cells 9.8 17.3 -7.6	(-18.5,	3.4) 0.169 0.359
PANEL1 Naive	CD4+	T	cells 8.3 6.1 2.2	(-2,	6.4) 0.297 0.485
PANEL1 Th1 10.7 7.7 3	(-2.9,	8.9) 0.311 0.485
PANEL1 Activated	Th1 16.4 8.1 8.4	(-0.3,	17) 0.058 0.283
PANEL1 Th17 10.4 8.5 1.9	(-3.1,	6.8) 0.452 0.576
PANEL1 Activated	Th17 19 12 7	(-7.8,	21.8) 0.345 0.518
PANEL1 Th1Th17 15.5 11.3 4.2	(-4.1,	12.5) 0.314 0.485
PANEL1 Activated	Th1Th17 29.5 33.2 -3.8	(-23.5,	16) 0.702 0.746
PANEL1 Th2 7.8 6.1 1.7	(-2.4,	5.8) 0.402 0.554
PANEL1 Activated	Th2 13.9 17.8 -3.9	(-14,	6.2) 0.439 0.574
PANEL1 CD8+	T	cells 5.8 4.3 1.5	(-1,	4) 0.238 0.434
PANEL1 Activated	CD8+	T	cells 15.7 13.6 2.2	(-5.8,	10.1) 0.582 0.675
PANEL1 Central	Memory	CD8+	T	cells 7.6 6.2 1.5	(-2.3,	5.2) 0.432 0.574
PANEL1 Activated	Central	Memory	CD8+	T	cells 23.6 7.9 15.7	(-1.4,	32.8) 0.071 0.283
PANEL1 Effector	CD8+	T	cells 4.5 3.8 0.7	(-1.6,	2.9) 0.539 0.658
PANEL1 Activated	Effector	CD8+	T	cells 16.4 14 2.4	(-16.2,	20.9) 0.797 0.83
PANEL1 Effector	Memory	CD8+	T	cells 5.1 4.5 0.5	(-1.9,	3) 0.656 0.727
PANEL1 Activated	Effector	Memory	CD8+	T	cells 10.6 11.4 -0.9	(-15.8,	14.1) 0.907 0.907
PANEL1 Naive	CD8+	T	cells 6.2 4 2.2	(-0.7,	5.1) 0.126 0.326
PANEL1 DP	T	cells 14.1 10 4	(-1.2,	9.3) 0.128 0.326
PANEL2 Treg 13.4 7.1 6.3	(-0.3,	12.9) 0.0601 0.283
PANEL2 Activated	Treg 18.8 9.3 9.5	(-1.7,	20.7) 0.0933 0.297
PANEL2 Memory	Treg 13.4 6.5 7	(0.5,	13.4) 0.0348 0.283
PANEL2 Naive	Treg 17.4 3.5 13.8	(2.9,	24.8) 0.0146 0.283
PANEL3 B	cells 59.3 10.8 48.5	(0.9,	96.2) 0.0463 0.283
PANEL3 DN	B	cells 51.9 8.5 43.4	(-7,	93.8) 0.0877 0.297
PANEL3 Naive	B	cells 53.4 7.1 46.3	(-1.9,	94.5) 0.059 0.283
PANEL3 Transitional	B	cells 69.8 8.2 61.6	(-6.1,	129.3) 0.0722 0.283
PANEL3 Plasmablasts 52.3 40 12.3	(-11,	35.7) 0.292 0.485
PANEL3 Switched	Memory	B	cells 50.4 12.4 38	(-13.8,	89.8) 0.142 0.345
PANEL3 Non	Switched	Memory	B	cells 78.3 11.6 66.7	(8.5,	124.9) 0.0268 0.283
PANEL3 Plasma	cells 86.9 54 32.9	(-13.9,	79.8) 0.162 0.359
PANEL4 DCs 27.5 16 11.5	(-0.6,	23.6) 0.0621 0.283
PANEL4 Myeloid	DCs 31.6 20.9 10.7	(-2.3,	23.8) 0.103 0.309
PANEL4 Plasmacytoid	DCs 5.7 4.8 0.9	(-3.2,	5) 0.652 0.727
PANEL4 NK	cells 4.7 2.3 2.4	(-1.6,	6.4) 0.222 0.419
PANEL4 CD16+	NK	cells 4.9 2.4 2.5	(-1.1,	6.1) 0.169 0.359
PANEL4 CD16-	NK	cells 6.2 2.2 4	(-3.3,	11.3) 0.267 0.47
PANEL4 Monocytes 70.8 53.2 17.6	(-9.8,	45) 0.2 0.408
PANEL4 Classical	Monocytes 70.7 53.7 17	(-10.5,	44.5) 0.217 0.419
PANEL4 Non-classical	Monocytes 80.6 47.7 32.9	(0.7,	65.1) 0.0455 0.283








Figure 6- 10. Protein expression of OX40L across all cell types identified. 
The x-axis shows the cell types and the y-axis shows the protein level (MFI) of OX40L.  For the 
protein level of OX40L on the corresponding cell types, mean and 95%CI is showed. (a) T cell 




















































































































































































































































































































































6.5  IKZF1 protein expression 
In general, SLE patients tended to have less IKZF1 protein levels across T cell subsets than in 
healthy controls (Figure 6-11 and Table 6-5).  In the T cell panel, IKZF1 was significantly 
decreased in SLE patients for the following subsets:  Activated CD4+ T cells (-272 (-531, -13), P 
= 0.0401), Effector CD4+ T cells (-195 (-367, -22), P = 0.028), Activated Effector memory CD4+ 
T cells (-271 (-502, -40), P = 0.023), Activated Th2 cells (-319 (-567, -72); P  = 0.013), Activated 
CD8+ T cells (-289 (-561, -18), P = 0.037), and Activated Effector memory CD4+ T cells (-296 (-
543, -49), P = 0.020), though all the significance level failed to pass the multiple testing burden 
(q > 0.05).  No statistically significant differences were observed in the IKZF1 expression between 






Table 6- 5. Average level of IKZF1 on immune subpopulations in SLE and controls.  
 
Notes: colours in the table: 1) purple indicates a significant difference of IKZF1 between SLE and 
controls with a p-value ≤ 0.05 & q-value >	0.05; 2) grey and italic indicates the cell subpopulation 
is excluded due to the limited number of cell counts. 
 
PANEL Cell	Type SLE	Mean Control	Mean Mean	difference	(95%	CI) p-value q-value
PANEL1 PBMC 774 881 -106	(-308,	96) 0.292 0.581
PANEL1 CD3	T	cells 731 850 -119	(-314,	76) 0.225 0.522
PANEL1 CD4+	T	cells 680 802 -121	(-299,	56) 0.175 0.454
PANEL1 Activated	CD4+	T	cells 893 1165 -272	(-531,	-13) 0.0401 0.256
PANEL1 Central	Memory	CD4+	T	cells 700 823 -124	(-299,	52) 0.162 0.454
PANEL1 Activated	Central	Memory	CD4+	T	cells 869 1038 -168	(-411,	74) 0.168 0.454
PANEL1 Effector	CD4+	T	cells 583 778 -195	(-367,	-22) 0.028 0.256
PANEL1 Activated	Effector	CD4+	T	cells 776 1261 -484	(-791,	-178) 0.00284 0.145
PANEL1 Effector	Memory	CD4+	T	cells 635 781 -146	(-322,	31) 0.103 0.454
PANEL1 Activated	Effector	Memory	CD4+	T	cells 734 1005 -271	(-502,	-40) 0.0229 0.256
PANEL1 Naive	CD4+	T	cells 692 782 -90	(-274,	94) 0.328 0.581
PANEL1 Th1 683 783 -99	(-278,	80) 0.269 0.572
PANEL1 Activated	Th1 908 1085 -177	(-429,	75) 0.164 0.454
PANEL1 Th17 761 829 -68	(-254,	118) 0.461 0.619
PANEL1 Activated	Th17 1028 1272 -244	(-531,	43) 0.0928 0.454
PANEL1 Th1Th17 791 839 -48	(-234,	138) 0.602 0.663
PANEL1 Activated	Th1Th17 1145 1355 -210	(-586,	166) 0.264 0.572
PANEL1 Th2 670 796 -126	(-303,	52) 0.16 0.454
PANEL1 Activated	Th2 811 1131 -319	(-567,	-72) 0.0128 0.256
PANEL1 CD8+	T	cells 765 845 -80	(-288,	127) 0.436 0.619
PANEL1 Activated	CD8+	T	cells 905 1195 -289	(-561,	-18) 0.0371 0.256
PANEL1 Central	Memory	CD8+	T	cells 821 920 -99	(-329,	131) 0.388 0.586
PANEL1 Activated	Central	Memory	CD8+	T	cells 1071 1456 -385	(-735,	-35) 0.0318 0.256
PANEL1 Effector	CD8+	T	cells 679 820 -141	(-349,	67) 0.178 0.454
PANEL1 Activated	Effector	CD8+	T	cells 842 1080 -238	(-586,	111) 0.175 0.454
PANEL1 Effector	Memory	CD8+	T	cells 666 796 -130	(-328,	68) 0.192 0.466
PANEL1 Activated	Effector	Memory	CD8+	T	cells 778 1074 -296	(-543,	-49) 0.0202 0.256
PANEL1 Naive	CD8+	T	cells 808 909 -101	(-318,	117) 0.354 0.582
PANEL1 DP	T	cells 911 988 -77	(-351,	198) 0.574 0.657
PANEL2 Treg 538 616 -78	(-236,	80) 0.326 0.581
PANEL2 Activated	Treg 719 878 -159	(-368,	50) 0.131 0.454
PANEL2 Memory	Treg 535 613 -78	(-235,	80) 0.326 0.581
PANEL2 Naive	Treg 590 639 -50	(-231,	131) 0.58 0.657
PANEL3 B	cells 753 674 79	(-133,	291) 0.451 0.619
PANEL3 DN	B	cells 856 764 92	(-123,	307) 0.391 0.586
PANEL3 Naive	B	cells 604 580 24	(-152,	201) 0.78 0.829
PANEL3 Transitional	B	cells 714 713 2	(-169,	173) 0.983 0.983
PANEL3 Plasmablasts 1115 1348 -233	(-523,	56) 0.111 0.454
PANEL3 Switched	Memory	B	cells 892 876 15	(-191,	222) 0.88 0.91
PANEL3 Non	Switched	Memory	B	cells 750 764 -14	(-222,	194) 0.892 0.91
PANEL3 Plasma	cells 1004 1166 -163	(-687,	362) 0.53 0.644
PANEL4 DCs 1390 1552 -162	(-496,	171) 0.331 0.581
PANEL4 Myeloid	DCs 1364 1446 -82	(-405,	241) 0.611 0.663
PANEL4 Plasmacytoid	DCs 1888 1735 154	(-282,	589) 0.477 0.624
PANEL4 NK	cells 794 734 60	(-117,	237) 0.496 0.632
PANEL4 CD16+	NK	cells 787 734 53	(-122,	228) 0.545 0.646
PANEL4 CD16-	NK	cells 806 740 66	(-114,	245) 0.461 0.619
PANEL4 Monocytes 1043 1165 -122	(-398,	154) 0.378 0.586
PANEL4 Classical	Monocytes 1010 1138 -128	(-397,	141) 0.342 0.581
PANEL4 Non-classical	Monocytes 1550 1821 -271	(-671,	129) 0.178 0.454








Figure 6- 11. Protein expression of IKZF1 across all cell types identified. 
The x-axis shows the cell types and the y-axis shows the protein level (MFI) of IKZF1.  For the 























































































































































































































































































































































6.6  IKZF2 protein expression 
No significant differences were observed in terms of IKZF2 expression between SLE patients and 
healthy controls across all T cell subsets. However, a higher level of IKZF2 was found in activated 
CD4+ T cell subsets than in non-activated ones in both patients and controls as shown in Figure 
6-12 and Table 6-6.  For example, protein level of IKZF2 was higher in activated Th1 than in Th1 
cells, and higher in activated regulatory T cells than in naïve regulatory T cells.  In the non-T cells 
panel, NK cells (131 (-272, 534), P = 0.51) showed a trend of increasing in IKZF2 in patients, 
while monocytes (-160 (-429, 109); P = 0.23) and dendritic cells (-122 (-464, 220), P = 0.47) 
showed a trend of decrease in patients than in controls.  No clear difference was observed 
between patients and controls in the B cell subsets.  Overall, differences of IKZF2 protein level 
between SLE patients and controls failed to reach the statistically significance across all immune 






Table 6- 6. Average level of IKZF2 on immune subpopulations in SLE and controls.  
 
Notes: text in grey and italic indicates the cell subpopulation is excluded due to the limited number 
of cell counts. 
 
PANEL Cell	Type SLE	Mean Control	Mean Mean	difference	(95%	CI) p-value q-value
PANEL1 PBMC 1180 1355 -176	(-485,	134) 0.258 0.848
PANEL1 CD3	T	cells 1182 1275 -93	(-404,	218) 0.548 0.942
PANEL1 CD4+	T	cells 1124 1160 -37	(-314,	241) 0.791 0.942
PANEL1 Activated	CD4+	T	cells 1720 2074 -354	(-761,	53) 0.0864 0.848
PANEL1 Central	Memory	CD4+	T	cells 1167 1135 31	(-253,	316) 0.824 0.942
PANEL1 Activated	Central	Memory	CD4+	T	cells 1892 2057 -165	(-612,	281) 0.458 0.934
PANEL1 Effector	CD4+	T	cells 1052 1095 -43	(-325,	240) 0.761 0.942
PANEL1 Activated	Effector	CD4+	T	cells 1348 1572 -224	(-710,	262) 0.357 0.934
PANEL1 Effector	Memory	CD4+	T	cells 1090 1064 26	(-243,	296) 0.844 0.942
PANEL1 Activated	Effector	Memory	CD4+	T	cells 1507 1734 -226	(-575,	122) 0.195 0.848
PANEL1 Naive	CD4+	T	cells 1118 1243 -125	(-415,	165) 0.387 0.934
PANEL1 Th1 1125 1100 24	(-258,	307) 0.863 0.942
PANEL1 Activated	Th1 1657 1883 -226	(-630,	179) 0.266 0.848
PANEL1 Th17 1122 1094 28	(-237,	293) 0.831 0.942
PANEL1 Activated	Th17 1951 2242 -291	(-763,	181) 0.219 0.848
PANEL1 Th1Th17 1182 1124 58	(-229,	345) 0.684 0.942
PANEL1 Activated	Th1Th17 1873 2396 -523	(-1050,	3) 0.0511 0.848
PANEL1 Th2 1129 1223 -94	(-379,	190) 0.506 0.934
PANEL1 Activated	Th2 1806 2160 -354	(-759,	51) 0.085 0.848
PANEL1 CD8+	T	cells 1194 1326 -132	(-451,	188) 0.409 0.934
PANEL1 Activated	CD8+	T	cells 1409 1738 -329	(-695,	37) 0.0771 0.848
PANEL1 Central	Memory	CD8+	T	cells 1258 1253 5	(-354,	363) 0.979 0.979
PANEL1 Activated	Central	Memory	CD8+	T	cells 1603 1915 -312	(-747,	123) 0.155 0.848
PANEL1 Effector	CD8+	T	cells 1264 1497 -233	(-630,	164) 0.241 0.848
PANEL1 Activated	Effector	CD8+	T	cells 1352 1562 -210	(-671,	251) 0.362 0.934
PANEL1 Effector	Memory	CD8+	T	cells 1128 1330 -202	(-494,	89) 0.167 0.848
PANEL1 Activated	Effector	Memory	CD8+	T	cells 1185 1479 -294	(-612,	25) 0.0697 0.848
PANEL1 Naive	CD8+	T	cells 1169 1254 -84	(-397,	228) 0.586 0.942
PANEL1 DP	T	cells 1419 1455 -36	(-422,	350) 0.851 0.942
PANEL2 Treg 1367 1475 -108	(-427,	210) 0.494 0.934
PANEL2 Activated	Treg 1969 2225 -256	(-705,	193) 0.255 0.848
PANEL2 Memory	Treg 1369 1476 -108	(-427,	211) 0.498 0.934
PANEL2 Naive	Treg 1387 1477 -90	(-425,	245) 0.589 0.942
PANEL3 B	cells 994 957 38	(-227,	302) 0.774 0.942
PANEL3 DN	B	cells 907 882 25	(-209,	260) 0.827 0.942
PANEL3 Naive	B	cells 932 903 29	(-249,	307) 0.832 0.942
PANEL3 Transitional	B	cells 1206 1184 22	(-266,	309) 0.88 0.942
PANEL3 Plasmablasts 754 714 40	(-212,	292) 0.747 0.942
PANEL3 Switched	Memory	B	cells 1013 1031 -19	(-281,	244) 0.887 0.942
PANEL3 Non	Switched	Memory	B	cells 1082 1059 23	(-264,	310) 0.873 0.942
PANEL3 Plasma	cells 653 644 8	(-423,	439) 0.969 0.979
PANEL4 DCs 1287 1408 -122	(-464,	220) 0.475 0.934
PANEL4 Myeloid	DCs 1359 1516 -158	(-529,	214) 0.396 0.934
PANEL4 Plasmacytoid	DCs 1122 1130 -8	(-314,	299) 0.96 0.979
PANEL4 NK	cells 1700 1569 131	(-272,	534) 0.513 0.934
PANEL4 CD16+	NK	cells 1786 1608 178	(-242,	598) 0.395 0.934
PANEL4 CD16-	NK	cells 1264 1223 41	(-258,	340) 0.783 0.942
PANEL4 Monocytes 1025 1185 -160	(-429,	109) 0.235 0.848
PANEL4 Classical	Monocytes 1001 1166 -165	(-429,	99) 0.212 0.848
PANEL4 Non-classical	Monocytes 1572 1836 -264	(-733,	205) 0.261 0.848








Figure 6- 12. Protein expression of IKZF2 across all immune subsets. 
The x-axis shows the cell types and the y-axis shows the protein level (MFI) of IKZF2.  For the 





















































































































































































































































































































































6.7  IKZF3 protein expression 
In general, the expression level of IKZF3 was decreased in SLE patients compared to healthy 
controls in T cell subsets (Figure 6-13 and Table 6-7).   Similar to IKZF2, IKZF3 the protein level 
is increased in activated CD4+ T cells subsets comparing to the non-activated ones.  Specifically, 
the differences between activated CD4+ T cells were exaggerated after activation, i.e., the 
differences of IKZF3 protein level between SLE and controls in Activated CD4+ T cells (-165 (-
323, -6), P = 0.042), Activated Central Memory CD4+ T cells (-154 (-285, -23), P = 0.0225), 
Activated Th1 (-160 (-306, -13), P = 0.0339), Activated Th17 (-198 (-370, -26), P = 0.0249), 
Activated Th2 (-146 (-282, -10), P = 0.0356 )  and Activated Regulatory T cells (-122 (-229, -15), 
P = 0.026) were statistically significant though failed to pass the multiple testing burdens (q > 
0.05).  
The protein level of IKZF3 in the non-T cells subsets were similar between SLE and controls with 
modest differences in certain cell subsets.  Notably, the expression level of IKZF3 peaked in 
plasmablasts (MFI ranging from 800 ~ 1000) in both patients and controls.  Specifically, IKZF3 
protein level was increased in NK cells while decreased in monocytes in SLE patients when 






Table 6- 7. Average level of IKZF3 on immune subpopulations in SLE and controls.  
 
Notes: colours in the table: 1) purple indicates a significant difference of IKZF3 between SLE and 
controls with a p-value ≤ 0.05 & q-value >	0.05; 2) grey and italic indicates the cell subpopulation 
is excluded due to the limited number of cell counts. 
  
PANEL Cell	Type SLE	Mean Control	Mean Mean	difference	(95%	CI) p-value q-value
PANEL1 PBMC 374 451 -77	(-184,	30) 0.155 0.549
PANEL1 CD3	T	cells 365 436 -70	(-172,	31) 0.169 0.549
PANEL1 CD4+	T	cells 333 392 -59	(-148,	29) 0.183 0.549
PANEL1 Activated	CD4+	T	cells 496 660 -165	(-323,	-6) 0.042 0.306
PANEL1 Central	Memory	CD4+	T	cells 349 415 -66	(-152,	20) 0.127 0.498
PANEL1 Activated	Central	Memory	CD4+	T	cells 459 613 -154	(-285,	-23) 0.0225 0.303
PANEL1 Effector	CD4+	T	cells 320 428 -108	(-225,	8) 0.0682 0.386
PANEL1 Activated	Effector	CD4+	T	cells 497 837 -340	(-548,	-133) 0.00202 0.103
PANEL1 Effector	Memory	CD4+	T	cells 324 395 -71	(-160,	19) 0.117 0.497
PANEL1 Activated	Effector	Memory	CD4+	T	cells 470 574 -104	(-264,	56) 0.196 0.555
PANEL1 Naive	CD4+	T	cells 332 364 -32	(-125,	61) 0.487 0.792
PANEL1 Th1 354 410 -55	(-148,	38) 0.235 0.599
PANEL1 Activated	Th1 505 665 -160	(-306,	-13) 0.0339 0.303
PANEL1 Th17 397 434 -37	(-130,	56) 0.421 0.74
PANEL1 Activated	Th17 551 749 -198	(-370,	-26) 0.0249 0.303
PANEL1 Th1Th17 405 421 -17	(-115,	82) 0.732 0.879
PANEL1 Activated	Th1Th17 666 790 -124	(-386,	139) 0.344 0.675
PANEL1 Th2 321 368 -48	(-134,	38) 0.269 0.635
PANEL1 Activated	Th2 450 597 -146	(-282,	-10) 0.0356 0.303
PANEL1 CD8+	T	cells 418 442 -23	(-151,	104) 0.712 0.879
PANEL1 Activated	CD8+	T	cells 621 718 -96	(-299,	106) 0.338 0.675
PANEL1 Central	Memory	CD8+	T	cells 514 446 68	(-159,	296) 0.542 0.838
PANEL1 Activated	Central	Memory	CD8+	T	cells 745 866 -121	(-440,	198) 0.446 0.758
PANEL1 Effector	CD8+	T	cells 412 480 -67	(-206,	72) 0.334 0.675
PANEL1 Activated	Effector	CD8+	T	cells 581 629 -47	(-289,	194) 0.693 0.879
PANEL1 Effector	Memory	CD8+	T	cells 388 399 -11	(-140,	118) 0.864 0.958
PANEL1 Activated	Effector	Memory	CD8+	T	cells 545 642 -98	(-294,	99) 0.318 0.675
PANEL1 Naive	CD8+	T	cells 414 457 -43	(-170,	84) 0.497 0.792
PANEL1 DP	T	cells 509 497 13	(-162,	187) 0.885 0.96
PANEL2 Treg 262 322 -60	(-131,	11) 0.0977 0.453
PANEL2 Activated	Treg 357 479 -122	(-229,	-15) 0.026 0.303
PANEL2 Memory	Treg 264 323 -59	(-130,	11) 0.097 0.453
PANEL2 Naive	Treg 273 295 -22	(-116,	72) 0.637 0.855
PANEL3 B	cells 596 532 64	(-86,	215) 0.391 0.712
PANEL3 DN	B	cells 642 602 40	(-114,	193) 0.603 0.839
PANEL3 Naive	B	cells 461 442 19	(-95,	133) 0.741 0.879
PANEL3 Transitional	B	cells 591 505 86	(-40,	212) 0.174 0.549
PANEL3 Plasmablasts 831 924 -93	(-299,	113) 0.365 0.689
PANEL3 Switched	Memory	B	cells 726 750 -24	(-192,	144) 0.773 0.883
PANEL3 Non	Switched	Memory	B	cells 587 620 -32	(-179,	114) 0.659 0.862
PANEL3 Plasma	cells 759 751 8	(-468,	484) 0.972 0.972
PANEL4 DCs 395 399 -4	(-110,	102) 0.941 0.972
PANEL4 Myeloid	DCs 390 375 15	(-91,	120) 0.779 0.883
PANEL4 Plasmacytoid	DCs 398 396 3	(-91,	97) 0.954 0.972
PANEL4 NK	cells 501 447 54	(-45,	154) 0.274 0.635
PANEL4 CD16+	NK	cells 516 455 62	(-39,	163) 0.222 0.596
PANEL4 CD16-	NK	cells 364 287 77	(-1,	155) 0.053 0.338
PANEL4 Monocytes 337 365 -27	(-134,	79) 0.609 0.839
PANEL4 Classical	Monocytes 326 355 -29	(-133,	76) 0.584 0.839
PANEL4 Non-classical	Monocytes 454 493 -39	(-179,	102) 0.579 0.839








Figure 6- 13. Protein expression of IKZF3 across all cell types identified. 
The x-axis shows the cell types and the y-axis shows the protein level (MFI) of IKZF3.  For the 






















































































































































































































































































































































6.8  Correlation between protein expression and SLEDAI 
Only SLEDAI for 15 patients were available, see Chapter 2. Methods, Table 2-4.  In order to test 
if the protein level of target molecules (OX40L and IKZF1/2/3) correlated with the disease activity, 
I performed a Spearm correlation test between SLEDAI and the protein level of target molecules 
for all cell types identified.   Only the expression of OX40L on Th17 cells showed significant 
correlation with SLEDAI (P = 0.029) (Figure 6-14a).  Protein level of IKZF3 on B cells (P = 0.089) 
and plasmablasts (P = 0.097) showed suggestive correlation with SLEDAI, with higher level of 
IKZF3 correlated with more active disease status (Figure 6-14b).  Similarly, increasing expression 
of IKZF2 in monocytes and DCs were positively associated with SLEDAI.  Interestingly, only 
expression of IKZF2 on non-classical monocytes (P  = 0.069) was observed to be correlated with 
the activity of SLE, but not classical monocytes (P = 0.308), suggesting the differential roles of 
IKZF2 on monocytes subpopulations (Figure 6-14c).   While for the DCs (Figure 6-14d), only 
IKZF2 on myeloid DCs (P = 0.099) showed slightly correlation with SLEDAI, but not plasmacytoid 
DCs (P= 0.422).  No statistically significant correlations were observed for the protein level of 






Figure 6- 14.  Correlation between protein expression and SLEDAI. 
For all the scatter plots, SLEDAI is plotted on the x-axis and the protein level of target molecule 
is showed on the y-axis. The lines within the scatter plots are their corresponding linear regression 
lines. The summary statistics are showed under each plot. a) Correlation between OX40L on 
Th17 cells and SLEDAI. b) For correlation between IKZF3 and SLEDAI, red and black represent 
IKZF3 in plasmablasts and B cells, respectively.  c) For correlation between IKZF2 in monocytes 
and SLEDA, black, blue and red represent IKZF2 in all monocytes, classical monocytes, and non-
classical monocytes, respectively. d) For correlation between IKZF2 in DCs and SLEDA, black, 
blue and red represent IKZF2 in all DCs, Myeloid DCs, and plasmacytoid DCs, respectively. 
 
  





















Beta = 1.638 ± 0.6682
P value = 0.029*





















Spearman correlation All Monocytes Classical Monocytes Non-classical Monocytes
coefficient 0.2447 0.2919 0.5029
P value 0.3955 0.3084 0.069






















All B cells:       r = 0.47 & P = 0.0888
Plasmablasts: r = 0.46 & P = 0.0974





















Spearman correlation All DCs Myeloid DCs Plasmacytoid DCs
coefficient 0.4692 0.4603 0.2313







6.9  Discussion 
Genetic studies have identified robust associations of IKZF1, IKZF2, IKZF3 and OX40L with SLE 
(Chapter 1. Introduction, Figure 1-8) [43].  Functional studies on the Ikaros transcription factor 
family [114, 202-205] and OX40L [201] have shown that dysfunctions of these factors will lead to 
autoimmune and inflammatory disorders.  Since PBMC (peripheral blood mononuclear cell) has 
a heterogeneous composition, comprising a variety of different immune cells with discrete 
functions, measuring protein level of target molecules in each immune subpopulation provides 
clues to infer their potential functions.  Hence, I measured the protein products of the target genes 
across a range of immune subsets in PBMC derived from 22 SLE patients and 20 healthy controls. 
The panel design for detecting immune subpopulations of T, B and NK cells, monocytes, and DCs 
is mainly derived from a set of defined eight-colour antibody cocktails proposed by the Human 
Immunophenotyping Consortium (HIPC) [100], but with some modifications as we want to 
measure the protein level of four target genes simultaneously.  That is to say, we used the cellular 
markers as proposed by HIPC (Chapter 2. Methods, Figure 2-6to distinguish the immune sub-
populations, but the antibody clones and fluorochromes for each cellular marker were changed 
when needed.   Though Finak et al [206] suggested that the evaluation of helper T cell panel 
(Th1/2/17 panel) by the HIPC [100] is too variable to be reliable, the data quality of this panel in 
my study was relatively good as the modified antibody-conjugates for these cell subsets could 
distinguish them clearly (Figure 6-1).  
By comparing the absolute number of cells as well as the cell proportions of immune subsets 
between SLE and controls, I observed that either the absolute number or cell proportions of 
immune cells from adaptive immune system were increased in SLE patients when comparing to 
healthy controls, including naïve CD8+ T cells, Th2 cells, activated CD4+ T cells, activated Th1 
cells, activated Th2 cells, and B cells.  While immune cells derived from the innate immune system 
were generally observed to be decrease in SLE patients, such as plasmacytoid DCs and CD16+ 
NK cells (Figure 6-6/8).  In addition, modest negative correlations were observed between 
proportions of immune subsets, such as NK and B cell, and SLEDAI (Figure 6-7/9), suggesting 




For the first time, this study shows the protein expression pattern of OX40L and the Ikaros 
transcription factor family (IKZF1/2/3) across a range of immune cells (Figure 6-10/11/12/13).  In 
general, protein levels of OX40L is increased while IKZF1, IKZF2 and IKZF3 are decreased in 
SLE patients.  GWAS and family-based studies [41, 45, 128] have underlined the importance of 
OX40L as a SLE susceptibility gene, with an increased expression of OX40L in individuals 
carrying the disease risk allele according to the eQTL results found in the FHS whole blood 
dataset [85].  Consistently, the protein level of OX40L on B cells was significantly increased in 
SLE patients in my study.  The higher level of OX40L could augment the B-cell hyperactivity and 
the resulting autoantibodies and immune complexes may lead to the development of autoimmune 
diseases.  Studies by Jacquemin et al [207] and Cortini et al [201] both showed that OX40L-OX40 
axis plays a major role in lupus pathogenesis by promoting the responses of T follicular helper 
(TFH) cells.   Cortini et al’s study applying a spontaneous congenic lupus murine model shows that 
OX40L on B cells facilitates the development of TFH.  However, no correlation between blood B 
cells expressing OX40L and TFH cells was observed in Jacquemin et al’s study on SLE patients, 
which could be due to the compartmentalisation of activated B cells expressing OX40L in the 
secondary lymphoid organs rather than an evidence of their lack of involvement in the 
development of pathogenic TFH cells in SLE as suggested by Cortini et al.  
The Ikaros transcription factor family, including IKZF1, IKZF2 and IKZF3 are genetically 
associated with a variety of human autoimmune diseases [43, 208-217].  eQTL studies based on 
the exon-level and junction level suggest that non-coding aberrations disrupt regulation of 
expression of these genes [80, 184, 218].  Though not all the differences between cases and 
controls in my study are statistically significant, the expression patterns of all three Ikaros family 
members are quite similar – their protein products are decreased in patients comparing to controls 
in the T cells panel.  While in NK cells, all there IKZFs are slightly higher in SLE patients than in 
controls, suggesting cell specificity should be taken into account when studying target genes’ 
functions.   
IKZF1 (Ikaros) is important to limit autoimmunity and its down regulation is associated with 
autoimmune disease [219].  Consistently, I observed decreased Ikaros in SLE across a variety of 
immune cell subsets.  In particular cell types, Ikaros was significantly lower in patients than that 
in controls, including effector CD4+ T cells, activated CD4+ T cells, activated Th2 cells, and 




investigate the underlying roles of Ikaros in activated T cell may provide insights to the 
pathogenesis of SLE.  IKZF1 acts as both a transcriptional suppressor and activator depending 
on the co-factors it interacts [220] .  Studies in the murine system [221-223] show that Ikaros co-
factors are over-expressing in non-lymphoid cell lines with suppressive functions.  While Ikaros 
may also function as a transcriptional activator possibly by recruiting SWI/SNF or promoting 
transcriptional elongation [224, 225].  Moreover, Ikaros is found to control multiple levels of B cell 
lymphopoiesis and function, which is required for earliest B cell progenitors [226], efficient pro-B 
to pre-B transition [227, 228], repression of non-B cell fates [228], and promoting Igh 
rearrangement and Rag expression [228, 229].  I observed a higher level of Ikaros in DCs and 
monocytes compared to T cells and B cells in both patients and controls, supporting the 
suppressive roles of Ikaros in the non-lymphoid cell lines. 
IKZF2 (Helios) is expressed in early hematopoietic progenitors of the bone marrow and Treg cells 
[112], and regulates Treg associated genes, such as FoxP3 [230, 231].  Functional analysis using 
ChIP and knocking-down techniques found that suppression of IKZF2 in Treg significantly 
attenuates their suppressive function [113].  Although no significant differences of IKZF2 between 
SLE and controls have been found, modest correlations between SLEDAI and IKZF2 were 
observed in non-classical monocytes and myeloid DCs (Figure 6-12), suggesting the perturbation 
of IKZF2 in specific immune subsets may correlate with the subtle progression in disease course.  
Consistently, previous studies [114, 232] reported that IKZF2+ Treg were significantly increased 
in SLE patients and expanded in active SLE, supporting the concept that IKZF2 suppress the 
function of Treg, leading to the dysfunction of immune suppressive effect of Treg and resulting in 
an increase of autoimmune response.   
IKZF3 (Aiolos) is a transcription factor helps regulate transition of Pro-B cells and Pre-B cells and 
is critical in differentiation of plasma cells and development of B-cell memory [233].  IKZF3 knock-
out mice which lack B-cell immunological memory develop SLE-like disease as well as 
haematological malignancies [234].  Recent studies have reported that IKZF3 is overexpressed 
in SLE B cell subtype [235] and PBMCs [205]. Consistently, I show that the expression of IKZF3 
on B cell subsets is slightly increased in SLE patients (Figure 6-13) and is positively correlated 
with SLEDAI (Figure 6-14), supporting the important role of IKZF3 in the development and 
progression of SLE.  Intriguingly, the expression of IKZF3 is significantly decreased in SLE in 




cells, activated Th1, activated Th2, activated Th17 and activated Treg, suggesting a potential role 
of IKZF3 in activated T cells may be involved in SLE. 
In summary, the comprehensive immunophenotyping of target molecules’ protein expression to 
scrutinize the subtle differences across discrete immune subsets provides insights into the 
functions of the target molecules in the pathogenesis of SLE.  In general, the expression of these 
molecules (OX40L, IKZF1, IKZF2, and IKZF4) is higher/lower in some cell types than others, 
indicating their involvements and functions in the immune system are likely to be cell specific.  
Understanding the cell-specific effects of these molecules involved in the immune system holds 
great promise for developing them as potential therapeutic targets in the manipulation of SLE.  
Therefore, further functional studies should focus on specific cell types, including those that have 
enriched expression of particular molecules (e.g., IKZF2 in Tregs; OX40L in B cells and APCs) 
and those that exhibit differential expression levels between cases and controls (e.g. IKZF3 in T 
cells and B cells), in order to better scrutinize these molecules’ potential roles on their dominant 
cell types.  Moreover, genotyping all these samples, including patients and controls, will provide 





Chapter 7.  Conclusions 
 
In this thesis, I integrated genetics, epigenetics and gene expression to delineate the regulatory 
functions of SLE risk loci and their roles on the severity of SLE.  I believe my findings are novel 
contributions to the understanding of SLE genetics. 
 
I have demonstrated that eQTL mapping, incorporating co-localization analysis of genetic 
association across a variety of immune cell types is essential to detect the full array of disease 
associated eQTLs.  By doing so in chapter 3, I have identified candidate-causal genes for almost 
half of the SLE risk loci.  In particular, my data have pinpointed some candidate-causal genes 
acting in specific cell type or under certain context (resting or stimulation), which warrant further 
study into certain condition to delineate the molecular function of causal genes.  Moreover, by 
mapping eQTLs across populations, I have identified candidate-causal eGenes which may be 
masked by strong LD within genomic regions when analysing in a single population.  Though 
expression data generated from MicroArray are a good surrogate for measuring transcript at 
probe level, using RNA-seq to quantify transcript level at multiple resolutions, including gene-, 
exon-, splice-junction, and isoform, is very likely to advance our understanding of the implications 
of the genetic control of gene expression.  
 
In Chapter 4, I expanded my analyses on the functional roles of disease associated loci with 
regulatory epigenomes across a variety of tissues and primary cells and showed that SLE risk 
loci were primarily enriched in regulatory regions within a range of immune cells.  Furthermore, I 
pinpointed that a large proportion (66%) of SLE eQTLs were overlapped with DHS hotspots, 
denoting extensive local coordination of genetic influences on gene expression and epigenetics.  
With the development of NGS technologies, the resolution on measuring gene expression and 
epigenetics is largely improved and the power to detect QTLs (i.e., expression QTL and chromatin 
accessibility QTL) is much extended.  Therefore, I emphasize that large gene expression and 
epigenome datasets for QTL studies should be generated across trait-associated cell types and 




expression and chromatin assays (RNA-seq and ATAC-seq) in whole-blood and later decompose 
measurements into component cell types statistically. 
 
As kidney involvement is strongly associated with disease severity of SLE, I chose this sub-
phenotype to investigate its relationship with the SLE genetic risk factors in Chapter 5.  Due to 
the lack of significant genetic associations in SLE Renal GWAS, I tested the hypothesis that the 
genetic risk loading of SLE may correlate with kidney involvement in a quantitative way and found 
that the genetic risk factors that influence the severity of SLE were through a quantitative way 
(multiple genes’ contribution, GRS).  The inclusion of SLE risk alleles into a GRS can modestly 
predict the renal involvement in SLE patients (LN), shows consistent discriminatory ability in 
independent cohorts, and is enhanced by the inclusion of age-of-onset into the model.  Therefore, 
I suggest that the GRS will make a contribution to predicting LN in SLE patients in a clinical or 
research setting. 
 
As part of the functional study of post-GWAS in Chapter 6, I investigated the protein expression 
of selected SLE-susceptibility gene products (the Ikaros family members and OX40L) in a range 
of immune cells, using multi-parameter flow cytometry. The results reveal some cellular specificity 
in gene expression in disease. In particular, IKZF3 expression on activated regulatory T cell and 
helper T cell subsets was decreased, while OX40L expression on B cell subsets was increased 
in SLE.  This is a comprehensive immunephenotyping of target molecules to dissect their potential 
roles in SLE, which provides good evidence for further functional experiments to focus on target 
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Appendix A. Chapter 2 Supplementary Tables 
Supplementary Table 2-1. 424 DHS hotspots from ENCODE and Roadmap for functional 
enrichment analysis in GARFIELD. 
Tissue Celltype Annotation Tissue Celltype Annotation
epithelium A549 A549-all.twopass.merge150.wgt10.zgt2.wig fetal_kidney Fetal_Kidney_Left UW.Fetal_Kidney_Left.ChromatinAccessibility.H-24089.DS18466.twopass.merge150.wgt10.zgt2.wig
blood Adult_CD4+ Adult_Th0_AllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_kidney Fetal_Kidney_Right UW.Fetal_Kidney_Right.ChromatinAccessibility.H-23435.DS15651.twopass.merge150.wgt10.zgt2.wig
skin AG04449 AG04449-DS12319.twopass.merge150.wgt10.zgt2.wig fetal_kidney Fetal_Kidney_Right UW.Fetal_Kidney_Right.ChromatinAccessibility.H-23589.DS16441.twopass.merge150.wgt10.zgt2.wig
lung AG04450 AG04450-DS12270.twopass.merge150.wgt10.zgt2.wig fetal_kidney Fetal_Kidney_Right UW.Fetal_Kidney_Right.ChromatinAccessibility.H-23640.DS16801.twopass.merge150.wgt10.zgt2.wig
skin AG09309 AG09309-DS12352.twopass.merge150.wgt10.zgt2.wig fetal_kidney Fetal_Kidney_Right UW.Fetal_Kidney_Right.ChromatinAccessibility.H-23758.DS17144.twopass.merge150.wgt10.zgt2.wig
gingival AG09319 AG09319-DS12291.twopass.merge150.wgt10.zgt2.wig fetal_kidney Fetal_Kidney_Right UW.Fetal_Kidney_Right.ChromatinAccessibility.H-24089.DS18463.twopass.merge150.wgt10.zgt2.wig
skin AG10803 AG10803-DS12384.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-22676.DS12646.twopass.merge150.wgt10.zgt2.wig
blood_vessel AoAF AoAF-DS13523.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-22727.DS12817.twopass.merge150.wgt10.zgt2.wig
brain BE2_C BE_2_C-DS14625.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-22934B.DS13507.twopass.merge150.wgt10.zgt2.wig
skin BJ BJ-DS10081.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23090.DS13985.twopass.merge150.wgt10.zgt2.wig
colon Caco-2 CACO2-DS8235.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23247.DS14666.twopass.merge150.wgt10.zgt2.wig
blood CD14+ CD14-DS18065.hg19.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23266.DS14724.twopass.merge150.wgt10.zgt2.wig
blood CD20+ CD20-DS17541.hg19.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23266.DS14751.twopass.merge150.wgt10.zgt2.wig
blood CD34+ CD34-DS16814.hg19.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23284.DS14809.twopass.merge150.wgt10.zgt2.wig
blood CMK CMK-DS12393.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23284.DS14820.twopass.merge150.wgt10.zgt2.wig
muscle E_myoblast E_myoblast_AllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23365.DS15227.twopass.merge150.wgt10.zgt2.wig
blood GM06990 GM06990-DS7748.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23399.DS15461.twopass.merge150.wgt10.zgt2.wig
blood GM12864 GM12864-DS12431.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung UW.Fetal_Lung.ChromatinAccessibility.H-23419.DS15573.twopass.merge150.wgt10.zgt2.wig
blood GM12865 GM12865-DS12436.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23435.DS15637.twopass.merge150.wgt10.zgt2.wig
blood GM12878 GM12878-all.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23604.DS16570.twopass.merge150.wgt10.zgt2.wig
cerebellar HAc HAc-DS14765.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23640.DS18170.twopass.merge150.wgt10.zgt2.wig
epithelium HAEpiC HAEpiC-DS12663.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23744.DS17105.twopass.merge150.wgt10.zgt2.wig
brain_hippocampus HA-h HAh-DS15192.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23758.DS17154.twopass.merge150.wgt10.zgt2.wig
spinal_cord HA-sp HAsp-DS14790.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23833.DS17464.twopass.merge150.wgt10.zgt2.wig
blood_vessel HBMEC HBMEC-DS13817.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23887.DS17674.twopass.merge150.wgt10.zgt2.wig
heart HCFaa HCFaa-DS13480.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23914.DS17739.twopass.merge150.wgt10.zgt2.wig
heart HCF HCF-DS12501.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-23964.DS17835.twopass.merge150.wgt10.zgt2.wig
heart HCM HCM-DS12599.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-24005.DS17959.twopass.merge150.wgt10.zgt2.wig
eye HConF HConF-DS11642.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-24089.DS18421.twopass.merge150.wgt10.zgt2.wig
epithelium HCPEpiC HCPEpiC-DS12447.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Left UW.Fetal_Lung_Left.ChromatinAccessibility.H-24111.DS18487.twopass.merge150.wgt10.zgt2.wig
colon HCT-116 HCT116-DS13551.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-23435.DS15632.twopass.merge150.wgt10.zgt2.wig
epithelium HEEpiC HEEpiC-DS12763.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-23604.DS16566.twopass.merge150.wgt10.zgt2.wig
cervix HeLa-S3 Hela-all.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-23640.DS16790.twopass.merge150.wgt10.zgt2.wig
liver HepG2 HepG2-all.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-23744.DS17101.twopass.merge150.wgt10.zgt2.wig
es_cell HESC HESC-all.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-23758.DS17162.twopass.merge150.wgt10.zgt2.wig
es_cell hESCT0 hESCT0-DS11909.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-23887.DS17670.twopass.merge150.wgt10.zgt2.wig
foreskin HFF HFF-DS15115.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-23964.DS17831.twopass.merge150.wgt10.zgt2.wig
foreskin HFF-Myc HFF_MyC-DS15079.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-24005.DS17954.twopass.merge150.wgt10.zgt2.wig
gingival HGF HGF-DS11752.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-24089.DS18418.twopass.merge150.wgt10.zgt2.wig
epithelium HIPEpiC HIPEpiC-DS12684.twopass.merge150.wgt10.zgt2.wig fetal_lung Fetal_Lung_Right UW.Fetal_Lung_Right.ChromatinAccessibility.H-24111.DS18492.twopass.merge150.wgt10.zgt2.wig
blood HL-60 HL60-DS11809.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-23808.DS17432.twopass.merge150.wgt10.zgt2.wig
breast HMEC HMEC-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-23914.DS17765.twopass.merge150.wgt10.zgt2.wig
breast HMF HMF-DS13363.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-23941.DS17825.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-dAd HMVEC_dAd-DS12957.hg19.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-23964.DS17848.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-dBl-Ad HMVEC_dBlAd-DS13337.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24005.DS18080.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-dBl-Neo HMVEC_dBlNeo-DS13242.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24042.DS18176.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-dLy-Ad HMVEC_dLyAd-DS13261.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24078.DS18379.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-dLy-Neo HMVEC_dLyNeo-DS13150.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24089.DS18452.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-dNeo HMVEC_dNeo-DS12937.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24111.DS18473.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-LBl HMVEC_LBl-DS13372.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24125.DS18559.twopass.merge150.wgt10.zgt2.wig
blood_vessel HMVEC-LLy HMVEC_LLy-DS13185.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24143.DS18992.twopass.merge150.wgt10.zgt2.wig
epithelium HNPCEpiC HNPCEpiC-DS12467.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24198.DS19051.twopass.merge150.wgt10.zgt2.wig
blood_vessel HPAEC HPAEC-DS12916.hg19.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24218.DS19053.twopass.merge150.wgt10.zgt2.wig
Tissue Celltype Annotation Tissue Celltype Annotation
blood_vessel HPAF HPAF-DS13411.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24244.DS19270.twopass.merge150.wgt10.zgt2.wig
epithelium HPdLF HPdLF-DS13573.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24259.DS19295.twopass.merge150.wgt10.zgt2.wig
lung HPF HPF-DS13390.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24272.DS19380.twopass.merge150.wgt10.zgt2.wig
epithelium HRCEpiC HRCE-DS10666.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Arm UW.Fetal_Muscle_Arm.ChromatinAccessibility.H-24297.DS19646.twopass.merge150.wgt10.zgt2.wig
epithelium HRE HRE-DS10641.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-23914.DS17767.twopass.merge150.wgt10.zgt2.wig
kidney HRGEC HRGEC-DS13716.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-23964.DS17850.twopass.merge150.wgt10.zgt2.wig
epithelium HRPEpiC HRPEpiC-DS12583.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24005.DS18083.twopass.merge150.wgt10.zgt2.wig
muscle HSMM HSMM-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24078.DS18377.twopass.merge150.wgt10.zgt2.wig
muscle HSMM HSMM_D-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24089.DS18454.twopass.merge150.wgt10.zgt2.wig
blood Th1 hTH1-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24111.DS18468.twopass.merge150.wgt10.zgt2.wig
blood Th2 hTH2-DS7842.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24143.DS18842.twopass.merge150.wgt10.zgt2.wig
blood_vessel HUVEC HUVEC-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24218.DS19117.twopass.merge150.wgt10.zgt2.wig
connective HVMF HVMF-DS13981.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24244.DS19283.twopass.merge150.wgt10.zgt2.wig
uterus Ishikawa Ishikawa_E_AllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24272.DS19384.twopass.merge150.wgt10.zgt2.wig
uterus Ishikawa Ishikawa_T_AllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24279.DS19441.twopass.merge150.wgt10.zgt2.wig
blood Jurkat Jurkat-DS12659.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24297.DS19648.twopass.merge150.wgt10.zgt2.wig
blood K562 K562-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Back UW.Fetal_Muscle_Back.ChromatinAccessibility.H-24409.DS20244.twopass.merge150.wgt10.zgt2.wig
prostate LNCaP LNCap-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-23808.DS17429.twopass.merge150.wgt10.zgt2.wig
breast MCF-7 MCF7-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24078.DS18386.twopass.merge150.wgt10.zgt2.wig
blood NB4 NB4-DS12543.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24089.DS18456.twopass.merge150.wgt10.zgt2.wig
nervous NH-A NHA-DS12800.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24111.DS18471.twopass.merge150.wgt10.zgt2.wig
skin NHDF-Ad NHDF_Ad-DS12863.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24143.DS18844.twopass.merge150.wgt10.zgt2.wig
skin NHDF-neo NHDF_Neo-DS11923.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24198.DS19158.twopass.merge150.wgt10.zgt2.wig
skin NHEK NHEK-all.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24218.DS19115.twopass.merge150.wgt10.zgt2.wig
lung NHLF NHLF-DS12829.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24244.DS19272.twopass.merge150.wgt10.zgt2.wig
testis NT2-D1 NT2_D1-DS14575.hg19.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24259.DS19291.twopass.merge150.wgt10.zgt2.wig
pancreas PANC-1 PANC1-DS9955.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24279.DS19436.twopass.merge150.wgt10.zgt2.wig
prostate PrEC PrEC-DS12098.hg19.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24297.DS19643.twopass.merge150.wgt10.zgt2.wig
epithelium RPTEC RPTEC-DS14061.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Leg UW.Fetal_Muscle_Leg.ChromatinAccessibility.H-24409.DS20239.twopass.merge150.wgt10.zgt2.wig
prostate RWPE1 RWPE_AllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_muscle,_lower_limb Fetal_Muscle_Lower_Limb_Skeletal UW.Fetal_Muscle_Lower_Limb_Skeletal.ChromatinAccessibility.H-24042.DS18174.twopass.merge150.wgt10.zgt2.wig
epithelium SAEC SAEC-DS10518.twopass.merge150.wgt10.zgt2.wig fetal_muscle,_trunk Fetal_Muscle_Trunk UW.Fetal_Muscle_Trunk.ChromatinAccessibility.H-23941.DS17827.twopass.merge150.wgt10.zgt2.wig
muscle SKMC SkMC-DS11949.twopass.merge150.wgt10.zgt2.wig fetal_muscle,_trunk Fetal_Muscle_Trunk UW.Fetal_Muscle_Trunk.ChromatinAccessibility.H-24409.DS20242.twopass.merge150.wgt10.zgt2.wig
brain SK-N-MC SK_N_MC-DS14408.twopass.merge150.wgt10.zgt2.wig fetal_muscle,_trunk Fetal_Muscle_Trunk UW.Fetal_Muscle_Trunk.ChromatinAccessibility.H-24507.DS20544.twopass.merge150.wgt10.zgt2.wig
brain SK-N-SH SKNSH-DS8482.twopass.merge150.wgt10.zgt2.wig fetal_muscle Fetal_Muscle_Upper_Limb_Skeletal UW.Fetal_Muscle_Upper_Limb_Skeletal.ChromatinAccessibility.H-23887.DS17661.twopass.merge150.wgt10.zgt2.wig
eye WERI-Rb-1 WERI_Rb1-DS13681.twopass.merge150.wgt10.zgt2.wig fetal_muscle,_upper_trunk Fetal_Muscle_Upper_Trunk UW.Fetal_Muscle_Upper_Trunk.ChromatinAccessibility.H-23887.DS17664.twopass.merge150.wgt10.zgt2.wig
liver 8988T wgEncodeOpenChromDnase8988tAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_placenta Fetal_Placenta UW.Fetal_Placenta.ChromatinAccessibility.H-23887.DS17639.twopass.merge150.wgt10.zgt2.wig
blood_vessel AoSMC wgEncodeOpenChromDnaseAosmcSerumfreeAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_placenta Fetal_Placenta UW.Fetal_Placenta.ChromatinAccessibility.H-23914.DS17744.twopass.merge150.wgt10.zgt2.wig
fetal_membrane Chorion wgEncodeOpenChromDnaseChorionAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_placenta Fetal_Placenta UW.Fetal_Placenta.ChromatinAccessibility.H-24272.DS19391.twopass.merge150.wgt10.zgt2.wig
blood CLL wgEncodeOpenChromDnaseCllAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_placenta Fetal_Placenta UW.Fetal_Placenta.ChromatinAccessibility.H-24409.DS20346.twopass.merge150.wgt10.zgt2.wig
skin Fibrobl wgEncodeOpenChromDnaseFibroblAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-23769.DS17307.twopass.merge150.wgt10.zgt2.wig
skin FibroP wgEncodeOpenChromDnaseFibropAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-23790.DS17387.twopass.merge150.wgt10.zgt2.wig
brain Gliobla wgEncodeOpenChromDnaseGlioblaAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-23833.DS17455.twopass.merge150.wgt10.zgt2.wig
blood GM12891 wgEncodeOpenChromDnaseGm12891AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-23914.DS17756.twopass.merge150.wgt10.zgt2.wig
blood GM12892 wgEncodeOpenChromDnaseGm12892AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-23941.DS17804.twopass.merge150.wgt10.zgt2.wig
blood GM18507 wgEncodeOpenChromDnaseGm18507AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-24078.DS18428.twopass.merge150.wgt10.zgt2.wig
blood GM19238 wgEncodeOpenChromDnaseGm19238AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-24259.DS19388.twopass.merge150.wgt10.zgt2.wig
blood GM19239 wgEncodeOpenChromDnaseGm19239AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex UW.Fetal_Renal_Cortex.ChromatinAccessibility.H-24493.DS20568.twopass.merge150.wgt10.zgt2.wig
blood GM19240 wgEncodeOpenChromDnaseGm19240AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex_Left UW.Fetal_Renal_Cortex_Left.ChromatinAccessibility.H-23871.DS17550.twopass.merge150.wgt10.zgt2.wig
es_cell H9ES wgEncodeOpenChromDnaseH9esAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex_Left UW.Fetal_Renal_Cortex_Left.ChromatinAccessibility.H-24111.DS18542.twopass.merge150.wgt10.zgt2.wig
cervix HeLa-S3 wgEncodeOpenChromDnaseHelas3Ifna4hAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex_Left UW.Fetal_Renal_Cortex_Left.ChromatinAccessibility.H-24169.DS18931.twopass.merge150.wgt10.zgt2.wig
liver Hepatocytes wgEncodeOpenChromDnaseHepatocytesAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex_Left UW.Fetal_Renal_Cortex_Left.ChromatinAccessibility.H-24232.DS19257.twopass.merge150.wgt10.zgt2.wig
pancreatic_duct HPDE6-E6E7 wgEncodeOpenChromDnaseHpde6e6e7AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex_Right UW.Fetal_Renal_Cortex_Right.ChromatinAccessibility.H-23871.DS17545.twopass.merge150.wgt10.zgt2.wig






Tissue Celltype Annotation Tissue Celltype Annotation
liver Huh-7.5 wgEncodeOpenChromDnaseHuh75AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_cortex Fetal_Renal_Cortex_Right UW.Fetal_Renal_Cortex_Right.ChromatinAccessibility.H-24232.DS19254.twopass.merge150.wgt10.zgt2.wig
liver Huh-7 wgEncodeOpenChromDnaseHuh7AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis UW.Fetal_Renal_Pelvis.ChromatinAccessibility.H-23790.DS17381.twopass.merge150.wgt10.zgt2.wig
ips_cell iPS wgEncodeOpenChromDnaseIpsAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis UW.Fetal_Renal_Pelvis.ChromatinAccessibility.H-23833.DS17451.twopass.merge150.wgt10.zgt2.wig
prostate LNCaP wgEncodeOpenChromDnaseLncapAndroAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis UW.Fetal_Renal_Pelvis.ChromatinAccessibility.H-23914.DS17760.twopass.merge150.wgt10.zgt2.wig
breast MCF-7 wgEncodeOpenChromDnaseMcf7HypoxlacAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis UW.Fetal_Renal_Pelvis.ChromatinAccessibility.H-24005.DS18088.twopass.merge150.wgt10.zgt2.wig
brain Medullo wgEncodeOpenChromDnaseMedulloAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis UW.Fetal_Renal_Pelvis.ChromatinAccessibility.H-24078.DS18431.twopass.merge150.wgt10.zgt2.wig
skin Melano wgEncodeOpenChromDnaseMelanoAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis UW.Fetal_Renal_Pelvis.ChromatinAccessibility.H-24259.DS19386.twopass.merge150.wgt10.zgt2.wig
myometrium Myometr wgEncodeOpenChromDnaseMyometrAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis UW.Fetal_Renal_Pelvis.ChromatinAccessibility.H-24477.DS20448.twopass.merge150.wgt10.zgt2.wig
bone Osteobl wgEncodeOpenChromDnaseOsteoblAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Left UW.Fetal_Renal_Pelvis_Left.ChromatinAccessibility.H-23871.DS17553.twopass.merge150.wgt10.zgt2.wig
pancreas PanIsletD wgEncodeOpenChromDnasePanisdAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Left UW.Fetal_Renal_Pelvis_Left.ChromatinAccessibility.H-24111.DS18666.twopass.merge150.wgt10.zgt2.wig
pancreas PanIslets wgEncodeOpenChromDnasePanisletsAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Left UW.Fetal_Renal_Pelvis_Left.ChromatinAccessibility.H-24169.DS18964.twopass.merge150.wgt10.zgt2.wig
epithelium pHTE wgEncodeOpenChromDnasePhteAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Left UW.Fetal_Renal_Pelvis_Left.ChromatinAccessibility.H-24232.DS19238.twopass.merge150.wgt10.zgt2.wig
skin ProgFib wgEncodeOpenChromDnaseProgfibAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Right UW.Fetal_Renal_Pelvis_Right.ChromatinAccessibility.H-23871.DS17548.twopass.merge150.wgt10.zgt2.wig
liver Stellate wgEncodeOpenChromDnaseStellateAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Right UW.Fetal_Renal_Pelvis_Right.ChromatinAccessibility.H-24111.DS18663.twopass.merge150.wgt10.zgt2.wig
breast T-47D wgEncodeOpenChromDnaseT47dAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Right UW.Fetal_Renal_Pelvis_Right.ChromatinAccessibility.H-24169.DS18961.twopass.merge150.wgt10.zgt2.wig
urothelium Urothelia wgEncodeOpenChromDnaseUrotsaAlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_renal_pelvis Fetal_Renal_Pelvis_Right UW.Fetal_Renal_Pelvis_Right.ChromatinAccessibility.H-24232.DS19235.twopass.merge150.wgt10.zgt2.wig
urothelium Urothelia wgEncodeOpenChromDnaseUrotsaUt189AlnAllReps.30000000.twopass.merge150.wgt10.zgt2.wig fetal_skin Fetal_Skin UW.Fetal_Skin.ChromatinAccessibility.H-22337.DS10987.twopass.merge150.wgt10.zgt2.wig
embryonic_lung WI-38 WI_38-DS14315.twopass.merge150.wgt10.zgt2.wig fetal_spinal_cord Fetal_Spinal_Cord UW.Fetal_Spinal_Cord.ChromatinAccessibility.H-24111.DS18501.twopass.merge150.wgt10.zgt2.wig
embryonic_lung WI-38 WI_38_TAM-DS14323.twopass.merge150.wgt10.zgt2.wig fetal_spinal_cord Fetal_Spinal_Cord UW.Fetal_Spinal_Cord.ChromatinAccessibility.H-24409.DS20351.twopass.merge150.wgt10.zgt2.wig
breast Breast_vHMEC UW.Breast_vHMEC.ChromatinAccessibility.RM035.DS18406.twopass.merge150.wgt10.zgt2.wig fetal_spinal_cord Fetal_Spinal_Cord UW.Fetal_Spinal_Cord.ChromatinAccessibility.H-24493.DS20530.twopass.merge150.wgt10.zgt2.wig
breast Breast_vHMEC UW.Breast_vHMEC.ChromatinAccessibility.RM035.DS18438.twopass.merge150.wgt10.zgt2.wig fetal_spleen Fetal_Spleen UW.Fetal_Spleen.ChromatinAccessibility.H-23399.DS17448.twopass.merge150.wgt10.zgt2.wig
blood CD14_Primary_Cells UW.CD14_Primary_Cells.ChromatinAccessibility.RO_01689.DS17391.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-23589.DS16530.twopass.merge150.wgt10.zgt2.wig
blood CD14_Primary_Cells UW.CD14_Primary_Cells.ChromatinAccessibility.RO_01701.DS17889.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-23758.DS17172.twopass.merge150.wgt10.zgt2.wig
blood CD19_Primary_Cells UW.CD19_Primary_Cells.ChromatinAccessibility.RO_01679.DS17186.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-23769.DS17325.twopass.merge150.wgt10.zgt2.wig
blood CD19_Primary_Cells UW.CD19_Primary_Cells.ChromatinAccessibility.RO_01689.DS17281.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-23887.DS17659.twopass.merge150.wgt10.zgt2.wig
blood CD19_Primary_Cells UW.CD19_Primary_Cells.ChromatinAccessibility.RO_01701.DS17440.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-23914.DS17750.twopass.merge150.wgt10.zgt2.wig
blood CD20_Primary_Cells UW.CD20_Primary_Cells.ChromatinAccessibility.RO_01778.DS17371.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-23964.DS17878.twopass.merge150.wgt10.zgt2.wig
blood CD3_Primary_Cells UW.CD3_Primary_Cells.ChromatinAccessibility.CB1_1-3-2011.DS17702.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-24005.DS17963.twopass.merge150.wgt10.zgt2.wig
blood CD3_Primary_Cells UW.CD3_Primary_Cells.ChromatinAccessibility.CB6_1-4-2011.DS17706.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-24078.DS18389.twopass.merge150.wgt10.zgt2.wig
blood CD3_Primary_Cells UW.CD3_Primary_Cells.ChromatinAccessibility.RO_01679.DS17198.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-24125.DS18821.twopass.merge150.wgt10.zgt2.wig
blood CD3_Primary_Cells UW.CD3_Primary_Cells.ChromatinAccessibility.RO_01701.DS17534.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-24401.DS20349.twopass.merge150.wgt10.zgt2.wig
blood CD4_Primary_Cells UW.CD4_Primary_Cells.ChromatinAccessibility.RO_01549.DS15947.twopass.merge150.wgt10.zgt2.wig fetal_stomach Fetal_Stomach UW.Fetal_Stomach.ChromatinAccessibility.H-24507.DS20546.twopass.merge150.wgt10.zgt2.wig
blood CD4_Primary_Cells UW.CD4_Primary_Cells.ChromatinAccessibility.RO_01679.DS17212.twopass.merge150.wgt10.zgt2.wig fetal_testes Fetal_Testes UW.Fetal_Testes.ChromatinAccessibility.H24198_H23640_H24042.DS18942.twopass.merge150.wgt10.zgt2.wig
blood CD4_Primary_Cells UW.CD4_Primary_Cells.ChromatinAccessibility.RO_01689.DS17329.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-23589.DS16490.twopass.merge150.wgt10.zgt2.wig
blood CD4_Primary_Cells UW.CD4_Primary_Cells.ChromatinAccessibility.RO_01701.DS17881.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-23663.DS16841.twopass.merge150.wgt10.zgt2.wig
blood CD56_Primary_Cells UW.CD56_Primary_Cells.ChromatinAccessibility.RO_01679.DS17189.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-23769.DS17323.twopass.merge150.wgt10.zgt2.wig
blood CD56_Primary_Cells UW.CD56_Primary_Cells.ChromatinAccessibility.RO_01701.DS17443.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-23833.DS17474.twopass.merge150.wgt10.zgt2.wig
blood CD8_Primary_Cells UW.CD8_Primary_Cells.ChromatinAccessibility.RO_01549.DS16012.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-23964.DS17875.twopass.merge150.wgt10.zgt2.wig
blood CD8_Primary_Cells UW.CD8_Primary_Cells.ChromatinAccessibility.RO_01679.DS17203.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-23964.DS17876.twopass.merge150.wgt10.zgt2.wig
blood CD8_Primary_Cells UW.CD8_Primary_Cells.ChromatinAccessibility.RO_01689.DS17332.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-24078.DS18382.twopass.merge150.wgt10.zgt2.wig
blood CD8_Primary_Cells UW.CD8_Primary_Cells.ChromatinAccessibility.RO_01701.DS17885.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-24259.DS19287.twopass.merge150.wgt10.zgt2.wig
fetal_adrenal_gland Fetal_Adrenal_Gland UW.Fetal_Adrenal_Gland.ChromatinAccessibility.H-22662.DS12528.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-24401.DS20335.twopass.merge150.wgt10.zgt2.wig
fetal_adrenal_gland Fetal_Adrenal_Gland UW.Fetal_Adrenal_Gland.ChromatinAccessibility.H-23769.DS17319.twopass.merge150.wgt10.zgt2.wig fetal_thymus Fetal_Thymus UW.Fetal_Thymus.ChromatinAccessibility.H-24409.DS20341.twopass.merge150.wgt10.zgt2.wig
fetal_adrenal_gland Fetal_Adrenal_Gland UW.Fetal_Adrenal_Gland.ChromatinAccessibility.H-24409.DS20343.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Abdomen UW.Fibroblasts_Fetal_Skin_Abdomen.ChromatinAccessibility.H-24259.DS19558.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-22510.DS11872.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Abdomen UW.Fibroblasts_Fetal_Skin_Abdomen.ChromatinAccessibility.H-24259.DS19561.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-22510.DS11877.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Back UW.Fibroblasts_Fetal_Skin_Back.ChromatinAccessibility.H-24218.DS19233.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-22911.DS14464.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Biceps_Left UW.Fibroblasts_Fetal_Skin_Biceps_Left.ChromatinAccessibility.H-24259.DS19857.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-23266.DS14717.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Biceps_Left UW.Fibroblasts_Fetal_Skin_Biceps_Left.ChromatinAccessibility.H-24259.DS19867.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-23266.DS14718.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Biceps_Right UW.Fibroblasts_Fetal_Skin_Biceps_Right.ChromatinAccessibility.H-24259.DS19745.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-23284.DS14803.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Biceps_Right UW.Fibroblasts_Fetal_Skin_Biceps_Right.ChromatinAccessibility.H-24259.DS19761.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-23284.DS14815.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Quadriceps_Left UW.Fibroblasts_Fetal_Skin_Quadriceps_Left.ChromatinAccessibility.H-24259.DS20046.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-23399.DS15453.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Quadriceps_Left UW.Fibroblasts_Fetal_Skin_Quadriceps_Left.ChromatinAccessibility.H-24259.DS20056.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-23548.DS16302.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Quadriceps_Right UW.Fibroblasts_Fetal_Skin_Quadriceps_Right.ChromatinAccessibility.H-24259.DS19943.twopass.merge150.wgt10.zgt2.wig
Tissue Celltype Annotation Tissue Celltype Annotation
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-24279.DS20221.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Quadriceps_Right UW.Fibroblasts_Fetal_Skin_Quadriceps_Right.ChromatinAccessibility.H-24259.DS19948.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-24297.DS20226.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Scalp UW.Fibroblasts_Fetal_Skin_Scalp.ChromatinAccessibility.H-24259.DS19444.twopass.merge150.wgt10.zgt2.wig
fetal_brain Fetal_Brain UW.Fetal_Brain.ChromatinAccessibility.H-24381.DS20231.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Scalp UW.Fibroblasts_Fetal_Skin_Scalp.ChromatinAccessibility.H-24259.DS19449.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-22662.DS12531.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Upper_Back UW.Fibroblasts_Fetal_Skin_Upper_Back.ChromatinAccessibility.H-24259.DS19696.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-22727.DS12810.twopass.merge150.wgt10.zgt2.wig fibroblast Fibroblasts_Fetal_Skin_Upper_Back UW.Fibroblasts_Fetal_Skin_Upper_Back.ChromatinAccessibility.H-24259.DS19706.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23468.DS15839.twopass.merge150.wgt10.zgt2.wig es_cell H1_BMP4_Derived_Mesendoderm_Cultured_Cells UW.H1_BMP4_Derived_Mesendoderm_Cultured_Cells.ChromatinAccessibility.DS18732.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23500.DS16018.twopass.merge150.wgt10.zgt2.wig es_cell H1_BMP4_Derived_Mesendoderm_Cultured_Cells UW.H1_BMP4_Derived_Mesendoderm_Cultured_Cells.ChromatinAccessibility.DS19310.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23524.DS16146.twopass.merge150.wgt10.zgt2.wig es_cell H1_BMP4_Derived_Trophoblast_Cultured_Cells UW.H1_BMP4_Derived_Trophoblast_Cultured_Cells.ChromatinAccessibility.DS18736.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23589.DS16500.twopass.merge150.wgt10.zgt2.wig es_cell H1_BMP4_Derived_Trophoblast_Cultured_Cells UW.H1_BMP4_Derived_Trophoblast_Cultured_Cells.ChromatinAccessibility.DS19317.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23604.DS16582.twopass.merge150.wgt10.zgt2.wig es_cell H1 UW.H1.ChromatinAccessibility.DS18873.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23617.DS16621.twopass.merge150.wgt10.zgt2.wig es_cell H1 UW.H1.ChromatinAccessibility.DS19100.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23663.DS16819.twopass.merge150.wgt10.zgt2.wig es_cell H1_Derived_Mesenchymal_Stem_Cells UW.H1_Derived_Mesenchymal_Stem_Cells.ChromatinAccessibility.DS20671.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-23744.DS19431.twopass.merge150.wgt10.zgt2.wig es_cell H1_Derived_Mesenchymal_Stem_Cells UW.H1_Derived_Mesenchymal_Stem_Cells.ChromatinAccessibility.DS21042.twopass.merge150.wgt10.zgt2.wig
fetal_heart Fetal_Heart UW.Fetal_Heart.ChromatinAccessibility.H-24042.DS19427.twopass.merge150.wgt10.zgt2.wig es_cell H1_Derived_Neuronal_Progenitor_Cultured_Cells UW.H1_Derived_Neuronal_Progenitor_Cultured_Cells.ChromatinAccessibility.DS18739.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23500.DS16027.twopass.merge150.wgt10.zgt2.wig es_cell H1_Derived_Neuronal_Progenitor_Cultured_Cells UW.H1_Derived_Neuronal_Progenitor_Cultured_Cells.ChromatinAccessibility.DS20153.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23524.DS16164.twopass.merge150.wgt10.zgt2.wig es_cell H9 UW.H9.ChromatinAccessibility.DS18517.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23604.DS16563.twopass.merge150.wgt10.zgt2.wig es_cell H9 UW.H9.ChromatinAccessibility.DS18522.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23744.DS17094.twopass.merge150.wgt10.zgt2.wig lung IMR90 UW.IMR90.ChromatinAccessibility.DS11759.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23758.DS17157.twopass.merge150.wgt10.zgt2.wig lung IMR90 UW.IMR90.ChromatinAccessibility.DS11764.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23769.DS17313.twopass.merge150.wgt10.zgt2.wig lung IMR90 UW.IMR90.ChromatinAccessibility.DS13219.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23808.DS17422.twopass.merge150.wgt10.zgt2.wig lung IMR90 UW.IMR90.ChromatinAccessibility.DS13229.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23833.DS17462.twopass.merge150.wgt10.zgt2.wig ips_cell iPS_DF_19.11 UW.iPS_DF_19.11.ChromatinAccessibility.DS15153.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23855.DS17502.twopass.merge150.wgt10.zgt2.wig ips_cell iPS_DF_19.7 UW.iPS_DF_19.7.ChromatinAccessibility.DS15148.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23887.DS17647.twopass.merge150.wgt10.zgt2.wig ips_cell iPS_DF_4.7 UW.iPS_DF_4.7.ChromatinAccessibility.DS15169.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23914.DS17748.twopass.merge150.wgt10.zgt2.wig ips_cell iPS_DF_6.9 UW.iPS_DF_6.9.ChromatinAccessibility.DS15164.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23941.DS17785.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_00738.DS13199.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-23964.DS17841.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01480.DS12771.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-24005.DS17990.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01492.DS12774.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_large Fetal_Intestine_Large UW.Fetal_Intestine_Large.ChromatinAccessibility.H-24111.DS18499.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01492.DS14206.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23604.DS16559.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01508.DS11202.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23640.DS16712.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01517.DS14129.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23663.DS16822.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01520.DS12785.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23724.DS16975.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01527.DS11666.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23744.DS17092.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01535.DS12274.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23758.DS17150.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01535.DS14197.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23769.DS17317.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01536.DS12339.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23808.DS17425.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01549.DS12734.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23864.DS17844.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01562.DS13196.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23887.DS17643.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD34_Primary_Cells UW.Mobilized_CD34_Primary_Cells.ChromatinAccessibility.RO_01701.DS17112.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23914.DS17763.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD4_Primary_Cells UW.Mobilized_CD4_Primary_Cells.ChromatinAccessibility.RO_01679.DS16955.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-23941.DS17808.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD4_Primary_Cells UW.Mobilized_CD4_Primary_Cells.ChromatinAccessibility.RO_01701.DS17175.twopass.merge150.wgt10.zgt2.wig
fetal_intestine,_small Fetal_Intestine_Small UW.Fetal_Intestine_Small.ChromatinAccessibility.H-24111.DS18495.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD56_Primary_Cells UW.Mobilized_CD56_Primary_Cells.ChromatinAccessibility.RO_01689.DS16376.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney UW.Fetal_Kidney.ChromatinAccessibility.H-22337.DS10986.twopass.merge150.wgt10.zgt2.wig blood Mobilized_CD8_Primary_Cells UW.Mobilized_CD8_Primary_Cells.ChromatinAccessibility.RO_01679.DS16962.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney UW.Fetal_Kidney.ChromatinAccessibility.H-22676.DS12635.twopass.merge150.wgt10.zgt2.wig fibroblast Penis_Foreskin_Fibroblast_Primary_Cells UW.Penis_Foreskin_Fibroblast_Primary_Cells.ChromatinAccessibility.skin01.DS18224.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney UW.Fetal_Kidney.ChromatinAccessibility.H-23524.DS16139.twopass.merge150.wgt10.zgt2.wig fibroblast Penis_Foreskin_Fibroblast_Primary_Cells UW.Penis_Foreskin_Fibroblast_Primary_Cells.ChromatinAccessibility.skin01.DS18229.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney UW.Fetal_Kidney.ChromatinAccessibility.H-23663.DS16837.twopass.merge150.wgt10.zgt2.wig fibroblast Penis_Foreskin_Fibroblast_Primary_Cells UW.Penis_Foreskin_Fibroblast_Primary_Cells.ChromatinAccessibility.skin02.DS18252.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney UW.Fetal_Kidney.ChromatinAccessibility.H-23855.DS17522.twopass.merge150.wgt10.zgt2.wig fibroblast Penis_Foreskin_Fibroblast_Primary_Cells UW.Penis_Foreskin_Fibroblast_Primary_Cells.ChromatinAccessibility.skin02.DS18256.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney UW.Fetal_Kidney.ChromatinAccessibility.H-23914.DS17753.twopass.merge150.wgt10.zgt2.wig skin Penis_Foreskin_Keratinocyte_Primary_Cells UW.Penis_Foreskin_Keratinocyte_Primary_Cells.ChromatinAccessibility.skin01.DS18692.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney UW.Fetal_Kidney.ChromatinAccessibility.H-24507.DS20564.twopass.merge150.wgt10.zgt2.wig skin Penis_Foreskin_Keratinocyte_Primary_Cells UW.Penis_Foreskin_Keratinocyte_Primary_Cells.ChromatinAccessibility.skin01.DS18695.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney_Left UW.Fetal_Kidney_Left.ChromatinAccessibility.H-23589.DS16446.twopass.merge150.wgt10.zgt2.wig skin Penis_Foreskin_Keratinocyte_Primary_Cells UW.Penis_Foreskin_Keratinocyte_Primary_Cells.ChromatinAccessibility.skin02.DS18714.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney_Left UW.Fetal_Kidney_Left.ChromatinAccessibility.H-23604.DS16579.twopass.merge150.wgt10.zgt2.wig skin Penis_Foreskin_Keratinocyte_Primary_Cells UW.Penis_Foreskin_Keratinocyte_Primary_Cells.ChromatinAccessibility.skin02.DS18718.twopass.merge150.wgt10.zgt2.wig
fetal_kidney Fetal_Kidney_Left UW.Fetal_Kidney_Left.ChromatinAccessibility.H-23640.DS16805.twopass.merge150.wgt10.zgt2.wig skin Penis_Foreskin_Melanocyte_Primary_Cells UW.Penis_Foreskin_Melanocyte_Primary_Cells.ChromatinAccessibility.skin01.DS18590.twopass.merge150.wgt10.zgt2.wig




Supplementary Table 2-2. 95 SLE risk SNPs for eQTL analyses and for GRS calculation. 
SNP chr pos Reference_gene Risk.allele Alt.allele OR 
rs4649203 1 24519920 IFNLR1_LOC284632 G A 1.16 
rs2476601 1 114377568 PTPN22 A G 1.35 
rs1801274 1 161479745 FCGR2A G A 1.16 
rs2205960 1 173191475 TNFSF4_LOC100506023 T G 1.46 
rs1418190 1 173361979 LOC100506023 T C 1.23 
rs17849502 1 183532580 NCF2 T G 2.57 
rs10911628 1 184649503 C1orf21_EDEM3 A C 1.95 
rs34889541 1 198594769 ATP6V1G3_PTPRC G A 1.23 
rs2297550 1 206643772 IKBKE G C 1.16 
rs3024505 1 206939904 MAPKAPK2_IL10 A G 1.19 
rs9782955 1 236039877 LYST C T 1.16 
rs7579944 2 30445026 SNORA10B_LBH C T 1.13 
rs17321999 2 30479857 LBH C A 1.20 
rs13385731 2 33701890 RASGRP3 T C 1.43 
rs6740462 2 65667272 SPRED2_MIR4778 A C 1.10 
rs6705628 2 74208362 DGUOK-AS1 C T 1.33 
rs2111485 2 163110536 FAP_IFIH1 G A 1.15 
rs3821236 2 191902758 STAT4 A G 1.49 
rs11889341 2 191943742 STAT4 T C 1.73 
rs3768792 2 213871709 IKZF2 G A 1.24 
rs6445972 3 58321707 PXK T C 1.23 
rs1132200 3 119150836 TMEM39A C T 1.39 
rs2222631 3 119272391 CD80 A G 1.09 
rs564799 3 159728987 IL12A-AS1 C T 1.14 
rs10936599 3 169492101 MYNN C T 1.14 
rs6762714 3 188470238 LPP T C 1.16 
rs4690229 4 970724 DGKQ_SLC26A1 T A 1.13 
rs340630 4 87958395 AFF1 A G 1.21 
rs10028805 4 102737250 BANK1 G A 1.20 
rs907715 4 123535053 IL21 C T 1.16 
rs7726159 5 1282319 TERT A C 1.21 
rs7726414 5 133431834 VDAC1_TCF7 T C 1.45 
rs7708392 5 150457485 TNIP1 C G 1.27 
rs2421184 5 158886939 LINC01845 A G 1.19 
rs2431697 5 159879978 PTTG1_MIR3142HG T C 1.45 
rs17603856 6 16630898 ATXN1 T G 1.14 
rs36014129 6 25884519 SLC17A3_SLC17A2 A G 1.50 
rs597325 6 91002494 BACH2 G A 1.12 
rs6568431 6 106588806 PRDM1_ATG5 A C 1.20 
rs6932056 6 138242437 TNFAIP3_PERP C T 1.83 




SNP chr pos Reference_gene Risk.allele Alt.allele OR 
rs849142 7 28185891 JAZF1 T C 1.19 
rs4917014 7 50305863 C7orf72_IKZF1 T G 1.39 
rs73135369 7 73940978 GTF2IRD1 C T 1.32 
rs1167796 7 75173180 HIP1 G A 1.20 
rs4728142 7 128573967 KCP_IRF5 A G 1.43 
rs2070197 7 128589000 IRF5 C T 1.88 
rs2980512 8 8140901 FAM86B3P_PRAG1 C T 1.15 
rs2736340 8 11343973 FAM167A_BLK T C 1.35 
rs7829816 8 56849386 LYN A G 1.30 
rs1966115 8 79556891 PKIA_ZC2HC1A A G 1.14 
rs1887428 9 4984530 JAK2 G C 1.16 
rs7097397 10 50025396 WDFY4 G A 1.30 
rs877819 10 50042951 WDFY4 A G 1.46 
rs4948496 10 63805617 ARID5B C T 1.18 
rs4917385 10 105003721 NT5C2_RPEL1 G T 1.39 
rs12802200 11 566936 MIR210HG C A 1.23 
rs2732552 11 35084592 PDHX_LOC100507144 C T 1.22 
rs494003 11 65542298 AP5B1 A G 1.14 
rs3794060 11 71187679 NADSYN1 C T 1.23 
rs4639966 11 118573519 TREH_DDX6 C T 1.29 
rs6590330 11 128311059 LINC02098_ETS1 A G 1.37 
rs7941765 11 128499000 ETS1_LOC101929538 C T 1.14 
rs12822507 12 12773521 CREBL2 A G 1.16 
rs34330 12 12870695 CDKN1B C T 1.19 
rs10506216 12 43130885 LINC02450_LINC02461 A G 1.67 
rs4622329 12 102321935 DRAM1_WASHC3 A G 1.19 
rs10774625 12 111910219 ATXN2 A G 1.13 
rs1059312 12 129278864 SLC15A4 G A 1.17 
rs8016947 14 35832666 PSMA6_NFKBIA G T 1.12 
rs4902562 14 68731458 RAD51B A G 1.14 
rs11073328 15 38764843 FAM98B T C 1.94 
rs34933034 15 75079474 CSK A G 1.32 
rs2289583 15 75311036 SCAMP5 A C 1.19 
rs8023715 15 97607681 SPATA8_LINC02254 A C 1.81 
rs9652601 16 11174365 CLEC16A G A 1.21 
rs16972959 16 23901376 PRKCB A G 1.23 
rs7197475 16 30642867 ZNF689_PRR14 T C 1.31 
rs34572943 16 31272353 ITGAM A G 1.71 
rs223881 16 57386566 PLLP_CCL22 T C 1.15 
rs1170426 16 68603798 ZFP90 C T 1.12 
rs2934498 16 85968282 IRF8_LINC01082 G A 1.25 




SNP chr pos Reference_gene Risk.allele Alt.allele OR 
rs2286672 17 4712617 PLD2 T C 1.25 
rs2941509 17 37921194 IKZF3 T C 1.35 
rs930297 17 73404537 MIR3678_TMEM94 T C 1.21 
rs1610555 18 67543147 CD226 T G 1.19 
rs3093030 19 10397403 ICAM4_ICAM1 T C 1.16 
rs2304256 19 10475652 TYK2 C A 1.24 
rs2305772 19 52033742 SIGLEC6 G A 1.16 
rs4810485 20 44747947 CD40 T G 1.59 
rs11697848 20 48575315 RNF114_SNAI1 T C 2.12 
rs463426 22 21809185 HIC2_TMEM191C T C 1.28 
rs7444 22 21976934 UBE2L3 C T 1.27 
rs61616683 22 39755773 SYNGR1 T C 1.27 





Appendix B. Chapter 5 Supplementary Tables 
 
Supplementary Table 5-1: SLE Renal GWAS in SLE main Cohort (35 Suggestive regions, 
P ≤ 1E-05) 
 
 




Suggetive	Regions tagSNP* Position Reference Alternative SLE	main	cohort SLEGEN	cohort Meta-analysis	of	two	cohorts Function Reference	Gene
1p36.12 rs10607584 21678940 GGA G 6.17742E-06 0.791527 1.29379E-05 intergenic ECE1;NBPF3
1q31.3 rs9427906 195926095 T C 4.89737E-06 0.558663 6.32048E-05 intergenic NONE;LINC01724
1q41 rs11572579 217011607 C T 4.39503E-06 0.0985657 0.011945786 intronic ESRRG
1q42.2 rs57268081 230866723 A C 3.12406E-06 0.3431 0.000215125 intergenic AGT;CAPN9
2q24.3 rs79968435 168051427 T C 7.10432E-06 0.856816 3.92125E-05 intronic XIRP2
3p14.1 rs34242854 68061272 C G 6.08601E-06 0.672348 1.1343E-05 intronic FAM19A1
3q12.3 rs141037434 101966528 A G 4.80943E-06 0.340595 0.827584767 intergenic LOC101929411;ZPLD1
3q25.2 rs35259387 152805860 G T 6.67233E-06 0.0230238 0.000479802 intergenic P2RY1;RAP2B
3q26.2 rs2421072 168667440 C T 0.000006047 0.978959 2.71723E-05 intergenic LINC02082;MECOM
4p14 rs36185839 37312869 C T 6.76737E-06 0.386835 7.25473E-06 intronic NWD2
4q27 rs62324163 123501681 T G 3.68549E-06 0.270292 2.52989E-06 intergenic IL2;IL21
4q34.1 rs72698624 176025380 T C 9.08584E-06 0.807888 5.59577E-05 intergenic ADAM29;GPM6A
5p12 rs148454819 43585130 G A 7.39295E-06 0.093852 4.70122E-05 ncRNA_intronic NNT-AS1
5q13.3 rs77835099 73573014 C T 3.59984E-06 0.406199 0.198502641 intergenic ARHGEF28;LINC01335
6q14.1 rs117308968 83686996 T A 1.60468E-06 0.255017 3.21595E-05 intronic UBE3D
7q21.3 rs45499693 93067597 A C 8.0478E-06 0.433873 0.001278023 intronic CALCR
8p12 rs183396989 29161973 G A 4.4386E-06 0.777606 0.856533823 intergenic KIF13B;DUSP4
8q24.3 rs55883233 141463613 C
CCATTCTGCATATG
CAGAGCCCACGA
3.64049E-06 0.37963 3.54305E-06 intronic TRAPPC9
9q33.3 rs576074053 130262732 C T 8.4443E-07 0.756719 0.752306379 intronic LRSAM1
11q21 rs35054871 92823118 CT C 2.2403E-06 0.7869 6.6325E-06 intergenic MTNR1B;SLC36A4
12q14.1 rs61941637 61818040 A T 7.67775E-06 0.933739 3.20274E-05 intergenic SLC16A7;FAM19A2
12q23.3 rs7957648 104954189 T C 8.17982E-06 0.196864 0.000147574 intronic CHST11
13q12.12 rs59543007 23710017 G GA 6.15852E-06 0.799654 4.57152E-05 intergenic LINC00621;SGCG
13q14.11 rs11372973 41612202 T TA 9.00371E-06 0.399211 0.000147939 intergenic ELF1;WBP4
14q23.2 rs1271565 64044097 T C 4.57017E-06 0.886522 1.80464E-05 intergenic PPP2R5E;WDR89
14q24.1 rs4899257 69253984 G T 4.61264E-06 0.281105 3.14879E-06 downstream ZFP36L1
14q31.1 rs4904052 82755793 A G 7.54394E-06 0.0355177 0.013204381 intergenic LINC02311;LINC02301
15q21.1 rs112366266 48800870 G A 7.73387E-06 0.439979 0.475934483 exonic FBN1
15q26.1 rs8035491 90342353 G A 5.9188E-06 0.545431 5.92267E-05 intronic ANPEP
17q21.2 rs191116624 39042992 T C 3.3014E-06 0.283989 0.004173173 intergenic KRT20;KRT23
18q11.2 rs2226706 21650964 T C 9.50537E-06 0.488401 1.4465E-05 intronic TTC39C
18q22.2 rs561244604 67151529 A C 1.48608E-06 0.349488 0.902974114 intronic DOK6
20p12.3 rs16991615 5948227 G A 7.2717E-06 0.520827 1.73527E-05 exonic MCM8
22q13.2 rs191312901 43757297 G A 4.54433E-06 0.703811 0.002464557 intergenic SCUBE1;LINC01639
Xp21.1 rs2180203 32407001 A T 4.02123E-06 0.141587 1.75129E-06 intronic DMD
P	 valueAlleles Annotation
Suggetive	Regions tagSNP* Position Reference Alternative SLE	main	cohort SLEGEN	cohort Meta-analysis	of	two	cohorts Function Reference	Gene
1p33 rs3034530 48275827 C T 0.578785 8.20143E-06 0.030747717 intronic TRABD2B
3q29 rs71921811 192781673 G GT 0.0155719 8.06823E-06 0.000100578 intergenic MB21D2;HRASLS
4q26 rs200625880 120021625 TAA T 0.713795 9.55342E-07 0.045502639 intergenic SYNPO2;MYOZ2
5q14.2 rs76400304 82004240 G C 0.704575 9.27711E-06 0.698403444 intergenic ATP6AP1L;MIR3977
5q35.1 rs111947887 172767169 G GA 0.945642 2.62665E-06 0.124481492 intergenic STC2;MIR8056
5q35.1 rs74411785 172773769 T C 0.714371 6.12468E-06 0.203289887 upstream MIR8056
5q35.1 rs75428302 172775585 CG C 0.78758 7.86472E-06 0.199563186 intergenic MIR8056;LOC285593
7q31.1 rs201305724 108287113 TTAATA T 0.298926 8.70395E-06 0.310763925 intergenic DNAJB9;C7orf66
8p22 rs151276961 18034539 A C 0.00943098 3.83641E-06 0.148239853 intronic NAT1
8q12.2 rs4289856 61813615 G A 0.231764 9.21871E-06 0.861680027 intergenic CHD7;LOC100130298
9p13.3 rs10814291 35888258 G A 0.95064 5.46102E-06 0.094898991 intergenic OR13J1;HRCT1
10p12.1 rs111595213 25432752 C CA 0.414948 9.69865E-06 0.924353509 ncRNA_intronic LINC01516
10q26.13 rs17612814 123255847 G A 0.921274 6.94594E-06 0.142036482 intronic FGFR2
10q26.13 rs78233824 123383396 G A 0.790281 7.23021E-06 0.059657749 intergenic FGFR2;ATE1
11q22.1 rs6589875 98928962 T A 0.721736 2.13118E-06 0.219998653 intronic CNTN5
14q22.3 rs375958485 56514369 T TTTATATATA 0.552054 8.71121E-06 0.631190004 intergenic LINC00520;PELI2
14q31.1 rs34242066 80292343 A AT 0.372434 5.11099E-06 0.024380592 intronic NRXN3
16p13.3 rs1684584 4758465 C A 0.502354 6.46877E-06 0.034542246 intronic ANKS3
16p13.3 rs859315 4785807 G A 0.84269 3.96597E-06 0.086980447 intronic C16orf71
16p13.3 rs12162062 4800009 T C 0.555661 7.64271E-06 0.037843641 UTR3 ZNF500
16q23.2 rs11150231 79956229 A C 0.080014 8.40555E-06 0.001353785 intergenic LINC01229;LOC102724084
18q23 rs113566940 76381494 T C 0.897563 4.0874E-06 0.131387702 intergenic LINC01029;SALL3
21q22.11 rs13047194 32835057 T G 0.71495 7.24242E-06 0.207079984 intronic TIAM1




Supplementary Table 5-3. Meta-analysis of SLE Renal GWAS of SLE main cohort and 
SLEGEN Cohort (21 Suggestive regions, P ≤ 1E-05) 
 
  
Suggetive	Regions tagSNP Position Reference Alternative SLE	main	cohort SLEGEN	cohort Meta-analysis	of	two	cohorts Function Reference	Gene
1p36.13 rs4920553 19163656 G A 2.10452E-05 0.092638 4.24613E-06 intergenic PAX7;TAS1R2
1q22 rs10157319 156157258 C T 0.000022706 0.0519644 6.66881E-06 intergenic SEMA4A;SLC25A44
1q22 rs2842879 156163695 G T 0.000032893 0.0525782 9.45566E-06 upstream SLC25A44
2p23.3 rs142186512 26400413 AT A 0.000310971 0.00108808 6.41531E-06 intronic GAREM2
2p23.3 rs116300430 26444690 A G 0.00052792 0.000863644 9.48627E-06 intronic HADHA
2p23.3 rs143543307 26595574 A G 0.000171023 0.000457101 1.88256E-06 intronic SELENOI
2q33.1 rs16831252 200170530 T C 0.000171036 0.00278706 3.75403E-06 intronic SATB2
3p14.1 rs1374837 68065201 C G 5.27017E-06 0.660839 9.65206E-06 intronic FAM19A1
4p14 rs36185839 37312869 C T 6.76737E-06 0.386835 7.25473E-06 intronic NWD2
4q27 rs62324163 123501681 T G 3.68549E-06 0.270292 2.52989E-06 intergenic IL2;IL21
4q34.1 rs1600330 176033852 T C 1.42577E-06 0.959344 8.05694E-06 intergenic ADAM29;GPM6A
5q22.2 rs72797840 111839996 A G 4.32864E-05 0.0914914 8.81893E-06 intergenic EPB41L4A-AS2;LINC02200
6q21 rs6935764 105903329 C T 0.000175699 0.0070327 7.60639E-06 intergenic PREP;PRDM1
8q24.3 rs55883233 141463613 C
CCATTCTGCATATGCA
GAGCCCACGA
3.64049E-06 0.37963 3.54305E-06 intronic TRAPPC9
11q21 rs35054871 92823118 CT C 2.2403E-06 0.7869 6.6325E-06 intergenic MTNR1B;SLC36A4
13q14.2 rs117874987 47454497 C T 1.00164E-05 0.0462432 7.60529E-06 intronic HTR2A
14q24.1 rs4899257 69253984 G T 4.61264E-06 0.281105 3.14879E-06 downstream ZFP36L1
18q11.2 rs72196202 21750898 CACTGT C 3.09364E-06 0.728187 8.16927E-06 intronic OSBPL1A
18q21.32 rs373465415 57128168 AAAAT A 4.58707E-05 0.0129916 4.08426E-06 intronic CCBE1
21q22.13 rs2835447 38090161 T C 4.41334E-05 0.0224126 3.90073E-06 intronic SIM2
Xp21.1 rs2144498 32406349 G A 2.66455E-05 0.125521 9.62627E-06 intronic DMD
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2% PBS/BSA [200ml PBS + 4g BSA (store in 4oC)] 
Histopaque [Sigma] 
3x Stabilizing Fixative [BD Biosciences] 
Permeabilization Buffer [PBS (49ml), 2% FBS (1ml), 0.1% Triton-X100 (50ul)] 
Human TruStain FcX [Biolegend] 
Live/Dead Blue Fixable Viability Dye [Life Technologies] 
 
Antibodies Needed: 




• All antibodies are kept at 4oC, with the exception of the IKZF1 antibody and the 
Alexa Fluor 488 anti-goat IgG F(ab’)2 fragment which are kept at -80 and -20 
respectively. Thaw the IKZF1 antibody on ice prior to staining. The secondary 
antibody is diluted in glycerol, so will not need to be thawed first. 
• Buffers containing FBS should be made fresh before each experiment.  
• This protocol assumes a single blood sample is being stained. Adjust 
accordingly for additional samples. 
• g(RCF- relative centrifugal force) 
 
 
A.     PBMC Isolation 
 
1. Label flow cytometry tubes for each staining panel, crossed with each IKZF 
antibody, as well as for the IKZF Isotype control, viability dye single stained and an 
unstained sample. For a single blood sample, this will yield 18 tubes (4 ZF x 4 
Panel, 1 US, 1 VDSS). 
US VD SS   
Panel_1  & IKZF1 Panel_1 & IKZF2 Panel_1 & IKZF3 Panel_1 & IKZF IC 
Panel_2  & IKZF1 Panel_2 & IKZF2 Panel_2 & IKZF3 Panel_2 & IKZF IC 
Panel_3  & IKZF1 Panel_3 & IKZF2 Panel_3 & IKZF3 Panel_3 & IKZF IC 
Panel_4  & IKZF1 Panel_4 & IKZF2 Panel_4 & IKZF3 Panel_4 & IKZF IC 
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2. Add 15ml of Histopaque to the SepMate-50 tube, pipetting through the hole in the 
divider. 
(*The Histopaque should be added to the SepMate-50 tube 30min prior to the 
collecting of samples.  Keep it at room temperature in the dark.  Usually, each 
patient sample needs 4 tubes of Histopaque, and each control sample needs 2 tubes 
of Histopaque.  ) 
 
3. Dilute the blood with an equal volume of PBS. 
(*Usually, each patient sample needs two 50ml tubes to dilute ~40ml whole blood, 
and each control sample needs one 50ml tubes to dilute ~20ml whole blood.) 
 
4. Pipette the blood slowly into the SepMate tube, avoiding it passing through the hole 
in the divider. 
(*20ml diluted whole blood can be added into each 15ml Histopaque.) 
 
5. Spin the blood sample for 10 minutes at room temperature at 2000xg, with brake.  
 
6. Decant the plasma and PBMC portion into a new tube quickly and add equal 
volume of  2% PBS/BSA to each tube (up to 40ml for each tube), spin at 120 xg for 
10 minutes at room temperature, with the brake off. 
 
7. Aspirate the supernatant from the cells, and suspend the cells in 2ml 2%PBS/BSA 
for each tube and combine them into one tube. Add 2%PBS/BSA to 40ml. 
 
8. Spin at room temperature for 8minutes at 300 xg. 
 
9. Aspirate the supernatant from the cells, and resuspend in 10ml PBS.  Put the cells on 
ice.  
 
10. Count the cells, then aliquot 106 cells into each tube and place on ice. Add 1ml PBS 
to each tube, and then spin at 350xg for 5 minutes at 4oC. 
 
(*count cells: 2ul cell solution + 18ul trypan blue.  Number of cells/ml = X/4*105) 
 
 
B.     Surface Marker Staining and Fixation 
 
11. While the samples are in the centrifuge, bring the viability dye to room temperature. 
If the dye has not yet been reconstituted, then add 40ul DMSO and mix well with 
the pipette.  
(* Turn upside-down to mix the solution) 
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12. Prepare a master mix for the viability dye. In a 50ml tube, mix 20ml PBS with 20ul 
of viability dye. 
 
13. Decant the supernatant from the flow tubes by inversion and place them in a tube 
rack at room temperature. 
 
14. Resuspend the cells in 1ml of the viability dye master mix (* Vortex for 1sec). Place 
them at room temperature in the dark for 30 minutes. Add PBS to the US sample. 
 
15. Wash the cells in 1ml PBS and spin at 350xg for 5 minutes at 4oC. 
 
16. Resuspend the cells in 50ul 2% PBS/BSA. Add 5ul of TruStain FcX to each 
sample, including the US and VDSS samples, mix (*gently flick the bottom of 
the tubes to mix) and incubate in the dark for 10 minutes at room temperature. 
 
17. Add the following four antibodies to the appropriate tubes, with the following 
volumes of antibody per tube – 5ul CCR7 BV412 (Panel 1), 5ul CXCR3 BV605 
(Panel 1), 2ul CCR6 PE/Cy7 (Panel 1), 1ul CCR4 APC (Panel 2).  
 
18. Place all tubes in a 37oC incubator for 15 minutes. 
 
19. During these 15 minutes, prepare the 4 surface stain master mixes using 2% 
PBS/BSA as shown in Appendix 1. 
Panel_1  & IKZF1 Panel_1 & IKZF2 Panel_1 & IKZF3 Panel_1 & IKZF IC 
Panel_2  & IKZF1 Panel_2 & IKZF2 Panel_2 & IKZF3 Panel_2 & IKZF IC 
Panel_3  & IKZF1 Panel_3 & IKZF2 Panel_3 & IKZF3 Panel_3 & IKZF IC 
Panel_4  & IKZF1 Panel_4 & IKZF2 Panel_4 & IKZF3 Panel_4 & IKZF IC 
 
20. Remove tubes from the incubator. Add 50ul of the appropriate master mix (*gently 
flick the bottom of the tubes to mix) to the tubes (Panels 1-4). Add 50ul 2% 
PBS/BSA to the US and VD SS samples.  
 
21. To the four ZF1 tubes, add 5ul of the PE isotype control. To ZF2, ZF3 and the 
ZF IC tubes, add 5ul of OX40L PE. Incubate at room temperature for 20 minutes 
in the dark. 
PE isotype OX40L PE 
Panel_1  & IKZF1 Panel_1 & IKZF2 Panel_1 & IKZF3 Panel_1 & IKZF IC 
Panel_2  & IKZF1 Panel_2 & IKZF2 Panel_2 & IKZF3 Panel_2 & IKZF IC 
Panel_3  & IKZF1 Panel_3 & IKZF2 Panel_3 & IKZF3 Panel_3 & IKZF IC 
Panel_4  & IKZF1 Panel_4 & IKZF2 Panel_4 & IKZF3 Panel_4 & IKZF IC 
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*To detect the expression of OX40L on different cell types.  Different isotype 
control cannot be added into the same tube.  Therefore, we can add PE isotype 
control to any of ZF1-3, except for ZF IC. 
 
22. Wash the cells in 1ml PBS and spin at 350xg for 5 minutes at 4oC. 
 
23. Dilute 1333ul of fixation buffer to 1X concentration using 2667ul ddH2O. Mix 
well. 
 
24. Decant the supernatant from the samples and place them in a tube rack at room 
temperature. Add 200ul of fixation buffer to each sample and quickly vortex to 
fully resuspend the pellet. Incubate at room temperature in the dark for 10 minutes. 
 
25. Wash the cells in 1ml PBS and spin at 500xg for 5 minutes at 4oC.  
 
 
C.     Intracellular Staining 
 
26. Prepare the 4 master mixes for the intracellular staining. Add 4ul of the IKZF 
antibodies, or 2ul of the isotype control, to 400ul of permeabilization buffer in 
separate tubes. 
 
27. Decant the supernatant from the samples, ensuring that there is as little supernatant 
left as possible but without detaching the cell pellet from the tube. 
 
28. Add 100ul of “blank” permeabilization buffer to the US and the VD SS 
samples, and 100ul of the IKZF master mixes to their respective samples. 
Vortex all tubes to resuspend and incubate on ice in the dark for 20 minutes. 
Panel_1  & IKZF1 Panel_1 & IKZF2 Panel_1 & IKZF3 Panel_1 & IKZF IC 
Panel_2  & IKZF1 Panel_2 & IKZF2 Panel_2 & IKZF3 Panel_2 & IKZF IC 
Panel_3  & IKZF1 Panel_3 & IKZF2 Panel_3 & IKZF3 Panel_3 & IKZF IC 
Panel_4  & IKZF1 Panel_4 & IKZF2 Panel_4 & IKZF3 Panel_4 & IKZF IC 
 
29. Wash the cells in 1ml of 2% PBS/BSA and spin at 500xg for 5 minutes at 4oC. The 
US and VD SS samples do not need to be washed, leave them in the perm buffer 
until the final wash. 
 
30. Prepare the master mix for the secondary antibody. Add 10ul of Alexa Fluor 488 
anti-goat IgG to 2ml permeabilization buffer. Mix well and place on ice in the dark. 
 
31. Decant the supernatant from the samples and place on ice. Add 100ul of the 
permeabilization buffer containing the secondary antibody to the other samples 
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(except the US and VDSS). Vortex all tubes to resuspend and incubate on ice in the 
dark for 20 minutes. 
 
32. Wash the cells in 1ml of 2% PBS/BSA and spin at 500xg for 5 minutes at 4oC. 
 
33. Decant the supernatant and resuspend in 500ul of 2% PBS/BSA. Place lids on all the 
tubes and put them in a polystyrene tube holder. Wrap the whole tube holder in foil 
and keep in the fridge. 
 
 
Surface Marker Master Mixes (*Mix by pipetting) 
 
Panel 1     Panel 2 
178ul  2% PBS/BSA       152ul 2% PBS/BSA                   
4ul  CD8 Alexa 700        20ul  CD25 BV605                   
4ul  CD4 PE/Texas Red        4ul  CD4 PE/Texas Red           
4ul  CD45RA BV785        8ul  CD45RO BV785               
2ul  CD38 APC         8ul CD127 PE/Cy7                  
4ul CD3 APC/Cy7        4ul CD3 APC/Cy7                    
4ul  HLA-DR PerCP/Cy5.5      4ul  HLA-DR PerCP/Cy5.5       
 
 
Panel 3     Panel 4 
126ul  2% PBS/BSA      160ul 2% PBS/BSA                  
12ul  CD24 PerCP/Cy5.5      8ul  CD56 BV605                   
4ul  CD19 BV421        4ul  CD123 APC                      
8ul  CD27 BV785       4ul CD11c PE/CF594              
2ul  CD38 APC        4ul CD16 BV785                     
4ul  CD20 PE/Cy7        4ul  CD3 APC/Cy7                   
4ul CD3 APC/Cy7       4ul CD19 BV421                     
20ul  IgD BV605       4ul  CD20 PE/Cy7                    
20ul CD138 Alexa 700      4ul  HLA-DR PerCP/Cy5.5      
      4ul CD14 Alexa 700                
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Cytometer Setup and Tracking Beads [BD Biosciences] 
Mouse IgG Compensation Beads [BD Biosciences] 
 
Antibodies Needed: 




• This protocol is customized for the Full Immunophenotyping study involving 
the investigation of IKZF1-3 and OX40L expression on PBMC subsets. Several 
aspects of this protocol are not directly transferable to other similar protocols 
(filter setup, CS&T bead lot, application settings). 




A.     Compensation Bead Preparation 
 
1. Label 26 flow cytometry tubes with each of the antibodies being used, with the 
exception of the IKZF antibodies. Instead, label a tube simply as “Alexa 488”. 
 
CCR7 BV421 CXCR3 V605 CCR6 PE/Cy7 CCR4 APC OX40L PE 
CD8 Alexa 700 CD4  PE/Tex Red CD45RA BV785 CD38 APC CD3 APC/Cy7 
HLA-DR PerCP/Cy5.5 CD25 BV605 CD45RO BV785 CD127 PE/Cy7 CD24 PerCP/Cy5.5 
CD19 BV421 CD27 BV785 CD20 PE/Cy7 IgD BV605 CD138 Alexa 700 
CD56 BV605 CD123 APC CD11c PE/CF594 CD16 BV785 CD14 Alexa 700 
Anti-mouse IgG Alexa 488     
 
2. To each tube, add 100ul of 2% PBS/BSA.  
 
3. Vortex both vials of compensation beads (positive and negative beads). Add one 
drop (~60ul) of the positive and negative beads to each tube. Quickly vortex to 
mix. 
 
4. Add 1ul of each of the antibodies to their corresponding tube and mix gently 
(*gently flick the bottom of the tubes to mix). To the Alexa 488 tube, add 1ul of any 
Alexa 488-labelled mouse IgG antibody. 
 
5. Incubate for 20 minutes at room temperature in the dark. 
 
6. Add 1ml of 2% PBS/BSA to each tube and then centrifuge for 10 minutes at room 
temperature at 200xg. 
 
 183 
7. Remove the supernatant and resuspend the beads in 500ul 2% PBS/BSA. Place the 
beads in the ice box to be taken to the Flow Core, together with the prepared 




B.     Machine Setup 
 
8. Make sure the Fortessa is turned on and the fluidics is set to ‘Standby’. Open 
FACSDiva and login, then wait for the program to connect to the cytometer. 
(*FACSDiva:  Username: Lingyan; Password: lingyan) 
 
9. Open the front-right panel on the cytometer to expose the red laser detector array. 
Remove the filter labelled 670/14 from detector C (APC) and replace it with the 
filter 670/30. Ensure that the filter is inserted the right way round, with the bottom 
of the writing on the label facing the inside of the detector array. Close the panel 
door. 
 
10. Open the side drawer on the left of the cytometer by pushing the black button in the 
centre. When it pops out, turn it anticlockwise and pull open the draw to expose the 
violet, blue and yellow-green laser detector arrays. 
 
11. On the blue laser detector array, remove the filter labelled 670/30 from detector A 
and replace it with the filter 710/50. 
 
12. On the yellow-green laser detector array, remove the mirror placeholder from in 
front of the filter on detector E and insert the longpass mirror labelled 550LP. Close 
the draw and push the button to lock. 
 
13. On FACSDiva, open the menu ‘Cytometer’ and select the option ‘CST’. Once the 
CST window has opened, wait for it to connect to the cytometer.  
 
14. Vortex vial of beads. Prepare the CST beads by adding 400ul PBS to a flow 
cytometry tube and adding 1 drop of CST beads (Lot 43523). Vortex the beads 
gently before dispensing. 
 
15. In the Setup Control window, click ‘Select Configuration’. From the list, select the 
configuration labelled ‘CP-Blue 6Violet 2NUV 3Red 5YG’. Click ‘Set 
Configuration’ then click okay.  Make sure that the box before “Load tubes 
manually” has been ticked. 
 
16. Select the correct bead lot from the dropdown menu (43523). 
 
17. Verify that the baseline for this bead lot is detected, then load the bead tube on to 
the sample acquisition platform. On the machine, press ‘Run’ and set the acquisition 
rate to ‘Lo’. In the Setup Control window, press ‘Run’. 
 
18. Allow the performance check to run. Once the check is complete, make sure that it 
has passed. If the check has failed, run it again. Otherwise, troubleshoot the problem 
with the machine. 
 
19. Go to ‘File’ and ‘Exit’ to return to FACSDiva. 
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20. When the ‘CST Mismatch’ dialog appears, click ‘Use CST Settings’. Open a new 
experiment to run the samples using the CST settings. 
 
 
C.     Sample Acquisition 
 
21. Open a new experiment. Select Cytometer Settings, and in the Inspector window, 
delete any unused fluorochromes and replace them with any ones that are needed. 
The following channels should be selected – FITC, PE, APC, QDot800, QDot605, 
Pacific Blue, APC-Cy7, PerCP-Cy5.5, PE-Cy7, PE-TexasRed, Alexa700, UV 
(Violet). Tick the ‘H’ and ‘W’ checkboxes under FSC and SSC. Do not adjust any 
of the voltages. 
 
22. In the new experiment, right click on ‘Cytometer Settings’, go down to ‘Application 
Settings’ and click ‘Apply’. From the list of available application settings, select 
‘CP-VyseImmunophenotyping’. 
 
23. Create the necessary worksheets and samples. In the machine, set the acquisition 
rate to ‘Hi’. 
 
24. Set the SSC voltage to roughly 220 in order to bring the compensation beads into 
scale. Record 5000 events for all the compensation bead samples, but do not run the 
FACSDiva compensation module, since compensation will be done later on FlowJo. 
 
25. Adjust the FSC and SSC voltages for cells (roughly 280 SSC), and record the 
samples, including the US and VDSS.  Set a gate around the PBMCs, and set this as 
the stopping gate. Record 10,000 events for US and VDSS and record 300,000 
events per sample (within the stopping gate). 
 
26. Once all samples have been recorded, export the data as FCS files and upload to the 
web file server (*username: facsdrive; password: music). 
 
27. Begin the cleaning procedure. 
 
28. In the ‘Cytometer’ menu, select ‘View Configurations’. In the CST window, select 
the original cytometer configuration and apply it to set the machine back to standard 
settings. Close the window to return to FACSDiva. Once the cleaning is complete, 
close FACSDiva. 
 
29. Return the filters to their base configurations (* notes behind computer). 
 
 
